Drug Interactions Guide

Evidence-based guide to common drug interactions. Check 1404+ medication combinations with severity ratings, mechanisms, and recommendations.

Articles

• A

  abemaciclib and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Abemaciclib and Ketoconazole: major severity. Ketoconazole strongly inhibits CYP3A4-mediated metabolism of abemaciclib, increa

  ›
• A

  abiraterone and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Abiraterone and Metoprolol: moderate severity. Abiraterone inhibits CYP2D6, which can reduce metoprolol metabolism and increase

  ›
• A

  abiraterone and prednisolone: Interaction, Risks, and Safer

  Interaction between Abiraterone and Prednisolone: minor severity. Abiraterone inhibits CYP17, causing mineralocorticoid excess; prednisolone is co

  ›
• A

  abiraterone and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Abiraterone and Spironolactone: major severity. Spironolactone has partial androgen receptor agonist activity that may stimulate

  ›
• A

  acarbose and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Acarbose and Digoxin: minor severity. Acarbose can reduce gastrointestinal absorption and systemic exposure of digoxin

  ›
• A

  ace-inhibitor and allopurinol: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Allopurinol: moderate severity. Combined use of ACE inhibitors and allopurinol increases the risk of hypersensit

  ›
• A

  ace-inhibitor and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Lithium: major severity. ACE inhibitors reduce renal clearance of lithium through decreased glomerular fi

  ›
• A

  ace-inhibitor and potassium-sparing-diuretic: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Potassium Sparing Diuretic: major severity. Both drug classes reduce renal potassium excretion (ACE inhibitors via redu

  ›
• A

  ace-inhibitor and potassium-supplements: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Potassium Supplements: major severity. ACE inhibitors reduce aldosterone-mediated potassium excretion; concurrent potas

  ›
• A

  ace-inhibitor and potassium: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Potassium: moderate severity. ACE inhibitors raise serum potassium; supplements compound this.

  ›
• A

  ace-inhibitor and sacubitril-valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Sacubitril Valsartan: major severity. Concurrent neprilysin inhibition and ACE inhibition raise bradykinin levels mark

  ›
• A

  ace-inhibitor and spironolactone: Interaction, Risks, and Safer

  Interaction between Ace Inhibitor and Spironolactone: moderate severity. ACE inhibitors reduce aldosterone-mediated potassium excretion; combined with th

  ›
• A

  ace-inhibitor and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitor and Trimethoprim: moderate severity. Trimethoprim blocks epithelial sodium channels in the distal nephron (amiloride-

  ›
• A

  ace-inhibitors and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Ace Inhibitors and Spironolactone: moderate severity. Both agents reduce renal potassium excretion through angiotensin-aldosterone axi

  ›
• A

  acenocoumarol and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Acenocoumarol and Fluconazole: major severity. Fluconazole inhibits CYP2C9 and CYP3A4, reducing metabolism of acenocoumarol and

  ›
• A

  acenocoumarol and metronidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Acenocoumarol and Metronidazole: major severity. Metronidazole inhibits CYP2C9-mediated metabolism of coumarin anticoagulants. Th

  ›
• A

  acenocoumarol and miconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Acenocoumarol and Miconazole: major severity. Miconazole inhibits CYP2C9 even when administered topically or as oral gel, dram

  ›
• A

  acetaminophen and cholestyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Cholestyramine: minor severity. Cholestyramine can adsorb acetaminophen in the gastrointestinal tract and reduce

  ›
• A

  acetaminophen and colestyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Colestyramine: minor severity. Colestyramine can bind acetaminophen in the gastrointestinal tract and reduce or

  ›
• A

  acetaminophen and isoniazid: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Isoniazid: moderate severity. Isoniazid induces CYP2E1, increasing formation of the toxic acetaminophen metabo

  ›
• A

  acetaminophen and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Lamotrigine: minor severity. Regular acetaminophen use may modestly increase lamotrigine glucuronidation, red

  ›
• A

  acetaminophen and metoclopramide: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Metoclopramide: minor severity. Metoclopramide accelerates gastric emptying, which can increase the rate of acet

  ›
• A

  acetaminophen and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Acetaminophen and Warfarin: moderate severity. Repeated acetaminophen use may potentiate warfarin anticoagulation, likely throu

  ›
• A

  acetazolamide and aspirin: Interaction, Risks, and Safer Alternatives

  Interaction between Acetazolamide and Aspirin: moderate severity. High-dose aspirin can displace acetazolamide from protein binding and reduce ren

  ›
• A

  acetazolamide and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Acetazolamide and Lithium: moderate severity. Acetazolamide alkalinizes urine and reduces proximal tubular lithium reabsorptio

  ›
• A

  acetazolamide and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Acetazolamide and Topiramate: moderate severity. Both drugs inhibit carbonic anhydrase, increasing renal bicarbonate loss and the

  ›
• A

  acetylsalicylic-acid and apixaban: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Apixaban: moderate severity. Cyclooxygenase-1 inhibition impairs platelet aggregation while apixaban inhibits

  ›
• A

  acetylsalicylic-acid and atenolol: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Atenolol: minor severity. At anti-inflammatory doses, acetylsalicylic acid inhibits renal prostaglandin sy

  ›
• A

  acetylsalicylic-acid and bisoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Bisoprolol: minor severity. Cyclo-oxygenase inhibition can reduce renal prostaglandin synthesis, causing sod

  ›
• A

  acetylsalicylic-acid and clopidogrel: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Clopidogrel: moderate severity. Both drugs inhibit platelet aggregation through different pathways, producing an

  ›
• A

  acetylsalicylic-acid and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Ibuprofen: minor severity. Ibuprofen can reversibly occupy platelet COX-1 and reduce the irreversible antip

  ›
• A

  acetylsalicylic-acid and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Lisinopril: minor severity. Cyclooxygenase inhibition can reduce renal prostaglandin synthesis and mildly at

  ›
• A

  acetylsalicylic-acid and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Methotrexate: major severity. Salicylates can reduce renal tubular secretion of methotrexate and displace it f

  ›
• A

  acetylsalicylic-acid and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Ramipril: minor severity. Cyclooxygenase inhibition can reduce renal prostaglandin synthesis and modestly

  ›
• A

  acetylsalicylic-acid and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Sertraline: moderate severity. Sertraline inhibits serotonin uptake into platelets, impairing platelet aggregat

  ›
• A

  acetylsalicylic-acid and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Acetylsalicylic Acid and Warfarin: moderate severity. Acetylsalicylic acid inhibits platelet aggregation and can injure gastric mucosa

  ›
• A

  aciclovir and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Aciclovir and Probenecid: minor severity. Probenecid inhibits renal tubular secretion of aciclovir, increasing its plasma

  ›
• A

  aciclovir and tenofovir-disoproxil: Interaction, Risks, and Safer Alternatives

  Interaction between Aciclovir and Tenofovir Disoproxil: moderate severity. Both drugs undergo renal elimination and can cause proximal tubular injury, prod

  ›
• A

  aciclovir and tenofovir: Interaction, Risks, and Safer Alternatives

  Interaction between Aciclovir and Tenofovir: moderate severity. Both drugs undergo renal tubular handling and can cause proximal tubular injury;

  ›
• A

  acyclovir and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Acyclovir and Probenecid: minor severity. Probenecid inhibits renal tubular secretion of acyclovir through organic anion t

  ›
• A

  acyclovir and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Acyclovir and Tacrolimus: moderate severity. Acyclovir and tacrolimus can both impair renal function, and reduced kidney func

  ›
• A

  acyclovir and tenofovir-disoproxil: Interaction, Risks, and Safer Alternatives

  Interaction between Acyclovir and Tenofovir Disoproxil: moderate severity. Both drugs can cause renal tubular toxicity and are eliminated by renal transpor

  ›
• A

  adalimumab and anakinra: Interaction, Risks, and Safer Alternatives

  Interaction between Adalimumab and Anakinra: major severity. Combined biologic immunosuppression with TNF-alpha and IL-1 inhibitors produces

  ›
• A

  adenosine and dipyridamole: Interaction, Risks, and Safer Alternatives

  Interaction between Adenosine and Dipyridamole: major severity. Dipyridamole inhibits cellular uptake and metabolism of adenosine, markedly pote

  ›
• A

  alcohol and disulfiram: Interaction, Risks, and Safer Alternatives

  Interaction between Alcohol and Disulfiram: major severity. Disulfiram inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde

  ›
• A

  alcohol and metronidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Alcohol and Metronidazole: major severity. Metronidazole inhibits aldehyde dehydrogenase, allowing acetaldehyde to accumula

  ›
• A

  alcohol and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Alcohol and Zolpidem: moderate severity. Alcohol and zolpidem both enhance central nervous system depression through GABA

  ›
• A

  alcohol and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Alcohol and Zopiclone: major severity. Alcohol and zopiclone produce additive central nervous system depression through

  ›
• A

  alendronate and calcium-carbonate: Interaction, Risks, and Safer Alternatives

  Interaction between Alendronate and Calcium Carbonate: moderate severity. Calcium binds to bisphosphonates in the gastrointestinal tract, forming insolubl

  ›
• A

  alendronic-acid and calcium-carbonate: Interaction, Risks, and Safer Alternatives

  Interaction between Alendronic Acid and Calcium Carbonate: minor severity. Calcium salts bind alendronic acid in the gastrointestinal tract and markedly re

  ›
• A

  alendronic-acid and calcium: Interaction, Risks, and Safer Alternatives

  Interaction between Alendronic Acid and Calcium: moderate severity. Calcium binds alendronic acid in the gastrointestinal tract and substantially re

  ›
• A

  alendronic-acid and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Alendronic Acid and Omeprazole: minor severity. Proton pump inhibitors reduce gastric acidity and may modestly affect calcium ab

  ›
• A

  alfuzosin and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Alfuzosin and Ketoconazole: major severity. Ketoconazole is a potent CYP3A4 inhibitor that dramatically increases plasma con

  ›
• A

  alfuzosin and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Alfuzosin and Tamsulosin: moderate severity. Both are selective alpha-1 adrenergic receptor antagonists; concurrent use produ

  ›
• A

  aliskiren and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Aliskiren and Lisinopril: major severity. Dual blockade of the renin-angiotensin-aldosterone system increases the risk of

  ›
• A

  aliskiren and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Aliskiren and Losartan: major severity. Dual renin-angiotensin system blockade increases the risk of hyperkalemia, hypot

  ›
• A

  aliskiren and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Aliskiren and Ramipril: major severity. Combined renin inhibition and angiotensin-converting enzyme inhibition produce e

  ›
• A

  allopurinol and amoxicillin: Interaction, Risks, and Safer Alternatives

  Interaction between Allopurinol and Amoxicillin: minor severity. The combination increases the incidence of non-allergic morbilliform rash by an

  ›
• A

  allopurinol and ampicillin: Interaction, Risks, and Safer Alternatives

  Interaction between Allopurinol and Ampicillin: minor severity. Concomitant use is associated with an increased incidence of cutaneous rash, pos

  ›
• A

  allopurinol and azathioprine: Interaction, Risks, and Safer

  Interaction between Allopurinol and Azathioprine: major severity. Allopurinol inhibits xanthine oxidase, the enzyme responsible for inactivating 6

  ›
• A

  allopurinol and mercaptopurine: Interaction, Risks, and Safer Alternatives

  Interaction between Allopurinol and Mercaptopurine: major severity. Allopurinol inhibits xanthine oxidase, which is the primary enzyme metabolizing

  ›
• A

  alpha-blocker and sildenafil: Interaction, Risks, and Safer

  Interaction between Alpha Blocker and Sildenafil: moderate severity. Both phosphodiesterase-5 inhibitors and alpha-1 adrenergic blockers (doxazosin,

  ›
• A

  alprazolam and clarithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Clarithromycin: major severity. Clarithromycin strongly inhibits CYP3A4, reducing alprazolam metabolism and incr

  ›
• A

  alprazolam and fentanyl: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Fentanyl: major severity. Both drugs enhance central nervous system depression through GABA-A receptor mod

  ›
• A

  alprazolam and fluvoxamine: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Fluvoxamine: moderate severity. Fluvoxamine inhibits CYP3A4 and CYP1A2, reducing alprazolam clearance. This can

  ›
• A

  alprazolam and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Itraconazole: major severity. Itraconazole is a potent CYP3A4 inhibitor that doubles alprazolam AUC and prolon

  ›
• A

  alprazolam and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Ketoconazole: major severity. Ketoconazole is a potent CYP3A4 inhibitor and can substantially increase alprazo

  ›
• A

  alprazolam and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Morphine: major severity. Both drugs depress central nervous system and brainstem respiratory activity thr

  ›
• A

  alprazolam and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Oxycodone: major severity. Benzodiazepine GABA-A receptor modulation and opioid mu-receptor agonism produce

  ›
• A

  alprazolam and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Alprazolam and Ritonavir: major severity. Ritonavir strongly inhibits CYP3A4, the main metabolic pathway for alprazolam. T

  ›
• A

  alteplase and enoxaparin: Interaction, Risks, and Safer Alternatives

  Interaction between Alteplase and Enoxaparin: major severity. Concurrent fibrinolytic and therapeutic-dose low-molecular-weight heparin produc

  ›
• A

  aluminium-hydroxide and atenolol: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Atenolol: minor severity. Aluminium-containing antacids can adsorb atenolol in the gastrointestinal tract

  ›
• A

  aluminium-hydroxide and azithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Azithromycin: minor severity. Aluminium-containing antacids can delay or reduce the peak plasma concentration

  ›
• A

  aluminium-hydroxide and ciprofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Ciprofloxacin: moderate severity. Aluminium and magnesium antacids chelate fluoroquinolones in the gut, substanti

  ›
• A

  aluminium-hydroxide and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Digoxin: minor severity. Aluminium hydroxide can adsorb digoxin in the gastrointestinal tract and modestl

  ›
• A

  aluminium-hydroxide and doxycycline: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Doxycycline: minor severity. Aluminium forms non-absorbable chelation complexes with doxycycline in the gastr

  ›
• A

  aluminium-hydroxide and gabapentin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Gabapentin: minor severity. Aluminium-containing antacids reduce gabapentin absorption in the gastrointestin

  ›
• A

  aluminium-hydroxide and hydroxychloroquine: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Hydroxychloroquine: minor severity. Aluminium-containing antacids can adsorb hydroxychloroquine in the gastrointe

  ›
• A

  aluminium-hydroxide and isoniazid: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminium Hydroxide and Isoniazid: minor severity. Aluminium-containing antacids can adsorb isoniazid in the gastrointestinal tract

  ›
• A

  aluminum-hydroxide and atenolol: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Atenolol: minor severity. Aluminum-containing antacids can reduce gastrointestinal absorption and bioavail

  ›
• A

  aluminum-hydroxide and azithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Azithromycin: minor severity. Aluminum-containing antacids can reduce the peak plasma concentration of azithro

  ›
• A

  aluminum-hydroxide and ciprofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Ciprofloxacin: moderate severity. Aluminum ions chelate ciprofloxacin in the gastrointestinal tract, forming poorl

  ›
• A

  aluminum-hydroxide and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Digoxin: minor severity. Aluminum hydroxide can adsorb digoxin in the gastrointestinal tract and modestly

  ›
• A

  aluminum-hydroxide and doxycycline: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Doxycycline: moderate severity. Trivalent aluminum chelates doxycycline in the gastrointestinal tract, forming p

  ›
• A

  aluminum-hydroxide and gabapentin: Interaction, Risks, and Safer Alternatives

  Interaction between Aluminum Hydroxide and Gabapentin: minor severity. Aluminum-containing antacids reduce gabapentin absorption from the gastrointesti

  ›
• A

  amiloride and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Amiloride and Lisinopril: moderate severity. Both drugs reduce potassium excretion — amiloride through epithelial sodium chan

  ›
• A

  amiodarone and apixaban: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Apixaban: moderate severity. Amiodarone inhibits P-glycoprotein and CYP3A4, potentially reducing apixaban eli

  ›
• A

  amiodarone and atorvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Atorvastatin: moderate severity. Amiodarone inhibits CYP3A4 and P-glycoprotein, which can increase atorvastatin e

  ›
• A

  amiodarone and azithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Azithromycin: major severity. Additive QT-interval prolongation through inhibition of cardiac IKr potassium ch

  ›
• A

  amiodarone and citalopram: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Citalopram: major severity. Both drugs prolong the QT interval through cardiac potassium-channel effects, in

  ›
• A

  amiodarone and clarithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Clarithromycin: major severity. Both drugs prolong cardiac repolarization through effects on potassium channels,

  ›
• A

  amiodarone and dabigatran: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Dabigatran: major severity. Amiodarone inhibits P-glycoprotein (P-gp) efflux transporter in the gut and kidn

  ›
• A

  amiodarone and escitalopram: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Escitalopram: major severity. Both drugs prolong cardiac repolarization through potassium-channel effects, pro

  ›
• A

  amiodarone and flecainide: Interaction, Risks, and Safer

  Interaction between Amiodarone and Flecainide: major severity. Amiodarone inhibits CYP2D6 and CYP3A4, raising flecainide concentrations; both d

  ›
• A

  amiodarone and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Fluconazole: major severity. Both drugs prolong cardiac repolarization through potassium-channel effects, whi

  ›
• A

  amiodarone and fluoroquinolones: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Fluoroquinolones: major severity. Both agents can prolong cardiac repolarization through effects on potassium curr

  ›
• A

  amiodarone and haloperidol: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Haloperidol: major severity. Both drugs inhibit cardiac potassium currents and prolong the QT interval, incre

  ›
• A

  amiodarone and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Levofloxacin: major severity. Both drugs prolong cardiac repolarization by effects on cardiac potassium curren

  ›
• A

  amiodarone and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Ondansetron: major severity. Both drugs inhibit cardiac potassium currents and prolong the QT interval, incre

  ›
• A

  amiodarone and simvastatin: Interaction, Risks, and Safer

  Interaction between Amiodarone and Simvastatin: major severity. Amiodarone inhibits CYP3A4 metabolism of simvastatin, increasing systemic exposu

  ›
• A

  amiodarone and sofosbuvir: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Sofosbuvir: major severity. Co-administration causes symptomatic bradycardia and heart block via uncharacter

  ›
• A

  amiodarone and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Sotalol: major severity. Both agents block cardiac potassium channels and prolong the QT interval; additi

  ›
• A

  amiodarone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Amiodarone and Warfarin: major severity. Amiodarone raises warfarin INR by 30-50% within 1-2 weeks.

  ›
• A

  amitriptyline and bupropion: Interaction, Risks, and Safer Alternatives

  Interaction between Amitriptyline and Bupropion: moderate severity. Bupropion potently inhibits CYP2D6, reducing clearance of amitriptyline and its

  ›
• A

  amitriptyline and fluoxetine: Interaction, Risks, and Safer

  Interaction between Amitriptyline and Fluoxetine: major severity. Fluoxetine inhibits CYP2D6 metabolism of amitriptyline, raising tricyclic levels

  ›
• A

  amitriptyline and linezolid: Interaction, Risks, and Safer Alternatives

  Interaction between Amitriptyline and Linezolid: major severity. Linezolid is a reversible MAO inhibitor that potentiates serotonergic effects of

  ›
• A

  amitriptyline and terbinafine: Interaction, Risks, and Safer Alternatives

  Interaction between Amitriptyline and Terbinafine: moderate severity. Terbinafine is a potent CYP2D6 inhibitor that increases amitriptyline and nortri

  ›
• A

  amitriptyline and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Amitriptyline and Tramadol: moderate severity. Both drugs lower seizure threshold and increase serotonergic activity; tramadol'

  ›
• A

  amlodipine and atenolol: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Atenolol: minor severity. Their complementary vasodilatory and beta-adrenergic blocking effects can produc

  ›
• A

  amlodipine and atorvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Atorvastatin: minor severity. Amlodipine may weakly increase exposure to some CYP3A4-metabolized statins, incl

  ›
• A

  amlodipine and bisoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Bisoprolol: minor severity. Both drugs lower blood pressure through complementary pharmacodynamic effects, w

  ›
• A

  amlodipine and ciclosporin: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Ciclosporin: moderate severity. Ciclosporin inhibits CYP3A4 metabolism of amlodipine, increasing plasma levels a

  ›
• A

  amlodipine and clarithromycin: Interaction, Risks, and Safer

  Interaction between Amlodipine and Clarithromycin: moderate severity. Clarithromycin inhibits CYP3A4 metabolism of amlodipine, increasing plasma level

  ›
• A

  amlodipine and diltiazem: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Diltiazem: moderate severity. Diltiazem inhibits CYP3A4 metabolism of amlodipine, increasing exposure and addi

  ›
• A

  amlodipine and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Grapefruit Juice: minor severity. Grapefruit juice inhibits intestinal CYP3A4, modestly increasing amlodipine AUC

  ›
• A

  amlodipine and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Ibuprofen: minor severity. Ibuprofen inhibits renal prostaglandin synthesis, promoting sodium retention tha

  ›
• A

  amlodipine and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Lisinopril: minor severity. L-type calcium-channel blockade and inhibition of the renin-angiotensin-aldoster

  ›
• A

  amlodipine and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Ramipril: minor severity. Calcium-channel blockade and inhibition of the renin-angiotensin-aldosterone sys

  ›
• A

  amlodipine and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Sildenafil: minor severity. Calcium-channel blockade and PDE5 inhibition produce additive vasodilation and m

  ›
• A

  amlodipine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Simvastatin: moderate severity. Amlodipine inhibits CYP3A4, increasing simvastatin levels and risk of myopathy/r

  ›
• A

  amlodipine and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Amlodipine and Tacrolimus: moderate severity. Amlodipine modestly inhibits CYP3A4 and competes for P-glycoprotein, raising tac

  ›
• A

  amoxicillin and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Amoxicillin and Methotrexate: moderate severity. Penicillins compete with methotrexate for renal tubular secretion via organic an

  ›
• A

  amoxicillin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Amoxicillin and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters responsible for tubular sec

  ›
• A

  amoxicillin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Amoxicillin and Warfarin: minor severity. Broad-spectrum antibiotics such as amoxicillin may alter intestinal flora that c

  ›
• A

  amoxicillin-clavulanate and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Amoxicillin Clavulanate and Warfarin: moderate severity. Broad-spectrum antibiotic suppression of vitamin K-producing gut flora reduces v

  ›
• A

  amoxicillin-clavulanic-acid and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Amoxicillin Clavulanic Acid and Warfarin: moderate severity. Broad-spectrum antibiotic therapy may reduce intestinal vitamin K production

  ›
• A

  amphotericin-b and ciclosporin: Interaction, Risks, and Safer Alternatives

  Interaction between Amphotericin B and Ciclosporin: major severity. Both agents cause dose-dependent nephrotoxicity through afferent arteriolar vaso

  ›
• A

  amphotericin-b and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Amphotericin B and Digoxin: moderate severity. Amphotericin B can cause renal potassium and magnesium loss, increasing myocardi

  ›
• A

  amphotericin-b and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Amphotericin B and Furosemide: moderate severity. Both agents promote renal potassium and magnesium loss, producing additive hypok

  ›
• A

  amphotericin-b and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Amphotericin B and Tacrolimus: major severity. Both agents cause direct nephrotoxicity through afferent arteriolar vasoconstric

  ›
• A

  apalutamide and apixaban: Interaction, Risks, and Safer Alternatives

  Interaction between Apalutamide and Apixaban: major severity. Apalutamide strongly induces CYP3A4 and induces P-glycoprotein, potentially lowe

  ›
• A

  apixaban and aspirin: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Aspirin: moderate severity. Apixaban inhibits factor Xa while aspirin irreversibly inhibits platelet COX-1,

  ›
• A

  apixaban and carbamazepine: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Carbamazepine: major severity. Carbamazepine induces CYP3A4 and P-glycoprotein, reducing apixaban plasma concen

  ›
• A

  apixaban and clarithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Clarithromycin: major severity. Clarithromycin is a strong CYP3A4 and P-glycoprotein inhibitor, increasing apixa

  ›
• A

  apixaban and dexamethasone: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Dexamethasone: moderate severity. Prolonged or high-dose dexamethasone can induce CYP3A4 and P-glycoprotein, poten

  ›
• A

  apixaban and diclofenac: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Diclofenac: moderate severity. Apixaban inhibits factor Xa, while diclofenac inhibits cyclooxygenase-dependent

  ›
• A

  apixaban and diltiazem: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Diltiazem: moderate severity. Diltiazem moderately inhibits CYP3A4 and P-glycoprotein, raising apixaban plasma

  ›
• A

  apixaban and enzalutamide: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Enzalutamide: major severity. Enzalutamide strongly induces CYP3A4 and can substantially reduce exposure to ap

  ›
• A

  apixaban and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Fluconazole: moderate severity. Fluconazole inhibits CYP3A4 and may inhibit P-glycoprotein, increasing apixaban

  ›
• A

  apixaban and ibrutinib: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Ibrutinib: major severity. Ibrutinib impairs platelet signalling through Bruton's tyrosine kinase inhibitio

  ›
• A

  apixaban and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Ibuprofen: moderate severity. Ibuprofen inhibits platelet function and can damage gastrointestinal mucosa, pro

  ›
• A

  apixaban and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Itraconazole: major severity. Itraconazole is a strong inhibitor of both CYP3A4 and P-glycoprotein, leading to

  ›
• A

  apixaban and ketoconazole: Interaction, Risks, and Safer

  Interaction between Apixaban and Ketoconazole: major severity. Ketoconazole is a strong dual inhibitor of CYP3A4 and P-glycoprotein, doubling a

  ›
• A

  apixaban and naproxen: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Naproxen: moderate severity. Naproxen increases gastrointestinal bleeding risk through COX inhibition and muc

  ›
• A

  apixaban and rifampicin: Interaction, Risks, and Safer

  Interaction between Apixaban and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and P-glycoprotein, reducing apixaban exposur

  ›
• A

  apixaban and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Ritonavir: major severity. Ritonavir strongly inhibits CYP3A4 and P-glycoprotein, both important for apixab

  ›
• A

  apixaban and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Sertraline: moderate severity. Sertraline impairs platelet serotonin uptake, reducing platelet aggregation, whi

  ›
• A

  apixaban and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Apixaban and Verapamil: moderate severity. Verapamil inhibits P-glycoprotein and CYP3A4, which can reduce apixaban eliminat

  ›
• A

  apomorphine and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Apomorphine and Ondansetron: major severity. Concomitant use can cause profound hypotension and loss of consciousness, likely

  ›
• A

  aprepitant and dexamethasone: Interaction, Risks, and Safer Alternatives

  Interaction between Aprepitant and Dexamethasone: moderate severity. Aprepitant is a moderate CYP3A4 inhibitor and increases dexamethasone plasma con

  ›
• A

  ascorbic-acid and ferrous-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Ascorbic Acid and Ferrous Sulfate: minor severity. Ascorbic acid reduces ferric iron to the more absorbable ferrous form and can in

  ›
• A

  aspirin and atenolol: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Atenolol: minor severity. Analgesic or anti-inflammatory doses of aspirin can inhibit renal prostaglandin

  ›
• A

  aspirin and caffeine: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Caffeine: minor severity. Caffeine can accelerate gastrointestinal absorption of aspirin and provides addi

  ›
• A

  aspirin and clopidogrel: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Clopidogrel: moderate severity. Both drugs inhibit platelet function through complementary pathways: aspirin inh

  ›
• A

  aspirin and enalapril: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Enalapril: minor severity. Cyclooxygenase inhibition by aspirin can reduce renal prostaglandin synthesis an

  ›
• A

  aspirin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Furosemide: minor severity. Aspirin inhibits renal cyclooxygenase and prostaglandin synthesis, which can mod

  ›
• A

  aspirin and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Lisinopril: minor severity. Cyclooxygenase inhibition can reduce renal vasodilatory prostaglandins, potentia

  ›
• A

  aspirin and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Methotrexate: major severity. Aspirin and other NSAIDs reduce renal clearance of methotrexate by inhibiting tu

  ›
• A

  aspirin and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Metoprolol: minor severity. Regular anti-inflammatory doses of aspirin inhibit renal prostaglandin synthesis

  ›
• A

  aspirin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Prednisolone: moderate severity. Aspirin inhibits platelet aggregation and damages gastrointestinal mucosa, while

  ›
• A

  aspirin and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Ramipril: minor severity. High-dose aspirin inhibits cyclo-oxygenase-mediated renal prostaglandin synthesi

  ›
• A

  aspirin and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Rivaroxaban: moderate severity. Aspirin irreversibly inhibits platelet COX-1, while rivaroxaban inhibits factor

  ›
• A

  aspirin and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Aspirin and Sertraline: moderate severity. Sertraline inhibits platelet serotonin uptake, reducing platelet aggregation, wh

  ›
• A

  atazanavir and esomeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Atazanavir and Esomeprazole: major severity. Proton pump inhibitors raise gastric pH, reducing the dissolution and absorption

  ›
• A

  atazanavir and omeprazole: Interaction, Risks, and Safer

  Interaction between Atazanavir and Omeprazole: major severity. Proton pump inhibitors raise gastric pH, substantially reducing the dissolution

  ›
• A

  atazanavir and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Atazanavir and Pantoprazole: major severity. Proton-pump inhibitors raise gastric pH and reduce dissolution of atazanavir, de

  ›
• A

  atenolol and calcium-carbonate: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Calcium Carbonate: minor severity. Calcium salts may reduce gastrointestinal absorption of atenolol through physico

  ›
• A

  atenolol and clonidine: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Clonidine: moderate severity. Unopposed alpha-adrenergic activity from circulating catecholamines after abrupt

  ›
• A

  atenolol and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Digoxin: moderate severity. Both drugs suppress atrioventricular nodal conduction and reduce heart rate, pro

  ›
• A

  atenolol and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Ibuprofen: minor severity. Ibuprofen inhibits renal prostaglandin synthesis, which can blunt the antihypert

  ›
• A

  atenolol and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Insulin: moderate severity. Beta-blockade can mask adrenergic warning symptoms of hypoglycaemia, such as tre

  ›
• A

  atenolol and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Sildenafil: minor severity. Beta1-adrenoceptor blockade and PDE5-mediated vasodilation can produce a small a

  ›
• A

  atenolol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Atenolol and Verapamil: major severity. Both drugs depress sinoatrial and atrioventricular nodal conduction and reduce m

  ›
• A

  atomoxetine and fluoxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Atomoxetine and Fluoxetine: moderate severity. Fluoxetine inhibits CYP2D6, the main enzyme metabolizing atomoxetine, increasing

  ›
• A

  atomoxetine and paroxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Atomoxetine and Paroxetine: moderate severity. Paroxetine is a potent CYP2D6 inhibitor that increases atomoxetine plasma levels

  ›
• A

  atorvastatin and azithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Azithromycin: minor severity. Azithromycin has little CYP3A4 inhibition, but rare transporter-mediated increas

  ›
• A

  atorvastatin and ciclosporin: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Ciclosporin: major severity. Ciclosporin inhibits OATP1B1 and CYP3A4, markedly increasing atorvastatin plasma

  ›
• A

  atorvastatin and clarithromycin: Interaction, Risks, and Safer

  Interaction between Atorvastatin and Clarithromycin: major severity. Clarithromycin inhibits CYP3A4-mediated atorvastatin metabolism, increasing plas

  ›
• A

  atorvastatin and colestyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Colestyramine: minor severity. Colestyramine can bind atorvastatin in the gastrointestinal tract and reduce or

  ›
• A

  atorvastatin and cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Cyclosporine: major severity. Cyclosporine inhibits OATP1B1 uptake and CYP3A4 metabolism of atorvastatin, incr

  ›
• A

  atorvastatin and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Digoxin: minor severity. Atorvastatin may modestly inhibit intestinal P-glycoprotein, increasing digoxin

  ›
• A

  atorvastatin and diltiazem: Interaction, Risks, and Safer

  Interaction between Atorvastatin and Diltiazem: moderate severity. Diltiazem inhibits CYP3A4, increasing atorvastatin exposure approximately 50% wi

  ›
• A

  atorvastatin and ezetimibe: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Ezetimibe: minor severity. Both drugs reduce cholesterol through complementary pathways, but their combined

  ›
• A

  atorvastatin and fusidic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Fusidic Acid: major severity. Systemic fusidic acid inhibits CYP3A4 and OATP1B1 transport of atorvastatin, lea

  ›
• A

  atorvastatin and gemfibrozil: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Gemfibrozil: major severity. Gemfibrozil inhibits OATP1B1 hepatic uptake and CYP2C8/glucuronidation of statin

  ›
• A

  atorvastatin and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Grapefruit Juice: moderate severity. Grapefruit juice inhibits intestinal CYP3A4 and can increase atorvastatin bioava

  ›
• A

  atorvastatin and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Itraconazole: major severity. Itraconazole is a strong CYP3A4 inhibitor and reduces metabolism of atorvastatin

  ›
• A

  atorvastatin and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Rifampicin: moderate severity. Rifampicin is a potent inducer of CYP3A4 and OATP1B1, reducing atorvastatin AUC

  ›
• A

  atorvastatin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, raising atorvastatin exposure appr

  ›
• A

  atorvastatin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Atorvastatin and Warfarin: minor severity. Atorvastatin may produce a small increase in anticoagulant effect, possibly thro

  ›
• A

  atovaquone and metoclopramide: Interaction, Risks, and Safer Alternatives

  Interaction between Atovaquone and Metoclopramide: moderate severity. Metoclopramide can reduce plasma atovaquone concentrations, probably by altering

  ›
• A

  atropine and donepezil: Interaction, Risks, and Safer Alternatives

  Interaction between Atropine and Donepezil: moderate severity. Atropine antagonises muscarinic acetylcholine receptors, pharmacodynamically opp

  ›
• A

  atropine and oxybutynin: Interaction, Risks, and Safer Alternatives

  Interaction between Atropine and Oxybutynin: moderate severity. Both drugs antagonize muscarinic acetylcholine receptors, producing additive ant

  ›
• A

  azathioprine and febuxostat: Interaction, Risks, and Safer Alternatives

  Interaction between Azathioprine and Febuxostat: major severity. Febuxostat inhibits xanthine oxidase, the enzyme that inactivates azathioprine's

  ›
• A

  azathioprine and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Azathioprine and Trimethoprim Sulfamethoxazole: moderate severity. Both drugs can suppress bone marrow; trimethoprim also has antifolate

  ›
• A

  azithromycin and citalopram: Interaction, Risks, and Safer

  Interaction between Azithromycin and Citalopram: moderate severity. Both agents prolong the QT interval through delayed cardiac repolarization, prod

  ›
• A

  azithromycin and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Digoxin: moderate severity. Azithromycin disrupts intestinal flora that metabolize digoxin (Eggerthella lent

  ›
• A

  azithromycin and domperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Domperidone: major severity. Both drugs can prolong cardiac repolarization through effects on cardiac potassi

  ›
• A

  azithromycin and escitalopram: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Escitalopram: moderate severity. Both drugs can prolong cardiac repolarization through effects on ventricular pot

  ›
• A

  azithromycin and haloperidol: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Haloperidol: moderate severity. Azithromycin and haloperidol can both prolong the QT interval via effects on car

  ›
• A

  azithromycin and hydroxychloroquine: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Hydroxychloroquine: major severity. Both drugs block hERG potassium channels and prolong the QT interval; combined u

  ›
• A

  azithromycin and magnesium-hydroxide: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Magnesium Hydroxide: minor severity. Magnesium-containing antacids can reduce the peak plasma concentration of azithr

  ›
• A

  azithromycin and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Ondansetron: moderate severity. Both drugs prolong the QT interval through hERG potassium channel blockade, with

  ›
• A

  azithromycin and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Quetiapine: moderate severity. Both drugs can prolong cardiac repolarization through effects on cardiac potassi

  ›
• A

  azithromycin and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Sotalol: major severity. Both agents prolong the QT interval through blockade of the hERG potassium chann

  ›
• A

  azithromycin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Azithromycin and Warfarin: moderate severity. Azithromycin may alter gut flora that synthesize vitamin K and possibly displace

  ›
• A

  azole-antifungal and midazolam: Interaction, Risks, and Safer Alternatives

  Interaction between Azole Antifungal and Midazolam: major severity. Itraconazole, ketoconazole, and voriconazole are potent CYP3A4 inhibitors that b

  ›
• A

  azole-antifungal and tacrolimus: Interaction, Risks, and Safer

  Interaction between Azole Antifungal and Tacrolimus: major severity. Azole antifungals (fluconazole, voriconazole, itraconazole) potently inhibit CYP

  ›
• B

  baclofen and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Baclofen and Morphine: moderate severity. Additive CNS depression and respiratory depression through GABA-B agonism and mu

  ›
• B

  benzodiazepines and opioids: Interaction, Risks, and Safer Alternatives

  Interaction between Benzodiazepines and Opioids: major severity. Benzodiazepines enhance GABA-A receptor-mediated CNS depression, while opioids a

  ›
• B

  benzylpenicillin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Benzylpenicillin and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters, reducing tubular secretion

  ›
• B

  beta-blockers and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Beta Blockers and Verapamil: major severity. Both agents have negative inotropic and chronotropic effects on the heart and ad

  ›
• B

  bictegravir and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Bictegravir and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and UGT1A1, markedly lowering bictegravir con

  ›
• B

  bisoprolol and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Digoxin: moderate severity. Bisoprolol suppresses sinoatrial activity and atrioventricular conduction throug

  ›
• B

  bisoprolol and diltiazem: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Diltiazem: moderate severity. Bisoprolol reduces sympathetic cardiac stimulation, while diltiazem slows atriov

  ›
• B

  bisoprolol and glimepiride: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Glimepiride: moderate severity. Beta-adrenoceptor blockade can mask adrenergic warning signs of sulfonylurea-ind

  ›
• B

  bisoprolol and insulin-aspart: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Insulin Aspart: moderate severity. Beta-adrenoceptor blockade can mask adrenergic warning signs of hypoglycaemia, p

  ›
• B

  bisoprolol and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Insulin: moderate severity. Beta-adrenoceptor blockade can mask adrenergic warning signs of hypoglycaemia an

  ›
• B

  bisoprolol and salbutamol: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Salbutamol: minor severity. Beta-blockade can pharmacodynamically oppose beta-2 agonist bronchodilation, alt

  ›
• B

  bisoprolol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Bisoprolol and Verapamil: major severity. Beta-blockers and verapamil both depress atrioventricular nodal conduction and m

  ›
• B

  bosentan and cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Bosentan and Cyclosporine: major severity. Cyclosporine inhibits hepatic uptake and CYP3A4-mediated clearance of bosentan,

  ›
• B

  brivudine and fluorouracil: Interaction, Risks, and Safer Alternatives

  Interaction between Brivudine and Fluorouracil: major severity. A brivudine metabolite irreversibly inhibits dihydropyrimidine dehydrogenase, pr

  ›
• B

  budesonide and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Budesonide and Itraconazole: moderate severity. Itraconazole strongly inhibits CYP3A4-mediated budesonide metabolism, increasing

  ›
• B

  buprenorphine and diazepam: Interaction, Risks, and Safer Alternatives

  Interaction between Buprenorphine and Diazepam: major severity. Additive CNS depression and respiratory depression through opioid mu-receptor ag

  ›
• B

  bupropion and codeine: Interaction, Risks, and Safer Alternatives

  Interaction between Bupropion and Codeine: moderate severity. Bupropion strongly inhibits CYP2D6, reducing conversion of codeine to its active

  ›
• B

  bupropion and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Bupropion and Metoprolol: moderate severity. Bupropion is a potent CYP2D6 inhibitor and reduces metabolism of metoprolol, inc

  ›
• B

  bupropion and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Bupropion and Tamoxifen: major severity. Bupropion is a strong CYP2D6 inhibitor that blocks conversion of tamoxifen to it

  ›
• B

  bupropion and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Bupropion and Tramadol: moderate severity. Bupropion inhibits CYP2D6, which can reduce formation of tramadol's active opioi

  ›
• C

  caffeine and ciprofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Ciprofloxacin: minor severity. Ciprofloxacin inhibits CYP1A2, which can reduce caffeine clearance and increase

  ›
• C

  caffeine and clozapine: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Clozapine: moderate severity. Caffeine and clozapine share CYP1A2-dependent metabolism, and high or abruptly c

  ›
• C

  caffeine and ethinyl-estradiol: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Ethinyl Estradiol: minor severity. Ethinyl estradiol can inhibit CYP1A2-mediated caffeine metabolism, modestly prol

  ›
• C

  caffeine and ethinylestradiol: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Ethinylestradiol: minor severity. Ethinylestradiol can inhibit CYP1A2-mediated caffeine clearance, modestly prolon

  ›
• C

  caffeine and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Paracetamol: minor severity. Caffeine can accelerate gastrointestinal absorption of paracetamol and enhance i

  ›
• C

  caffeine and theophylline: Interaction, Risks, and Safer Alternatives

  Interaction between Caffeine and Theophylline: moderate severity. Both substances are methylxanthines with additive adenosine-receptor antagonism

  ›
• C

  calcium and ciprofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium and Ciprofloxacin: moderate severity. Divalent cations such as calcium chelate fluoroquinolones in the gut, reducing c

  ›
• C

  calcium-carbonate and ceftriaxone: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Ceftriaxone: major severity. Ceftriaxone forms insoluble calcium-ceftriaxone precipitates in the lungs and ki

  ›
• C

  calcium-carbonate and ciprofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Ciprofloxacin: moderate severity. Divalent calcium cations chelate with the fluoroquinolone in the gut lumen, form

  ›
• C

  calcium-carbonate and dolutegravir: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Dolutegravir: moderate severity. Calcium forms poorly absorbed chelation complexes with dolutegravir in the gastr

  ›
• C

  calcium-carbonate and doxycycline: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Doxycycline: moderate severity. Divalent calcium cations chelate doxycycline in the gut, forming insoluble compl

  ›
• C

  calcium-carbonate and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Hydrochlorothiazide: minor severity. Hydrochlorothiazide reduces renal calcium excretion, while calcium carbonate i

  ›
• C

  calcium-carbonate and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Levofloxacin: moderate severity. Calcium chelates levofloxacin in the gut, reducing fluoroquinolone absorption an

  ›
• C

  calcium-carbonate and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Levothyroxine: moderate severity. Calcium carbonate chelates levothyroxine in the gut, reducing its absorption and

  ›
• C

  calcium-carbonate and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Pantoprazole: minor severity. Pantoprazole inhibits the gastric H+/K+-ATPase and raises gastric pH, which can

  ›
• C

  calcium-carbonate and thyroid-hormone: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Thyroid Hormone: moderate severity. Calcium carbonate binds levothyroxine in the gastrointestinal tract, forming in

  ›
• C

  calcium-carbonate and thyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Carbonate and Thyroxine: moderate severity. Calcium carbonate forms an insoluble chelate with levothyroxine in the gut, redu

  ›
• C

  calcium-channel-blocker and beta-blocker: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Channel Blocker and Beta Blocker: moderate severity. Combined non-dihydropyridine CCBs (verapamil, diltiazem) plus beta-blocker r

  ›
• C

  calcium-containing-iv-solutions and ceftriaxone: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Containing Iv Solutions and Ceftriaxone: major severity. Ceftriaxone forms insoluble calcium-ceftriaxone precipitates in the lung

  ›
• C

  calcium-gluconate and ceftriaxone: Interaction, Risks, and Safer Alternatives

  Interaction between Calcium Gluconate and Ceftriaxone: major severity. Ceftriaxone forms insoluble calcium-ceftriaxone precipitates in lung and kidney

  ›
• C

  canagliflozin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Canagliflozin and Furosemide: moderate severity. Canagliflozin causes osmotic diuresis through SGLT2 inhibition, while furosemide

  ›
• C

  candesartan and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Candesartan and Spironolactone: moderate severity. ARBs reduce aldosterone-mediated potassium excretion and spironolactone blocks t

  ›
• C

  capecitabine and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Capecitabine and Phenytoin: moderate severity. Capecitabine or its fluorouracil metabolites can inhibit CYP2C9-mediated phenyto

  ›
• C

  capecitabine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Capecitabine and Warfarin: major severity. Capecitabine and its metabolite 5-FU inhibit CYP2C9-mediated warfarin metabolism

  ›
• C

  captopril and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Captopril and Lithium: major severity. ACE inhibitors reduce renal sodium availability and glomerular filtration, decre

  ›
• C

  captopril and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Captopril and Potassium Chloride: major severity. ACE inhibition reduces aldosterone-mediated renal potassium excretion; concomita

  ›
• C

  captopril and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Captopril and Spironolactone: moderate severity. ACE inhibition reduces aldosterone-driven potassium excretion, while spironolact

  ›
• C

  carbamazepine and clarithromycin: Interaction, Risks, and Safer

  Interaction between Carbamazepine and Clarithromycin: major severity. Clarithromycin is a potent CYP3A4 inhibitor that reduces carbamazepine clearance

  ›
• C

  carbamazepine and clozapine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Clozapine: major severity. Carbamazepine induces CYP1A2 and CYP3A4, lowering clozapine levels and reducing

  ›
• C

  carbamazepine and combined-oral-contraceptive: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Combined Oral Contraceptive: major severity. Carbamazepine is a potent inducer of CYP3A4 and UGT, accelerating ethinyle

  ›
• C

  carbamazepine and combined-oral-contraceptives: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Combined Oral Contraceptives: major severity. Carbamazepine induces CYP3A4 and UGT enzymes, increasing estrogen and pro

  ›
• C

  carbamazepine and doxycycline: Interaction, Risks, and Safer

  Interaction between Carbamazepine and Doxycycline: moderate severity. Carbamazepine induces hepatic CYP3A4, accelerating doxycycline metabolism and re

  ›
• C

  carbamazepine and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Erythromycin: major severity. Erythromycin is a potent CYP3A4 inhibitor that markedly reduces carbamazepine cl

  ›
• C

  carbamazepine and ethinyl-estradiol: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Ethinyl Estradiol: major severity. Carbamazepine induces CYP3A4 and UGT enzymes, increasing metabolism of ethinyl e

  ›
• C

  carbamazepine and ethinylestradiol-levonorgestrel: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Ethinylestradiol Levonorgestrel: major severity. Carbamazepine induces CYP3A4 and glucuronidation pathways, acceleratin

  ›
• C

  carbamazepine and ethinylestradiol: Interaction, Risks, and Safer

  Interaction between Carbamazepine and Ethinylestradiol: major severity. Carbamazepine is a strong inducer of CYP3A4 and UGT enzymes, accelerating metabo

  ›
• C

  carbamazepine and etinylestradiol: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Etinylestradiol: major severity. Carbamazepine induces CYP3A4 and UGT enzymes, increasing metabolism of ethinyles

  ›
• C

  carbamazepine and fluvoxamine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Fluvoxamine: moderate severity. Fluvoxamine inhibits CYP3A4 and CYP1A2, decreasing carbamazepine clearance and r

  ›
• C

  carbamazepine and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Lamotrigine: moderate severity. Carbamazepine induces UGT1A4 glucuronidation of lamotrigine, reducing lamotrigin

  ›
• C

  carbamazepine and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Levothyroxine: moderate severity. Carbamazepine induces hepatic drug-metabolizing enzymes, accelerating thyroid-ho

  ›
• C

  carbamazepine and norethisterone: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Norethisterone: major severity. Carbamazepine induces CYP3A4, increasing metabolism of progestins such as noreth

  ›
• C

  carbamazepine and olanzapine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Olanzapine: moderate severity. Carbamazepine induces CYP1A2 and CYP3A4, increasing olanzapine clearance and red

  ›
• C

  carbamazepine and oral-contraceptive: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Oral Contraceptive: major severity. Carbamazepine induces CYP3A4 and UGT enzymes, increasing metabolism of ethinyles

  ›
• C

  carbamazepine and oral-contraceptives: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Oral Contraceptives: major severity. Carbamazepine induces CYP3A4, increasing metabolism of ethinylestradiol and prog

  ›
• C

  carbamazepine and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Quetiapine: major severity. Carbamazepine strongly induces CYP3A4, the main metabolic pathway for quetiapine

  ›
• C

  carbamazepine and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Rivaroxaban: major severity. Carbamazepine induces both CYP3A4 and P-glycoprotein, reducing rivaroxaban expos

  ›
• C

  carbamazepine and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Sertraline: moderate severity. Carbamazepine induces hepatic CYP enzymes and may reduce sertraline exposure, wh

  ›
• C

  carbamazepine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Simvastatin: moderate severity. Carbamazepine induces CYP3A4, accelerating simvastatin metabolism and reducing p

  ›
• C

  carbamazepine and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Tacrolimus: major severity. Carbamazepine induces CYP3A4 and reduces tacrolimus exposure, risking subtherape

  ›
• C

  carbamazepine and ticagrelor: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Ticagrelor: major severity. Carbamazepine strongly induces CYP3A4, reducing exposure to ticagrelor and its a

  ›
• C

  carbamazepine and valproate: Interaction, Risks, and Safer

  Interaction between Carbamazepine and Valproate: moderate severity. Carbamazepine induces CYP2C9 and UGT enzymes that metabolize valproate, reducing

  ›
• C

  carbamazepine and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Valproic Acid: moderate severity. Carbamazepine induces CYP enzymes that metabolize valproic acid (lowering valpro

  ›
• C

  carbamazepine and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Carbamazepine and Voriconazole: major severity. Carbamazepine strongly induces CYP3A4 and CYP2C19, reducing voriconazole concent

  ›
• C

  carbamazepine and warfarin: Interaction, Risks, and Safer

  Interaction between Carbamazepine and Warfarin: major severity. Carbamazepine is a potent inducer of CYP2C9 and CYP3A4, accelerating warfarin me

  ›
• C

  carbapenem and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Carbapenem and Valproate: major severity. Carbapenems (meropenem, imipenem, ertapenem) inhibit valproate glucuronide hydro

  ›
• C

  carbapenems and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Carbapenems and Valproate: major severity. Carbapenems (meropenem, imipenem, ertapenem) reduce valproate serum levels by 60

  ›
• C

  carbidopa-levodopa and ferrous-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Carbidopa Levodopa and Ferrous Sulfate: moderate severity. Iron salts chelate levodopa and carbidopa in the gastrointestinal tract, reduc

  ›
• C

  carbidopa-levodopa and iron-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Carbidopa Levodopa and Iron Sulfate: moderate severity. Ferrous iron chelates levodopa and carbidopa in the gastrointestinal tract, redu

  ›
• C

  carbidopa-levodopa and metoclopramide: Interaction, Risks, and Safer Alternatives

  Interaction between Carbidopa Levodopa and Metoclopramide: major severity. Metoclopramide is a central dopamine D2 receptor antagonist that opposes levodop

  ›
• C

  carvedilol and ciclosporin: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Ciclosporin: moderate severity. Carvedilol inhibits P-glycoprotein-mediated efflux of ciclosporin, raising ciclo

  ›
• C

  carvedilol and clonidine: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Clonidine: moderate severity. Beta-blockade with carvedilol unopposes alpha-adrenergic activity if clonidine i

  ›
• C

  carvedilol and cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Cyclosporine: moderate severity. Carvedilol inhibits P-glycoprotein-mediated efflux of cyclosporine, increasing c

  ›
• C

  carvedilol and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Digoxin: moderate severity. Carvedilol inhibits P-glycoprotein-mediated digoxin elimination and adds negativ

  ›
• C

  carvedilol and fingolimod: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Fingolimod: major severity. Fingolimod causes negative chronotropic effects through S1P1 receptor modulation

  ›
• C

  carvedilol and fluoxetine: Interaction, Risks, and Safer

  Interaction between Carvedilol and Fluoxetine: moderate severity. Fluoxetine inhibits CYP2D6, the main enzyme for carvedilol metabolism, raising p

  ›
• C

  carvedilol and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Insulin: moderate severity. Non-selective beta-blockade by carvedilol blunts adrenergic warning signs of hyp

  ›
• C

  carvedilol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Carvedilol and Verapamil: major severity. Both agents have negative inotropic, chronotropic, and dromotropic effects on th

  ›
• C

  cefalexin and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Cefalexin and Metformin: minor severity. Cefalexin can reduce the renal tubular secretion of metformin, modestly increasi

  ›
• C

  cefalexin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Cefalexin and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters responsible for tubular sec

  ›
• C

  cefotaxime and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Cefotaxime and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters responsible for tubular sec

  ›
• C

  ceftriaxone and ringer-lactate: Interaction, Risks, and Safer Alternatives

  Interaction between Ceftriaxone and Ringer Lactate: major severity. Ceftriaxone forms insoluble calcium-ceftriaxone precipitates with calcium-contai

  ›
• C

  ceftriaxone and ringers-lactate: Interaction, Risks, and Safer Alternatives

  Interaction between Ceftriaxone and Ringers Lactate: major severity. Ceftriaxone forms insoluble calcium-ceftriaxone precipitates with calcium-contai

  ›
• C

  ceftriaxone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ceftriaxone and Warfarin: moderate severity. Ceftriaxone disrupts gut flora that synthesise vitamin K2 and may also displace

  ›
• C

  celecoxib and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Celecoxib and Fluconazole: moderate severity. Fluconazole inhibits CYP2C9, the primary enzyme metabolising celecoxib, approxim

  ›
• C

  celecoxib and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Celecoxib and Lithium: moderate severity. Celecoxib can reduce renal prostaglandin synthesis, lowering renal lithium clear

  ›
• C

  celecoxib and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Celecoxib and Warfarin: moderate severity. Celecoxib may increase bleeding risk through gastrointestinal mucosal injury and

  ›
• C

  cephalexin and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Cephalexin and Metformin: minor severity. Cephalexin can reduce the renal tubular secretion of metformin, producing a mode

  ›
• C

  cetirizine and diazepam: Interaction, Risks, and Safer Alternatives

  Interaction between Cetirizine and Diazepam: minor severity. Cetirizine and diazepam can produce additive central nervous system depression t

  ›
• C

  cetirizine and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Cetirizine and Zolpidem: minor severity. Both drugs can produce central nervous system depression through sedative pharma

  ›
• C

  chloramphenicol and gliclazide: Interaction, Risks, and Safer Alternatives

  Interaction between Chloramphenicol and Gliclazide: moderate severity. Chloramphenicol can inhibit hepatic metabolism of sulfonylureas such as gliclazi

  ›
• C

  chloramphenicol and tolbutamide: Interaction, Risks, and Safer Alternatives

  Interaction between Chloramphenicol and Tolbutamide: moderate severity. Chloramphenicol inhibits hepatic metabolism of sulfonylureas such as tolbutamide

  ›
• C

  chlorpromazine and levodopa: Interaction, Risks, and Safer Alternatives

  Interaction between Chlorpromazine and Levodopa: moderate severity. Chlorpromazine antagonizes dopamine D2 receptors, opposing levodopa's dopaminerg

  ›
• C

  cholecalciferol and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Cholecalciferol and Hydrochlorothiazide: minor severity. Cholecalciferol increases intestinal calcium absorption, while hydrochlorothiazi

  ›
• C

  cholestyramine and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Cholestyramine and Digoxin: moderate severity. Cholestyramine binds digoxin in the gut, reducing absorption and disrupting ente

  ›
• C

  cholestyramine and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Cholestyramine and Hydrochlorothiazide: minor severity. Cholestyramine can bind hydrochlorothiazide in the gastrointestinal tract and re

  ›
• C

  cholestyramine and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Cholestyramine and Levothyroxine: moderate severity. Cholestyramine binds levothyroxine in the gut lumen, reducing its absorption by

  ›
• C

  cholestyramine and mycophenolate-mofetil: Interaction, Risks, and Safer Alternatives

  Interaction between Cholestyramine and Mycophenolate Mofetil: moderate severity. Cholestyramine interrupts enterohepatic recirculation of mycophenolic acid b

  ›
• C

  cholestyramine and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Cholestyramine and Paracetamol: minor severity. Cholestyramine can adsorb paracetamol in the gastrointestinal tract, delaying or

  ›
• C

  ciclosporin and clarithromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Clarithromycin: major severity. Clarithromycin inhibits CYP3A4 and P-glycoprotein, substantially increasing cicl

  ›
• C

  ciclosporin and colchicine: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Colchicine: major severity. Ciclosporin inhibits P-glycoprotein and CYP3A4, markedly increasing colchicine e

  ›
• C

  ciclosporin and diltiazem: Interaction, Risks, and Safer

  Interaction between Ciclosporin and Diltiazem: moderate severity. Diltiazem inhibits CYP3A4 and P-glycoprotein, reducing ciclosporin metabolism an

  ›
• C

  ciclosporin and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Erythromycin: moderate severity. Erythromycin inhibits CYP3A4 and P-glycoprotein, increasing ciclosporin exposure

  ›
• C

  ciclosporin and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Fluconazole: moderate severity. Fluconazole inhibits CYP3A4, reducing ciclosporin metabolism. Increased ciclospo

  ›
• C

  ciclosporin and gentamicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Gentamicin: moderate severity. Ciclosporin and gentamicin both have nephrotoxic potential through renal tubular

  ›
• C

  ciclosporin and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Grapefruit Juice: moderate severity. Furanocoumarins in grapefruit juice irreversibly inhibit intestinal CYP3A4, incr

  ›
• C

  ciclosporin and pravastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Pravastatin: major severity. Ciclosporin inhibits OATP1B1-mediated hepatic uptake of pravastatin, increasing

  ›
• C

  ciclosporin and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Rosuvastatin: major severity. Ciclosporin inhibits OATP1B1 and BCRP transporters, dramatically increasing rosu

  ›
• C

  ciclosporin and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Simvastatin: major severity. Ciclosporin inhibits CYP3A4 and OATP1B1, raising simvastatin exposure up to 8-fo

  ›
• C

  ciclosporin and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and St Johns Wort: major severity. St John's wort induces CYP3A4 and P-glycoprotein, substantially reducing ciclosp

  ›
• C

  ciclosporin and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Tacrolimus: major severity. Both drugs inhibit calcineurin and have overlapping nephrotoxic, neurotoxic, and

  ›
• C

  ciclosporin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Ciclosporin and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, increasing ciclosporin concentrati

  ›
• C

  cimetidine and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Cimetidine and Metformin: moderate severity. Cimetidine competes with metformin for renal tubular secretion via the OCT2 tran

  ›
• C

  cimetidine and theophylline: Interaction, Risks, and Safer Alternatives

  Interaction between Cimetidine and Theophylline: moderate severity. Cimetidine inhibits CYP1A2 and CYP3A4, reducing theophylline clearance by 30-40%

  ›
• C

  ciprofloxacin and clozapine: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Clozapine: major severity. Ciprofloxacin inhibits CYP1A2, the primary enzyme metabolising clozapine, leadin

  ›
• C

  ciprofloxacin and duloxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Duloxetine: major severity. Ciprofloxacin strongly inhibits CYP1A2 which is the major metabolic pathway for

  ›
• C

  ciprofloxacin and ferrous-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Ferrous Sulfate: moderate severity. Iron forms insoluble chelates with fluoroquinolones in the gastrointestinal trac

  ›
• C

  ciprofloxacin and glibenclamide: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Glibenclamide: moderate severity. Fluoroquinolones can alter glucose homeostasis, and ciprofloxacin may enhance su

  ›
• C

  ciprofloxacin and insulin-human: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Insulin Human: moderate severity. Fluoroquinolones can disrupt pancreatic beta-cell ATP-sensitive potassium-channe

  ›
• C

  ciprofloxacin and iron-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Iron Sulfate: minor severity. Iron chelates ciprofloxacin in the gastrointestinal tract, reducing fluoroquinol

  ›
• C

  ciprofloxacin and magnesium-hydroxide: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Magnesium Hydroxide: moderate severity. Magnesium-containing antacids chelate ciprofloxacin in the gut and reduce fluor

  ›
• C

  ciprofloxacin and olanzapine: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Olanzapine: moderate severity. Ciprofloxacin is a potent CYP1A2 inhibitor and reduces olanzapine clearance, inc

  ›
• C

  ciprofloxacin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Prednisolone: moderate severity. Fluoroquinolone-associated tendon matrix injury is amplified by systemic cortico

  ›
• C

  ciprofloxacin and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Prednisone: moderate severity. Fluoroquinolone-associated tenocyte injury and collagen degradation are amplifie

  ›
• C

  ciprofloxacin and rasagiline: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Rasagiline: moderate severity. Ciprofloxacin is a potent CYP1A2 inhibitor that reduces the metabolism of rasagi

  ›
• C

  ciprofloxacin and sevelamer: Interaction, Risks, and Safer

  Interaction between Ciprofloxacin and Sevelamer: moderate severity. Sevelamer binds fluoroquinolones in the gastrointestinal tract, reducing oral bi

  ›
• C

  ciprofloxacin and sucralfate: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Sucralfate: moderate severity. Sucralfate contains aluminum which chelates fluoroquinolones in the gut, reducin

  ›
• C

  ciprofloxacin and theophylline: Interaction, Risks, and Safer

  Interaction between Ciprofloxacin and Theophylline: major severity. Ciprofloxacin inhibits CYP1A2-mediated metabolism of theophylline, raising serum

  ›
• C

  ciprofloxacin and tinidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Tinidazole: minor severity. Both agents prolong the QT interval to a minor degree via potassium channel effe

  ›
• C

  ciprofloxacin and tizanidine: Interaction, Risks, and Safer

  Interaction between Ciprofloxacin and Tizanidine: major severity. Ciprofloxacin is a potent CYP1A2 inhibitor, blocking metabolism of tizanidine an

  ›
• C

  ciprofloxacin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ciprofloxacin and Warfarin: moderate severity. Ciprofloxacin inhibits CYP1A2 and CYP3A4 and may disrupt vitamin K-producing gut

  ›
• C

  cisplatin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Cisplatin and Furosemide: moderate severity. Cisplatin and furosemide both cause direct cochlear hair cell damage, producing

  ›
• C

  cisplatin and gentamicin: Interaction, Risks, and Safer Alternatives

  Interaction between Cisplatin and Gentamicin: major severity. Cisplatin and gentamicin both cause renal tubular toxicity, producing additive n

  ›
• C

  cisplatin and paclitaxel: Interaction, Risks, and Safer Alternatives

  Interaction between Cisplatin and Paclitaxel: moderate severity. Administration of cisplatin before paclitaxel reduces paclitaxel clearance and i

  ›
• C

  cisplatin and vancomycin: Interaction, Risks, and Safer Alternatives

  Interaction between Cisplatin and Vancomycin: major severity. Both agents cause direct nephrotoxicity through proximal tubular damage and oxid

  ›
• C

  citalopram and domperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Domperidone: major severity. Both drugs can prolong cardiac repolarization through effects on hERG potassium

  ›
• C

  citalopram and donepezil: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Donepezil: moderate severity. Both drugs can prolong cardiac repolarisation, producing an additive risk of QT

  ›
• C

  citalopram and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Erythromycin: major severity. Both drugs prolong cardiac repolarization through potassium-channel effects, pro

  ›
• C

  citalopram and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Fluconazole: major severity. Fluconazole inhibits CYP2C19, increasing citalopram concentrations. Both drugs c

  ›
• C

  citalopram and haloperidol: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Haloperidol: major severity. Both drugs can prolong cardiac repolarization through effects on cardiac potassi

  ›
• C

  citalopram and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Ibuprofen: moderate severity. Citalopram reduces platelet serotonin uptake and impairs platelet aggregation, w

  ›
• C

  citalopram and linezolid: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Linezolid: major severity. Linezolid is a reversible non-selective monoamine oxidase inhibitor; combination

  ›
• C

  citalopram and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Omeprazole: moderate severity. Omeprazole inhibits CYP2C19, reducing citalopram clearance and increasing plasma

  ›
• C

  citalopram and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Ondansetron: major severity. Both drugs prolong the QT interval through blockade of the hERG potassium channe

  ›
• C

  citalopram and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Sotalol: major severity. Both drugs cause concentration-dependent QT interval prolongation through blocka

  ›
• C

  citalopram and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Citalopram and Tramadol: major severity. Both drugs increase central serotonergic activity (citalopram via SERT inhibitio

  ›
• C

  clarithromycin and colchicine: Interaction, Risks, and Safer

  Interaction between Clarithromycin and Colchicine: major severity. Clarithromycin inhibits CYP3A4 and P-glycoprotein, both responsible for colchici

  ›
• C

  clarithromycin and cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Cyclosporine: major severity. Clarithromycin inhibits CYP3A4 and P-glycoprotein, reducing cyclosporine metabol

  ›
• C

  clarithromycin and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Digoxin: moderate severity. Clarithromycin inhibits intestinal P-glycoprotein and suppresses gut flora that

  ›
• C

  clarithromycin and domperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Domperidone: major severity. Clarithromycin inhibits CYP3A4 and prolongs QT interval, while domperidone is a

  ›
• C

  clarithromycin and eplerenone: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Eplerenone: major severity. Clarithromycin strongly inhibits CYP3A4, the principal metabolic pathway for epl

  ›
• C

  clarithromycin and ergotamine: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Ergotamine: major severity. Strong CYP3A4 inhibition by clarithromycin elevates ergotamine levels causing in

  ›
• C

  clarithromycin and everolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Everolimus: major severity. Clarithromycin strongly inhibits CYP3A4 and P-glycoprotein, markedly increasing

  ›
• C

  clarithromycin and midazolam: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Midazolam: moderate severity. Clarithromycin strongly inhibits CYP3A4, reducing midazolam metabolism and prolo

  ›
• C

  clarithromycin and nifedipine: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Nifedipine: major severity. Clarithromycin inhibits CYP3A4 metabolism of nifedipine, increasing calcium-chan

  ›
• C

  clarithromycin and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Omeprazole: minor severity. Clarithromycin inhibits CYP3A4-mediated omeprazole metabolism, while omeprazole

  ›
• C

  clarithromycin and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Oxycodone: moderate severity. Clarithromycin inhibits CYP3A4-mediated oxycodone metabolism, increasing opioid

  ›
• C

  clarithromycin and palbociclib: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Palbociclib: major severity. Clarithromycin strongly inhibits CYP3A4, the principal pathway for palbociclib m

  ›
• C

  clarithromycin and pimozide: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Pimozide: major severity. Clarithromycin inhibits CYP3A4 metabolism of pimozide, leading to elevated level

  ›
• C

  clarithromycin and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Quetiapine: major severity. Clarithromycin strongly inhibits CYP3A4, the primary enzyme responsible for quet

  ›
• C

  clarithromycin and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Rivaroxaban: moderate severity. Clarithromycin inhibits CYP3A4 and P-glycoprotein, both involved in rivaroxaban

  ›
• C

  clarithromycin and simvastatin: Interaction, Risks, and Safer

  Interaction between Clarithromycin and Simvastatin: major severity. Clarithromycin is a strong CYP3A4 inhibitor that increases simvastatin plasma co

  ›
• C

  clarithromycin and tacrolimus: Interaction, Risks, and Safer

  Interaction between Clarithromycin and Tacrolimus: major severity. Clarithromycin strongly inhibits intestinal and hepatic CYP3A4 metabolism of tac

  ›
• C

  clarithromycin and ticagrelor: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Ticagrelor: major severity. Clarithromycin is a potent CYP3A4 inhibitor that markedly increases ticagrelor e

  ›
• C

  clarithromycin and venetoclax: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Venetoclax: major severity. Clarithromycin strongly inhibits CYP3A4 and P-glycoprotein, markedly increasing

  ›
• C

  clarithromycin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Verapamil: major severity. Clarithromycin inhibits CYP3A4-mediated verapamil metabolism, elevating concentr

  ›
• C

  clarithromycin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Warfarin: major severity. Clarithromycin inhibits CYP3A4 and CYP1A2 metabolism of warfarin and disturbs gu

  ›
• C

  clarithromycin and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Clarithromycin and Zopiclone: moderate severity. Clarithromycin inhibits CYP3A4, reducing zopiclone metabolism and increasing sed

  ›
• C

  clonazepam and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Clonazepam and Morphine: major severity. Clonazepam enhances GABA-A receptor-mediated inhibition, while morphine activate

  ›
• C

  clonazepam and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Clonazepam and Oxycodone: major severity. Clonazepam enhances GABA-A receptor-mediated inhibition, while oxycodone activat

  ›
• C

  clonidine and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Clonidine and Metoprolol: moderate severity. Both drugs suppress sympathetic cardiovascular activity and can cause additive b

  ›
• C

  clopidogrel and esomeprazole: Interaction, Risks, and Safer

  Interaction between Clopidogrel and Esomeprazole: moderate severity. Esomeprazole inhibits CYP2C19, reducing conversion of clopidogrel to its active

  ›
• C

  clopidogrel and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Fluconazole: moderate severity. Fluconazole inhibits CYP2C19, the enzyme required to convert clopidogrel to its

  ›
• C

  clopidogrel and fluoxetine: Interaction, Risks, and Safer

  Interaction between Clopidogrel and Fluoxetine: moderate severity. Fluoxetine inhibits CYP2C19, reducing conversion of clopidogrel to its active me

  ›
• C

  clopidogrel and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Omeprazole: moderate severity. Omeprazole inhibits CYP2C19, reducing conversion of clopidogrel to its active me

  ›
• C

  clopidogrel and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Pantoprazole: minor severity. Pantoprazole has relatively weak CYP2C19 inhibition and may produce a small redu

  ›
• C

  clopidogrel and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Rosuvastatin: moderate severity. Clopidogrel and its acyl glucuronide metabolite inhibit OATP1B1, increasing rosu

  ›
• C

  clopidogrel and ssri: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Ssri: moderate severity. Both increase bleeding risk; SSRI also inhibits CYP2C19 reducing clopidogrel act

  ›
• C

  clopidogrel and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Clopidogrel and Warfarin: major severity. Clopidogrel inhibits platelet P2Y12 signaling while warfarin impairs coagulation

  ›
• C

  clozapine and fluvoxamine: Interaction, Risks, and Safer

  Interaction between Clozapine and Fluvoxamine: major severity. Fluvoxamine potently inhibits CYP1A2, the primary enzyme metabolizing clozapine,

  ›
• C

  clozapine and smoking-cessation: Interaction, Risks, and Safer Alternatives

  Interaction between Clozapine and Smoking Cessation: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, the main enzyme

  ›
• C

  clozapine and smoking-tobacco: Interaction, Risks, and Safer Alternatives

  Interaction between Clozapine and Smoking Tobacco: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, accelerating cl

  ›
• C

  clozapine and smoking: Interaction, Risks, and Safer Alternatives

  Interaction between Clozapine and Smoking: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing clea

  ›
• C

  clozapine and tobacco-smoking: Interaction, Risks, and Safer Alternatives

  Interaction between Clozapine and Tobacco Smoking: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing cloz

  ›
• C

  co-trimoxazole and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Co Trimoxazole and Methotrexate: major severity. Trimethoprim and methotrexate both inhibit folate metabolism, while sulfamethoxa

  ›
• C

  co-trimoxazole and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Co Trimoxazole and Spironolactone: major severity. Trimethoprim inhibits epithelial sodium channels in the distal nephron, producin

  ›
• C

  co-trimoxazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Co Trimoxazole and Warfarin: moderate severity. Sulfamethoxazole inhibits CYP2C9-mediated metabolism of S-warfarin, while antimi

  ›
• C

  codeine and fluoxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Codeine and Fluoxetine: moderate severity. Fluoxetine inhibits CYP2D6, the enzyme that converts codeine to morphine; reduce

  ›
• C

  codeine and paroxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Codeine and Paroxetine: moderate severity. Paroxetine strongly inhibits CYP2D6, which converts codeine to its active metabo

  ›
• C

  colchicine and cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Colchicine and Cyclosporine: major severity. Cyclosporine inhibits both CYP3A4 and P-glycoprotein, dramatically increasing co

  ›
• C

  colchicine and diltiazem: Interaction, Risks, and Safer Alternatives

  Interaction between Colchicine and Diltiazem: major severity. Diltiazem inhibits both CYP3A4 and P-glycoprotein, the two main elimination path

  ›
• C

  colchicine and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Colchicine and Erythromycin: major severity. Erythromycin inhibits CYP3A4 and P-glycoprotein, markedly increasing colchicine

  ›
• C

  colchicine and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Colchicine and Verapamil: major severity. Verapamil inhibits both CYP3A4 and P-glycoprotein, increasing colchicine plasma

  ›
• C

  colecalciferol and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Colecalciferol and Hydrochlorothiazide: minor severity. Colecalciferol increases intestinal calcium absorption, while hydrochlorothiazid

  ›
• C

  colestyramine and digoxin: Interaction, Risks, and Safer Alternatives

  Interaction between Colestyramine and Digoxin: minor severity. Colestyramine binds digoxin in the gut, reducing oral absorption and enterohepat

  ›
• C

  colestyramine and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Colestyramine and Hydrochlorothiazide: minor severity. Colestyramine binds hydrochlorothiazide in the gastrointestinal tract and can mo

  ›
• C

  colestyramine and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Colestyramine and Levothyroxine: moderate severity. Colestyramine binds levothyroxine in the intestine and interrupts its absorption

  ›
• C

  colestyramine and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Colestyramine and Paracetamol: minor severity. Colestyramine can bind or sequester paracetamol in the gastrointestinal tract, r

  ›
• C

  colestyramine and pravastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Colestyramine and Pravastatin: minor severity. Colestyramine can bind pravastatin within the intestine and reduce its absorptio

  ›
• C

  combined-hormonal-contraceptives and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Combined Hormonal Contraceptives and Lamotrigine: moderate severity. Ethinylestradiol induces UGT1A4-mediated lamotrigine glucuronidation

  ›
• C

  combined-hormonal-contraceptives and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Combined Hormonal Contraceptives and Rifampicin: major severity. Rifampicin induces CYP3A4 and UGT enzymes that increase metabolism of es

  ›
• C

  combined-oral-contraceptives and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Combined Oral Contraceptives and Lamotrigine: moderate severity. Ethinylestradiol induces UGT-mediated glucuronidation of lamotrigine, lo

  ›
• C

  contrast-media and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Contrast Media and Metformin: major severity. Iodinated contrast media can cause acute kidney injury which reduces metformin r

  ›
• C

  cotrimoxazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Cotrimoxazole and Warfarin: major severity. Sulfamethoxazole inhibits CYP2C9 and can reduce vitamin K availability through a

  ›
• C

  cyanocobalamin and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyanocobalamin and Metformin: minor severity. Long-term metformin therapy can impair calcium-dependent absorption of the vitam

  ›
• C

  cyanocobalamin and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Cyanocobalamin and Omeprazole: minor severity. Long-term gastric acid suppression by omeprazole can impair the release of prote

  ›
• C

  cyclophosphamide and filgrastim: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclophosphamide and Filgrastim: moderate severity. G-CSF (filgrastim) mobilises proliferating myeloid precursors that are highly se

  ›
• C

  cyclophosphamide and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclophosphamide and Fluconazole: moderate severity. Fluconazole inhibits CYP2C9 and CYP3A4, reducing conversion of cyclophosphamide

  ›
• C

  cyclophosphamide and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclophosphamide and Ondansetron: minor severity. Both drugs can contribute to QT interval prolongation through effects on cardiac

  ›
• C

  cyclophosphamide and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclophosphamide and Warfarin: moderate severity. Cyclophosphamide alters warfarin metabolism via CYP induction effects and chemot

  ›
• C

  cyclosporine and diltiazem: Interaction, Risks, and Safer

  Interaction between Cyclosporine and Diltiazem: moderate severity. Diltiazem inhibits CYP3A4 and P-glycoprotein, increasing cyclosporine exposure a

  ›
• C

  cyclosporine and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Erythromycin: major severity. Erythromycin inhibits CYP3A4 and P-glycoprotein, increasing cyclosporine concent

  ›
• C

  cyclosporine and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Fluconazole: moderate severity. Fluconazole inhibits CYP3A4, decreasing cyclosporine metabolism. Cyclosporine ex

  ›
• C

  cyclosporine and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Grapefruit Juice: moderate severity. Grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein, increasing cyclo

  ›
• C

  cyclosporine and hypericum-perforatum: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Hypericum Perforatum: major severity. Hypericum perforatum induces CYP3A4 and P-glycoprotein, markedly reducing cyclos

  ›
• C

  cyclosporine and pravastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Pravastatin: moderate severity. Cyclosporine inhibits hepatic uptake transporters such as OATP1B1 and efflux tra

  ›
• C

  cyclosporine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and P-glycoprotein, dramatically lowering cyc

  ›
• C

  cyclosporine and rosuvastatin: Interaction, Risks, and Safer

  Interaction between Cyclosporine and Rosuvastatin: major severity. Cyclosporine inhibits OATP1B1 and BCRP transporters, increasing rosuvastatin AUC

  ›
• C

  cyclosporine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Simvastatin: major severity. Cyclosporine inhibits CYP3A4 and OATP1B1 transporters, increasing simvastatin ex

  ›
• C

  cyclosporine and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and St Johns Wort: major severity. St John's wort induces CYP3A4 and P-glycoprotein, increasing cyclosporine metabo

  ›
• C

  cyclosporine and statins: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Statins: major severity. Cyclosporine inhibits OATP1B1 hepatic uptake and CYP3A4 metabolism of most stati

  ›
• C

  cyclosporine and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Tacrolimus: major severity. Both calcineurin inhibitors cause dose-related nephrotoxicity, neurotoxicity, im

  ›
• C

  cyclosporine and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, reducing cyclosporine clearance. C

  ›
• C

  cyclosporine and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Cyclosporine and Voriconazole: major severity. Voriconazole inhibits CYP3A4, reducing cyclosporine metabolism and increasing cy

  ›
• D

  dabigatran and dronedarone: Interaction, Risks, and Safer

  Interaction between Dabigatran and Dronedarone: major severity. Dronedarone inhibits P-glycoprotein, increasing dabigatran plasma concentrations

  ›
• D

  dabigatran and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Dabigatran and Ketoconazole: major severity. Ketoconazole is a strong P-glycoprotein inhibitor that significantly increases d

  ›
• D

  dabigatran and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Dabigatran and Pantoprazole: minor severity. Pantoprazole increases gastric pH and can modestly reduce absorption and systemi

  ›
• D

  dabigatran and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Dabigatran and Rifampicin: major severity. Rifampicin strongly induces intestinal P-glycoprotein, substantially reducing da

  ›
• D

  dabigatran and verapamil: Interaction, Risks, and Safer

  Interaction between Dabigatran and Verapamil: moderate severity. Verapamil inhibits intestinal P-glycoprotein, increasing dabigatran absorption a

  ›
• D

  dabigatran-etexilate and dronedarone: Interaction, Risks, and Safer Alternatives

  Interaction between Dabigatran Etexilate and Dronedarone: major severity. Dronedarone inhibits P-glycoprotein, increasing absorption and systemic exposure

  ›
• D

  dabigatran-etexilate and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Dabigatran Etexilate and Verapamil: moderate severity. Verapamil inhibits intestinal P-glycoprotein, increasing absorption and systemic

  ›
• D

  dapagliflozin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Dapagliflozin and Furosemide: moderate severity. SGLT2 inhibition causes osmotic diuresis, which may add to loop diuretic natriur

  ›
• D

  dapagliflozin and insulin-aspart: Interaction, Risks, and Safer Alternatives

  Interaction between Dapagliflozin and Insulin Aspart: moderate severity. SGLT2-mediated urinary glucose loss adds to insulin-mediated glucose lowering, i

  ›
• D

  daptomycin and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Daptomycin and Simvastatin: moderate severity. Both drugs can independently injure skeletal muscle, producing additive risks of

  ›
• D

  dasatinib and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Dasatinib and Omeprazole: major severity. Omeprazole persistently raises gastric pH, substantially reducing the pH-depende

  ›
• D

  dexamethasone and ibrutinib: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Ibrutinib: moderate severity. Dexamethasone can induce CYP3A4, potentially lowering ibrutinib exposure. Reduce

  ›
• D

  dexamethasone and indinavir: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Indinavir: moderate severity. Dexamethasone induces CYP3A4, which can reduce indinavir concentrations. Lower p

  ›
• D

  dexamethasone and insulin-glargine: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Insulin Glargine: moderate severity. Glucocorticoid-receptor activation increases hepatic glucose production and peri

  ›
• D

  dexamethasone and insulin-human: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Insulin Human: moderate severity. Dexamethasone increases hepatic gluconeogenesis and peripheral insulin resistanc

  ›
• D

  dexamethasone and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Insulin: moderate severity. Dexamethasone promotes hepatic gluconeogenesis and peripheral insulin resistance

  ›
• D

  dexamethasone and nivolumab: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Nivolumab: moderate severity. Systemic corticosteroids such as dexamethasone suppress T-cell activation and in

  ›
• D

  dexamethasone and palbociclib: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Palbociclib: moderate severity. Dexamethasone induces CYP3A4, which is involved in palbociclib metabolism. Induc

  ›
• D

  dexamethasone and paxlovid: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Paxlovid: moderate severity. Ritonavir in paxlovid inhibits CYP3A4, which metabolizes dexamethasone. Increase

  ›
• D

  dexamethasone and pembrolizumab: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Pembrolizumab: moderate severity. Systemic corticosteroids such as dexamethasone suppress T-cell activation and cy

  ›
• D

  dexamethasone and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Phenytoin: moderate severity. Phenytoin induces CYP3A4, increasing dexamethasone metabolism and potentially re

  ›
• D

  dexamethasone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Rifampicin: moderate severity. Rifampicin strongly induces CYP3A4, increasing dexamethasone metabolism and redu

  ›
• D

  dexamethasone and rilpivirine: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Rilpivirine: major severity. Systemic dexamethasone induces CYP3A4, which can reduce rilpivirine concentratio

  ›
• D

  dexamethasone and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Ritonavir: moderate severity. Ritonavir inhibits CYP3A4 and can increase systemic corticosteroid exposure, whi

  ›
• D

  dexamethasone and rivaroxaban: Interaction, Risks, and Safer

  Interaction between Dexamethasone and Rivaroxaban: moderate severity. Dexamethasone is a moderate CYP3A4 and P-glycoprotein inducer that may reduce ri

  ›
• D

  dexamethasone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Dexamethasone and Warfarin: moderate severity. Dexamethasone can alter warfarin response through CYP enzyme effects and changes

  ›
• D

  dextromethorphan and phenelzine: Interaction, Risks, and Safer Alternatives

  Interaction between Dextromethorphan and Phenelzine: major severity. Dextromethorphan inhibits serotonin reuptake, while irreversible monoamine oxida

  ›
• D

  diazepam and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Diazepam and Fluconazole: moderate severity. Fluconazole inhibits CYP2C19 and CYP3A4-mediated diazepam metabolism, increasing

  ›
• D

  diazepam and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Diazepam and Morphine: major severity. Benzodiazepine GABA-A potentiation and opioid mu-receptor agonism produce additi

  ›
• D

  diazepam and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Diazepam and Omeprazole: minor severity. Omeprazole inhibits CYP2C19-mediated diazepam metabolism, which may modestly pro

  ›
• D

  diazepam and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Diazepam and Oxycodone: major severity. Additive CNS and respiratory depression via combined GABA-A potentiation and mu-

  ›
• D

  diazepam and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Diazepam and Zolpidem: minor severity. Both drugs enhance GABA-A receptor-mediated CNS inhibition, producing additive s

  ›
• D

  diclofenac and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Diclofenac and Lisinopril: moderate severity. Diclofenac inhibits renal prostaglandin synthesis, causing afferent arteriolar v

  ›
• D

  diclofenac and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Diclofenac and Lithium: major severity. NSAIDs reduce renal prostaglandin synthesis, decreasing glomerular filtration an

  ›
• D

  diclofenac and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Diclofenac and Methotrexate: major severity. NSAIDs reduce renal perfusion and compete for tubular secretion, decreasing meth

  ›
• D

  diclofenac and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Diclofenac and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, blunting the antihypertensive effe

  ›
• D

  diclofenac and tenofovir-disoproxil: Interaction, Risks, and Safer Alternatives

  Interaction between Diclofenac and Tenofovir Disoproxil: moderate severity. Diclofenac can reduce renal perfusion and may interfere with renal tubular trans

  ›
• D

  digoxin and amiodarone: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Amiodarone: major severity. Amiodarone doubles digoxin levels via P-glycoprotein inhibition.

  ›
• D

  digoxin and dronedarone: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Dronedarone: major severity. Dronedarone inhibits P-glycoprotein-mediated digoxin transport, raising digoxin

  ›
• D

  digoxin and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Erythromycin: moderate severity. Erythromycin inhibits intestinal P-glycoprotein and gut flora that inactivate di

  ›
• D

  digoxin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Furosemide: moderate severity. Furosemide-induced hypokalaemia and hypomagnesaemia sensitise the myocardium to

  ›
• D

  digoxin and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Hydrochlorothiazide: moderate severity. Hydrochlorothiazide can cause hypokalemia and hypomagnesemia, which increase myo

  ›
• D

  digoxin and ispaghula-husk: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Ispaghula Husk: minor severity. Ispaghula husk may adsorb digoxin or alter gastrointestinal transit, modestly re

  ›
• D

  digoxin and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Itraconazole: major severity. Itraconazole inhibits P-glycoprotein-mediated renal tubular secretion of digoxin

  ›
• D

  digoxin and macrogol: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Macrogol: minor severity. Severe diarrhea or rapid gastrointestinal transit from osmotic laxatives can red

  ›
• D

  digoxin and metoclopramide: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Metoclopramide: minor severity. Metoclopramide accelerates gastrointestinal transit and may reduce or make the i

  ›
• D

  digoxin and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Omeprazole: minor severity. Omeprazole may modestly increase digoxin exposure through altered gastric pH and

  ›
• D

  digoxin and psyllium: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Psyllium: minor severity. Psyllium may bind or entrap digoxin in the gastrointestinal tract and reduce or

  ›
• D

  digoxin and quinidine: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Quinidine: major severity. Quinidine inhibits P-glycoprotein-mediated renal tubular and biliary digoxin eli

  ›
• D

  digoxin and senna: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Senna: minor severity. Prolonged or excessive senna use can cause potassium loss, increasing myocardial

  ›
• D

  digoxin and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Spironolactone: moderate severity. Spironolactone inhibits P-glycoprotein-mediated tubular secretion of digoxin and

  ›
• D

  digoxin and sucralfate: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Sucralfate: minor severity. Sucralfate can adsorb digoxin within the gastrointestinal tract and modestly red

  ›
• D

  digoxin and thiazide-diuretic: Interaction, Risks, and Safer

  Interaction between Digoxin and Thiazide Diuretic: moderate severity. Thiazides cause hypokalemia and hypomagnesemia, which sensitize cardiac myocytes

  ›
• D

  digoxin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Digoxin and Verapamil: moderate severity. Verapamil inhibits P-glycoprotein-mediated tubular secretion of digoxin and adds

  ›
• D

  diltiazem and everolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Diltiazem and Everolimus: moderate severity. Diltiazem inhibits CYP3A4 and P-glycoprotein, increasing everolimus AUC roughly

  ›
• D

  diltiazem and ivabradine: Interaction, Risks, and Safer Alternatives

  Interaction between Diltiazem and Ivabradine: major severity. Diltiazem inhibits CYP3A4 metabolism of ivabradine and also slows heart rate ind

  ›
• D

  diltiazem and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Diltiazem and Metoprolol: major severity. Both drugs depress sinoatrial and atrioventricular nodal conduction; diltiazem a

  ›
• D

  diltiazem and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Diltiazem and Rivaroxaban: moderate severity. Diltiazem inhibits CYP3A4 and P-glycoprotein, potentially increasing rivaroxaban

  ›
• D

  diltiazem and simvastatin: Interaction, Risks, and Safer

  Interaction between Diltiazem and Simvastatin: major severity. Diltiazem inhibits CYP3A4 metabolism of simvastatin, increasing exposure and ris

  ›
• D

  diltiazem and tacrolimus: Interaction, Risks, and Safer

  Interaction between Diltiazem and Tacrolimus: moderate severity. Diltiazem inhibits CYP3A4 metabolism of tacrolimus, raising blood concentrations

  ›
• D

  diphenhydramine and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Diphenhydramine and Metoprolol: moderate severity. Diphenhydramine is a moderate CYP2D6 inhibitor that decreases metoprolol metabol

  ›
• D

  diuretic-thiazide and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Diuretic Thiazide and Lithium: major severity. Thiazide diuretics cause sodium depletion, leading to increased proximal tubular

  ›
• D

  dofetilide and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Dofetilide and Hydrochlorothiazide: major severity. Hydrochlorothiazide can inhibit renal cation transport involved in dofetilide cl

  ›
• D

  dofetilide and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Dofetilide and Trimethoprim: major severity. Trimethoprim inhibits renal cation transport involved in dofetilide elimination.

  ›
• D

  dofetilide and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Dofetilide and Verapamil: major severity. Verapamil inhibits renal cation transport involved in dofetilide elimination, in

  ›
• D

  dolutegravir and ferrous-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Dolutegravir and Ferrous Sulfate: moderate severity. Dolutegravir chelates polyvalent iron cations in the gastrointestinal tract, for

  ›
• D

  dolutegravir and magnesium-hydroxide: Interaction, Risks, and Safer Alternatives

  Interaction between Dolutegravir and Magnesium Hydroxide: moderate severity. Magnesium cations chelate dolutegravir in the gastrointestinal tract, substantia

  ›
• D

  dolutegravir and magnesium-oxide: Interaction, Risks, and Safer Alternatives

  Interaction between Dolutegravir and Magnesium Oxide: moderate severity. Magnesium forms poorly absorbed chelation complexes with dolutegravir in the gas

  ›
• D

  dolutegravir and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Dolutegravir and Metformin: moderate severity. Dolutegravir inhibits OCT2 and MATE1 transporters responsible for renal metformi

  ›
• D

  domperidone and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Domperidone and Erythromycin: major severity. Erythromycin inhibits CYP3A4 metabolism of domperidone and independently prolong

  ›
• D

  domperidone and fluconazole: Interaction, Risks, and Safer

  Interaction between Domperidone and Fluconazole: major severity. Fluconazole inhibits CYP3A4, raising domperidone exposure and additive QT-interv

  ›
• D

  domperidone and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Domperidone and Ketoconazole: major severity. Ketoconazole inhibits CYP3A4 metabolism of domperidone, increasing plasma levels

  ›
• D

  donepezil and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Donepezil and Metoprolol: moderate severity. Cholinesterase inhibition by donepezil increases vagal tone, which combined with

  ›
• D

  donepezil and oxybutynin: Interaction, Risks, and Safer Alternatives

  Interaction between Donepezil and Oxybutynin: moderate severity. Donepezil increases central and peripheral acetylcholine via cholinesterase inhi

  ›
• D

  donepezil and succinylcholine: Interaction, Risks, and Safer Alternatives

  Interaction between Donepezil and Succinylcholine: major severity. Donepezil inhibits acetylcholinesterase and pseudocholinesterase, prolonging the

  ›
• D

  doxazosin and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Doxazosin and Sildenafil: moderate severity. Alpha-1 blockade by doxazosin and phosphodiesterase-5 inhibition by sildenafil p

  ›
• D

  doxorubicin and trastuzumab: Interaction, Risks, and Safer Alternatives

  Interaction between Doxorubicin and Trastuzumab: major severity. Both doxorubicin and trastuzumab can impair cardiac function through different c

  ›
• D

  doxycycline and ferrous-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Ferrous Sulfate: moderate severity. Iron salts chelate doxycycline in the gastrointestinal tract, reducing absorptio

  ›
• D

  doxycycline and iron-salts: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Iron Salts: moderate severity. Divalent and trivalent metal cations chelate doxycycline in the gastrointestinal

  ›
• D

  doxycycline and iron-sulfate: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Iron Sulfate: moderate severity. Iron forms non-absorbable chelation complexes with doxycycline in the gastrointe

  ›
• D

  doxycycline and iron: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Iron: moderate severity. Iron salts chelate doxycycline in the gastrointestinal tract, reducing doxycycli

  ›
• D

  doxycycline and isotretinoin: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Isotretinoin: major severity. Tetracyclines and retinoids are each associated with raised intracranial pressur

  ›
• D

  doxycycline and magnesium-hydroxide: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Magnesium Hydroxide: moderate severity. Magnesium forms non-absorbable chelation complexes with doxycycline in the gastr

  ›
• D

  doxycycline and magnesium-oxide: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Magnesium Oxide: moderate severity. Magnesium forms poorly absorbed chelation complexes with doxycycline in the gast

  ›
• D

  doxycycline and magnesium-salts: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Magnesium Salts: moderate severity. Magnesium forms nonabsorbable chelation complexes with doxycycline in the gastro

  ›
• D

  doxycycline and magnesium: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Magnesium: moderate severity. Magnesium forms non-absorbable chelation complexes with doxycycline in the gastr

  ›
• D

  doxycycline and oral-calcium: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Oral Calcium: moderate severity. Calcium salts chelate doxycycline in the gastrointestinal tract, reducing absorp

  ›
• D

  doxycycline and oral-iron: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Oral Iron: minor severity. Iron salts chelate doxycycline in the gastrointestinal tract, reducing doxycycli

  ›
• D

  doxycycline and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Phenytoin: moderate severity. Phenytoin induces hepatic drug-metabolizing enzymes, accelerating doxycycline el

  ›
• D

  doxycycline and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Rifampicin: moderate severity. Rifampicin induces CYP3A4 and other oxidative enzymes that metabolise doxycyclin

  ›
• D

  doxycycline and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Doxycycline and Warfarin: moderate severity. Doxycycline may potentiate warfarin by reducing vitamin K-producing gut flora an

  ›
• D

  dronedarone and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Dronedarone and Rivaroxaban: major severity. Dronedarone inhibits both CYP3A4 and P-glycoprotein, markedly increasing rivarox

  ›
• D

  dronedarone and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Dronedarone and Simvastatin: major severity. Dronedarone inhibits CYP3A4 and OATP1B1, increasing simvastatin exposure and the

  ›
• D

  dulaglutide and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Dulaglutide and Insulin: moderate severity. Dulaglutide enhances glucose-dependent insulin secretion and slows gastric empty

  ›
• D

  duloxetine and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Duloxetine and Ibuprofen: moderate severity. Duloxetine impairs platelet serotonin uptake while ibuprofen inhibits platelet f

  ›
• D

  duloxetine and linezolid: Interaction, Risks, and Safer Alternatives

  Interaction between Duloxetine and Linezolid: major severity. Linezolid is a reversible monoamine oxidase inhibitor; combined with the SNRI du

  ›
• D

  duloxetine and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Duloxetine and Tamoxifen: moderate severity. Duloxetine is a moderate CYP2D6 inhibitor and may reduce conversion of tamoxifen

  ›
• D

  duloxetine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Duloxetine and Tramadol: major severity. Both drugs increase serotonergic activity (duloxetine via SNRI reuptake inhibiti

  ›
• E

  edoxaban and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Edoxaban and Ketoconazole: major severity. Ketoconazole strongly inhibits intestinal P-glycoprotein, increasing edoxaban ab

  ›
• E

  edoxaban and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Edoxaban and Rifampicin: major severity. Rifampicin induces CYP3A4 and P-glycoprotein, reducing edoxaban plasma concentra

  ›
• E

  edoxaban and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Edoxaban and Verapamil: moderate severity. Verapamil inhibits intestinal P-glycoprotein, increasing edoxaban exposure by ap

  ›
• E

  efavirenz and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Efavirenz and Voriconazole: major severity. Efavirenz induces CYP3A4 and can markedly reduce voriconazole exposure, while vo

  ›
• E

  empagliflozin and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Empagliflozin and Furosemide: moderate severity. Combined natriuretic and osmotic diuresis can cause volume depletion, hypotensio

  ›
• E

  empagliflozin and insulin-glargine: Interaction, Risks, and Safer Alternatives

  Interaction between Empagliflozin and Insulin Glargine: moderate severity. Empagliflozin increases urinary glucose excretion, adding to insulin-mediated gl

  ›
• E

  empagliflozin and insulin-human: Interaction, Risks, and Safer Alternatives

  Interaction between Empagliflozin and Insulin Human: moderate severity. Empagliflozin lowers glucose through SGLT2 inhibition, adding to insulin-mediate

  ›
• E

  empagliflozin and insulin: Interaction, Risks, and Safer Alternatives

  Interaction between Empagliflozin and Insulin: moderate severity. Empagliflozin lowers glucose independently of insulin, producing additive glucos

  ›
• E

  enalapril and furosemide: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Furosemide: moderate severity. Loop diuretics can cause volume and sodium depletion, increasing first-dose hypo

  ›
• E

  enalapril and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Ibuprofen: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, reducing the vasodilatory effect o

  ›
• E

  enalapril and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Lithium: moderate severity. ACE inhibitors reduce renal blood flow and aldosterone-mediated sodium excretion

  ›
• E

  enalapril and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Losartan: major severity. Both drugs inhibit the renin-angiotensin-aldosterone system, increasing risk of

  ›
• E

  enalapril and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Potassium Chloride: moderate severity. ACE inhibitors reduce aldosterone secretion, decreasing renal potassium excretio

  ›
• E

  enalapril and sacubitril-valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Sacubitril Valsartan: major severity. Concurrent ACE inhibitor and neprilysin inhibitor use causes additive bradykinin

  ›
• E

  enalapril and sacubitril: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Sacubitril: major severity. Simultaneous ACE and neprilysin inhibition increases bradykinin accumulation and

  ›
• E

  enalapril and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Spironolactone: major severity. Both drugs reduce renal potassium excretion — ACE inhibition lowers aldosterone

  ›
• E

  enalapril and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Trimethoprim Sulfamethoxazole: major severity. Trimethoprim blocks the renal epithelial sodium channel like a potassium-spa

  ›
• E

  enalapril and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Enalapril and Trimethoprim: moderate severity. Trimethoprim reduces renal potassium excretion through an amiloride-like effect

  ›
• E

  enzalutamide and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Enzalutamide and Rivaroxaban: major severity. Enzalutamide strongly induces CYP3A4, increasing rivaroxaban metabolism and pote

  ›
• E

  enzalutamide and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Enzalutamide and Warfarin: major severity. Enzalutamide strongly induces CYP3A4 and induces CYP2C9, increasing warfarin met

  ›
• E

  epinephrine and lidocaine: Interaction, Risks, and Safer Alternatives

  Interaction between Epinephrine and Lidocaine: minor severity. Epinephrine activates local alpha-1 receptors and causes vasoconstriction, slowi

  ›
• E

  epinephrine and propofol: Interaction, Risks, and Safer Alternatives

  Interaction between Epinephrine and Propofol: minor severity. Propofol-induced vasodilation and myocardial depression may attenuate the presso

  ›
• E

  epinephrine and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Epinephrine and Propranolol: major severity. Non-selective beta-blockade leaves alpha-1-mediated vasoconstriction unopposed w

  ›
• E

  epirubicin and trastuzumab: Interaction, Risks, and Safer Alternatives

  Interaction between Epirubicin and Trastuzumab: major severity. Epirubicin causes oxidative and topoisomerase-II-beta-mediated cardiomyocyte inj

  ›
• E

  eplerenone and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Eplerenone and Itraconazole: major severity. Itraconazole strongly inhibits CYP3A4, substantially increasing eplerenone conce

  ›
• E

  eplerenone and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Eplerenone and Ketoconazole: major severity. Ketoconazole strongly inhibits CYP3A4, markedly increasing eplerenone exposure a

  ›
• E

  eplerenone and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Eplerenone and Potassium Chloride: major severity. Eplerenone blocks mineralocorticoid receptors and reduces renal potassium excret

  ›
• E

  ergotamine and erythromycin: Interaction, Risks, and Safer Alternatives

  Interaction between Ergotamine and Erythromycin: major severity. Erythromycin inhibits CYP3A4 metabolism of ergotamine, leading to ergot accumula

  ›
• E

  erlotinib and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Erlotinib and Omeprazole: major severity. Omeprazole produces sustained gastric acid suppression, raising gastric pH and s

  ›
• E

  erlotinib and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Erlotinib and Pantoprazole: major severity. Pantoprazole produces sustained gastric acid suppression, reducing the pH-depend

  ›
• E

  erythromycin and fexofenadine: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Fexofenadine: minor severity. Erythromycin inhibits intestinal P-glycoprotein and may reduce biliary transport

  ›
• E

  erythromycin and haloperidol: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Haloperidol: major severity. Both medicines prolong cardiac repolarisation through hERG potassium-channel eff

  ›
• E

  erythromycin and ivabradine: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Ivabradine: major severity. Erythromycin inhibits CYP3A4, substantially increasing ivabradine exposure. Exce

  ›
• E

  erythromycin and loratadine: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Loratadine: minor severity. Erythromycin inhibits CYP3A4-mediated loratadine metabolism, increasing loratadi

  ›
• E

  erythromycin and pimozide: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Pimozide: major severity. Erythromycin inhibits CYP3A4-mediated pimozide clearance, and both drugs prolong

  ›
• E

  erythromycin and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Quetiapine: major severity. Erythromycin inhibits CYP3A4, the major metabolic pathway for quetiapine. Higher

  ›
• E

  erythromycin and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Rivaroxaban: moderate severity. Erythromycin inhibits CYP3A4 and P-glycoprotein, increasing rivaroxaban exposure

  ›
• E

  erythromycin and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Sildenafil: moderate severity. Erythromycin inhibits CYP3A4-mediated metabolism of sildenafil, approximately do

  ›
• E

  erythromycin and simvastatin: Interaction, Risks, and Safer

  Interaction between Erythromycin and Simvastatin: major severity. Erythromycin is a strong CYP3A4 inhibitor that markedly increases simvastatin ex

  ›
• E

  erythromycin and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Sotalol: major severity. Both agents block the cardiac IKr potassium channel, with additive QT-interval p

  ›
• E

  erythromycin and statin: Interaction, Risks, and Safer

  Interaction between Erythromycin and Statin: major severity. Erythromycin inhibits CYP3A4, increasing exposure of simvastatin, lovastatin, an

  ›
• E

  erythromycin and statins: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Statins: major severity. Erythromycin is a CYP3A4 inhibitor that raises plasma concentrations of CYP3A4-m

  ›
• E

  erythromycin and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Erythromycin and Tacrolimus: major severity. Erythromycin inhibits CYP3A4 and P-glycoprotein, significantly increasing tacrol

  ›
• E

  erythromycin and theophylline: Interaction, Risks, and Safer

  Interaction between Erythromycin and Theophylline: moderate severity. Erythromycin inhibits CYP3A4 metabolism of theophylline, raising serum concentra

  ›
• E

  erythromycin and warfarin: Interaction, Risks, and Safer

  Interaction between Erythromycin and Warfarin: moderate severity. Erythromycin inhibits CYP3A4 and CYP1A2 metabolism of warfarin and disrupts gut

  ›
• E

  escitalopram and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Fluconazole: moderate severity. Fluconazole inhibits CYP2C19, increasing escitalopram exposure. Both agents can

  ›
• E

  escitalopram and haloperidol: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Haloperidol: major severity. Both drugs inhibit cardiac potassium currents and prolong the QT interval, creat

  ›
• E

  escitalopram and hydroxyzine: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Hydroxyzine: major severity. Both drugs inhibit cardiac repolarizing potassium currents and can produce addit

  ›
• E

  escitalopram and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Ibuprofen: moderate severity. SSRIs reduce platelet serotonin uptake and impair platelet aggregation, while NS

  ›
• E

  escitalopram and linezolid: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Linezolid: major severity. Linezolid is a reversible MAO inhibitor; combined with the serotonergic effects

  ›
• E

  escitalopram and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Omeprazole: moderate severity. Omeprazole inhibits CYP2C19, the principal metabolic enzyme for escitalopram, in

  ›
• E

  escitalopram and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Ondansetron: moderate severity. Both prolong the QT interval and additively increase the risk of torsades de poi

  ›
• E

  escitalopram and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Escitalopram and Tramadol: major severity. Both drugs increase central serotonergic activity — escitalopram blocks serotoni

  ›
• E

  esomeprazole and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Esomeprazole and Methotrexate: moderate severity. Proton pump inhibitors reduce renal elimination of methotrexate by inhibiting tu

  ›
• E

  ethanol and metronidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ethanol and Metronidazole: moderate severity. Metronidazole inhibits acetaldehyde dehydrogenase, leading to acetaldehyde accum

  ›
• E

  ethanol and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Ethanol and Zolpidem: minor severity. Ethanol and zolpidem both enhance CNS depressant effects through GABAergic pathw

  ›
• E

  ethinyl-estradiol and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinyl Estradiol and Lamotrigine: moderate severity. Ethinyl estradiol induces UGT1A4-mediated glucuronidation of lamotrigine. This c

  ›
• E

  ethinyl-estradiol and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinyl Estradiol and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and glucuronidation pathways, increasing meta

  ›
• E

  ethinyl-estradiol and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinyl Estradiol and Topiramate: moderate severity. At higher doses, topiramate induces CYP3A4 and can increase metabolism of ethiny

  ›
• E

  ethinylestradiol and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Fluconazole: minor severity. Fluconazole inhibits CYP3A4 and CYP2C9, which can modestly increase ethinylestra

  ›
• E

  ethinylestradiol and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Lamotrigine: moderate severity. Ethinylestradiol induces UGT1A4-mediated glucuronidation of lamotrigine, reducin

  ›
• E

  ethinylestradiol and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Paracetamol: minor severity. Ethinylestradiol can increase paracetamol glucuronidation, while paracetamol may

  ›
• E

  ethinylestradiol and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Phenytoin: moderate severity. Phenytoin induces CYP3A4 and glucuronidation pathways, accelerating metabolism o

  ›
• E

  ethinylestradiol and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Rifampicin: major severity. Rifampicin induces CYP3A4 and SULT enzymes, accelerating metabolism of both ethi

  ›
• E

  ethinylestradiol and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol and Topiramate: moderate severity. Topiramate at doses above 200 mg/day induces CYP3A4 and increases estrogen clear

  ›
• E

  ethinylestradiol-levonorgestrel and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol Levonorgestrel and Lamotrigine: moderate severity. Ethinylestradiol induces UGT-mediated glucuronidation of lamotrigine,

  ›
• E

  ethinylestradiol-levonorgestrel and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol Levonorgestrel and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, uridine diphosphate-glucuronosyltrans

  ›
• E

  ethinylestradiol-levonorgestrel and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Ethinylestradiol Levonorgestrel and Topiramate: moderate severity. At higher doses, topiramate induces CYP3A4 and can reduce ethinylestra

  ›
• E

  etinylestradiol and lamotrigine: Interaction, Risks, and Safer Alternatives

  Interaction between Etinylestradiol and Lamotrigine: moderate severity. Combined oral contraceptives induce UGT1A4 glucuronidation of lamotrigine, reduc

  ›
• E

  everolimus and ketoconazole: Interaction, Risks, and Safer

  Interaction between Everolimus and Ketoconazole: major severity. Ketoconazole strongly inhibits CYP3A4 and P-glycoprotein, increasing everolimus

  ›
• E

  everolimus and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Everolimus and Rifampicin: major severity. Rifampicin induces CYP3A4 and P-glycoprotein, decreasing everolimus AUC by up to

  ›
• E

  everolimus and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Everolimus and Verapamil: major severity. Verapamil inhibits CYP3A4 and P-glycoprotein, increasing everolimus exposure and

  ›
• E

  everolimus and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Everolimus and Voriconazole: major severity. Voriconazole strongly inhibits CYP3A4 metabolism of everolimus, increasing evero

  ›
• E

  ezetimibe and gemfibrozil: Interaction, Risks, and Safer Alternatives

  Interaction between Ezetimibe and Gemfibrozil: moderate severity. Gemfibrozil inhibits OATP1B1 and glucuronidation of ezetimibe, increasing its pl

  ›
• F

  famotidine and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Famotidine and Itraconazole: moderate severity. Famotidine raises gastric pH and can reduce dissolution and absorption of itraco

  ›
• F

  febuxostat and mercaptopurine: Interaction, Risks, and Safer Alternatives

  Interaction between Febuxostat and Mercaptopurine: major severity. Febuxostat inhibits xanthine oxidase, an important metabolic pathway for mercapt

  ›
• F

  felodipine and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Felodipine and Grapefruit Juice: moderate severity. Grapefruit juice inhibits intestinal CYP3A4, increasing felodipine bioavailabili

  ›
• F

  fentanyl and fluconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Fentanyl and Fluconazole: moderate severity. Fluconazole inhibits CYP3A4, reducing fentanyl metabolism and increasing opioid

  ›
• F

  fentanyl and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Fentanyl and Ritonavir: major severity. Ritonavir is a potent CYP3A4 inhibitor that markedly reduces fentanyl clearance,

  ›
• F

  fentanyl and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Fentanyl and Voriconazole: major severity. Voriconazole inhibits CYP3A4, reducing fentanyl metabolism and increasing opioid

  ›
• F

  ferrous-sulfate and levodopa: Interaction, Risks, and Safer Alternatives

  Interaction between Ferrous Sulfate and Levodopa: moderate severity. Iron salts chelate levodopa in the gastrointestinal tract, reducing levodopa abs

  ›
• F

  ferrous-sulfate and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Ferrous Sulfate and Levofloxacin: moderate severity. Ferrous ions form poorly absorbed chelation complexes with levofloxacin in the g

  ›
• F

  ferrous-sulfate and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Ferrous Sulfate and Levothyroxine: moderate severity. Ferrous sulfate forms insoluble chelation complexes with levothyroxine in the gu

  ›
• F

  ferrous-sulfate and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ferrous Sulfate and Omeprazole: minor severity. Omeprazole raises gastric pH and can reduce dissolution and absorption of non-he

  ›
• F

  fexofenadine and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Fexofenadine and Grapefruit Juice: minor severity. Grapefruit juice inhibits intestinal OATP1A2 transporters required for fexofenad

  ›
• F

  fluconazole and glibenclamide: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Glibenclamide: moderate severity. Fluconazole inhibits CYP2C9, reducing metabolism of glibenclamide and increasing

  ›
• F

  fluconazole and gliclazide: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Gliclazide: moderate severity. Fluconazole inhibits CYP2C9, reducing metabolism of sulfonylureas such as glicla

  ›
• F

  fluconazole and glimepiride: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Glimepiride: moderate severity. Fluconazole inhibits CYP2C9-mediated metabolism of glimepiride, increasing plasm

  ›
• F

  fluconazole and glipizide: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Glipizide: moderate severity. Fluconazole inhibits CYP2C9, reducing metabolism of the sulfonylurea glipizide a

  ›
• F

  fluconazole and hydrochlorothiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Hydrochlorothiazide: minor severity. Hydrochlorothiazide reduces renal clearance of fluconazole and can modestly incr

  ›
• F

  fluconazole and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Losartan: moderate severity. Fluconazole inhibits CYP2C9, reducing conversion of losartan to its more active

  ›
• F

  fluconazole and methadone: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Methadone: moderate severity. Fluconazole inhibits CYP-mediated methadone metabolism, increasing methadone exp

  ›
• F

  fluconazole and phenytoin: Interaction, Risks, and Safer

  Interaction between Fluconazole and Phenytoin: moderate severity. Fluconazole inhibits CYP2C9 and CYP2C19, the principal enzymes metabolizing phen

  ›
• F

  fluconazole and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Quetiapine: moderate severity. Fluconazole inhibits CYP3A4, the main metabolic pathway for quetiapine, increasi

  ›
• F

  fluconazole and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Simvastatin: major severity. Fluconazole inhibits CYP3A4 metabolism of simvastatin, dramatically increasing s

  ›
• F

  fluconazole and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Sotalol: major severity. Both fluconazole and sotalol can inhibit cardiac repolarizing potassium currents

  ›
• F

  fluconazole and sulfonylurea: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Sulfonylurea: moderate severity. Fluconazole inhibits CYP2C9, reducing the metabolism of sulfonylureas (e.g., gli

  ›
• F

  fluconazole and sulfonylureas: Interaction, Risks, and Safer Alternatives

  Interaction between Fluconazole and Sulfonylureas: moderate severity. Fluconazole inhibits CYP2C9 metabolism of glimepiride, glipizide, and glyburide,

  ›
• F

  fluconazole and tacrolimus: Interaction, Risks, and Safer

  Interaction between Fluconazole and Tacrolimus: major severity. Fluconazole inhibits CYP3A4-mediated metabolism of tacrolimus, substantially inc

  ›
• F

  fluconazole and warfarin: Interaction, Risks, and Safer

  Interaction between Fluconazole and Warfarin: major severity. Fluconazole inhibits CYP2C9 and CYP3A4, the principal enzymes metabolizing warfa

  ›
• F

  fluorouracil and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Fluorouracil and Phenytoin: moderate severity. Fluorouracil can inhibit CYP2C9-mediated phenytoin metabolism, increasing phenyt

  ›
• F

  fluorouracil and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Fluorouracil and Warfarin: moderate severity. Fluorouracil can increase warfarin anticoagulant activity, possibly through redu

  ›
• F

  fluoxetine and linezolid: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Linezolid: major severity. Linezolid is a reversible MAO inhibitor that combined with SSRI-mediated seroton

  ›
• F

  fluoxetine and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Metoprolol: moderate severity. Fluoxetine and its metabolite norfluoxetine are potent CYP2D6 inhibitors; metopr

  ›
• F

  fluoxetine and moclobemide: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Moclobemide: major severity. Fluoxetine increases synaptic serotonin through serotonin-transporter inhibition

  ›
• F

  fluoxetine and olanzapine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Olanzapine: minor severity. Fluoxetine inhibits CYP2D6 and can modestly reduce olanzapine clearance, produci

  ›
• F

  fluoxetine and phenelzine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Phenelzine: major severity. Fluoxetine increases serotonergic neurotransmission, while phenelzine inhibits m

  ›
• F

  fluoxetine and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Propranolol: moderate severity. Fluoxetine inhibits CYP2D6, reducing propranolol metabolism. Increased beta-bloc

  ›
• F

  fluoxetine and risperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Risperidone: moderate severity. Fluoxetine inhibits CYP2D6, reducing conversion and clearance pathways for rispe

  ›
• F

  fluoxetine and selegiline: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Selegiline: major severity. Combined serotonin reuptake inhibition and monoamine oxidase inhibition can prod

  ›
• F

  fluoxetine and tamoxifen: Interaction, Risks, and Safer

  Interaction between Fluoxetine and Tamoxifen: major severity. Fluoxetine is a strong CYP2D6 inhibitor and reduces conversion of tamoxifen to i

  ›
• F

  fluoxetine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Tramadol: major severity. Combined serotonergic activity (SSRI plus tramadol's serotonin reuptake inhibiti

  ›
• F

  fluoxetine and tranylcypromine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Tranylcypromine: major severity. Combined serotonin reuptake inhibition and irreversible monoamine oxidase inhibi

  ›
• F

  fluoxetine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Fluoxetine and Warfarin: moderate severity. Fluoxetine can inhibit CYP2C9 and CYP2C19 and also impairs platelet serotonin up

  ›
• F

  fluticasone and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Fluticasone and Ritonavir: major severity. Ritonavir strongly inhibits CYP3A4, the main clearance pathway for fluticasone.

  ›
• F

  fluvoxamine and olanzapine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluvoxamine and Olanzapine: moderate severity. Fluvoxamine is a potent CYP1A2 inhibitor that decreases olanzapine clearance, in

  ›
• F

  fluvoxamine and ramelteon: Interaction, Risks, and Safer Alternatives

  Interaction between Fluvoxamine and Ramelteon: major severity. Fluvoxamine strongly inhibits CYP1A2, the primary enzyme metabolizing ramelteon,

  ›
• F

  fluvoxamine and theophylline: Interaction, Risks, and Safer

  Interaction between Fluvoxamine and Theophylline: major severity. Fluvoxamine potently inhibits CYP1A2, the principal enzyme metabolizing theophyl

  ›
• F

  fluvoxamine and tizanidine: Interaction, Risks, and Safer Alternatives

  Interaction between Fluvoxamine and Tizanidine: major severity. Fluvoxamine is a potent CYP1A2 inhibitor and markedly increases tizanidine expos

  ›
• F

  folic-acid and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Folic Acid and Methotrexate: minor severity. Folic acid replenishes reduced folate pools depleted by low-dose methotrexate, d

  ›
• F

  folic-acid and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Folic Acid and Phenytoin: minor severity. Folic acid supplementation may increase phenytoin metabolism or reduce its conce

  ›
• F

  folic-acid and sulfasalazine: Interaction, Risks, and Safer Alternatives

  Interaction between Folic Acid and Sulfasalazine: minor severity. Sulfasalazine inhibits intestinal folate absorption and metabolism, potentially

  ›
• F

  furosemide and gentamicin: Interaction, Risks, and Safer

  Interaction between Furosemide and Gentamicin: moderate severity. Loop diuretics potentiate aminoglycoside ototoxicity through additive cochlear d

  ›
• F

  furosemide and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Ibuprofen: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, reducing renal blood flow and blun

  ›
• F

  furosemide and lithium: Interaction, Risks, and Safer

  Interaction between Furosemide and Lithium: moderate severity. Loop diuretics reduce sodium reabsorption, leading to compensatory increased pro

  ›
• F

  furosemide and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Metformin: minor severity. Furosemide can modestly increase metformin exposure, while metformin may reduce

  ›
• F

  furosemide and non-steroidal-anti-inflammatory-drugs: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Non Steroidal Anti Inflammatory Drugs: moderate severity. Non-steroidal anti-inflammatory drugs inhibit renal prostaglandi

  ›
• F

  furosemide and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Prednisolone: minor severity. Furosemide promotes renal potassium loss, while systemic corticosteroid mineralo

  ›
• F

  furosemide and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Prednisone: moderate severity. Furosemide promotes renal potassium loss, while prednisone can increase mineralo

  ›
• F

  furosemide and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Ramipril: moderate severity. Loop diuretics can cause volume depletion, while ACE inhibitors reduce angiotens

  ›
• F

  furosemide and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Sotalol: moderate severity. Furosemide can cause hypokalaemia and hypomagnesaemia, which increases the proar

  ›
• F

  furosemide and sucralfate: Interaction, Risks, and Safer Alternatives

  Interaction between Furosemide and Sucralfate: minor severity. Sucralfate can bind furosemide within the gastrointestinal tract and reduce its

  ›
• G

  gabapentin and magnesium-hydroxide: Interaction, Risks, and Safer Alternatives

  Interaction between Gabapentin and Magnesium Hydroxide: minor severity. Magnesium-containing antacids reduce gastrointestinal absorption and bioavailabi

  ›
• G

  gabapentin and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Gabapentin and Morphine: moderate severity. Gabapentin and morphine produce additive CNS depression; morphine also increases

  ›
• G

  gabapentin and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Gabapentin and Oxycodone: moderate severity. The interaction is mainly pharmacodynamic, with additive central nervous system

  ›
• G

  ganciclovir and zidovudine: Interaction, Risks, and Safer Alternatives

  Interaction between Ganciclovir and Zidovudine: major severity. Both zidovudine and ganciclovir can suppress bone marrow, producing additive hem

  ›
• G

  gemfibrozil and pioglitazone: Interaction, Risks, and Safer Alternatives

  Interaction between Gemfibrozil and Pioglitazone: major severity. Gemfibrozil potently inhibits CYP2C8, increasing pioglitazone exposure approxima

  ›
• G

  gemfibrozil and repaglinide: Interaction, Risks, and Safer

  Interaction between Gemfibrozil and Repaglinide: major severity. Gemfibrozil and its glucuronide inhibit CYP2C8 and OATP1B1, raising repaglinide

  ›
• G

  gemfibrozil and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Gemfibrozil and Rosuvastatin: major severity. Gemfibrozil and its glucuronide inhibit OATP1B1-mediated hepatic uptake of rosuv

  ›
• G

  gemfibrozil and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Gemfibrozil and Simvastatin: major severity. Gemfibrozil inhibits OATP1B1 hepatic uptake and CYP-mediated metabolism of simva

  ›
• G

  gemfibrozil and statin: Interaction, Risks, and Safer Alternatives

  Interaction between Gemfibrozil and Statin: major severity. Gemfibrozil inhibits OATP1B1 hepatic uptake and CYP-independent glucuronidation

  ›
• G

  gentamicin and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Gentamicin and Tacrolimus: major severity. Both agents are independently nephrotoxic and combine to produce additive proxim

  ›
• G

  gentamicin and vancomycin: Interaction, Risks, and Safer

  Interaction between Gentamicin and Vancomycin: major severity. Both drugs cause direct nephrotoxicity through proximal tubular injury, and gent

  ›
• G

  ginkgo-biloba and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ginkgo Biloba and Warfarin: moderate severity. Ginkgo may inhibit platelet-activating factor and impair platelet aggregation, a

  ›
• G

  glibenclamide and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Glibenclamide and Propranolol: moderate severity. Propranolol blocks beta-adrenergic warning symptoms and counter-regulatory respo

  ›
• G

  glibenclamide and sitagliptin: Interaction, Risks, and Safer Alternatives

  Interaction between Glibenclamide and Sitagliptin: moderate severity. DPP-4 inhibitor-mediated enhancement of incretin activity adds to sulfonylurea-i

  ›
• G

  glibenclamide and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Glibenclamide and Trimethoprim: moderate severity. Trimethoprim inhibits CYP2C9-mediated metabolism of glibenclamide, increasing su

  ›
• G

  gliclazide and miconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Miconazole: major severity. Miconazole inhibits CYP2C9 metabolism of sulfonylureas such as gliclazide. Incre

  ›
• G

  gliclazide and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Propranolol: moderate severity. Nonselective beta-adrenoceptor blockade can mask adrenergic warning signs of sul

  ›
• G

  gliclazide and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Sulfamethoxazole Trimethoprim: moderate severity. Sulfamethoxazole-trimethoprim may inhibit sulfonylurea metabolism, espec

  ›
• G

  gliclazide and sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Sulfamethoxazole: moderate severity. Sulfamethoxazole can inhibit CYP2C9 and may displace sulfonylureas from protein

  ›
• G

  gliclazide and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Trimethoprim Sulfamethoxazole: moderate severity. Sulfonamides displace sulfonylureas from plasma protein binding and inhi

  ›
• G

  gliclazide and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Gliclazide and Trimethoprim: moderate severity. Trimethoprim may inhibit renal tubular secretion and alter sulfonylurea exposure

  ›
• G

  glimepiride and insulin-human: Interaction, Risks, and Safer Alternatives

  Interaction between Glimepiride and Insulin Human: moderate severity. Glimepiride stimulates pancreatic insulin release while administered insulin dir

  ›
• G

  glimepiride and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Glimepiride and Propranolol: moderate severity. Propranolol blocks beta-adrenergic warning signs and counter-regulatory response

  ›
• G

  glimepiride and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Glimepiride and Sulfamethoxazole Trimethoprim: major severity. Sulfamethoxazole-trimethoprim can inhibit sulfonylurea metabolism and may

  ›
• G

  glipizide and insulin-glargine: Interaction, Risks, and Safer Alternatives

  Interaction between Glipizide and Insulin Glargine: moderate severity. Glipizide stimulates insulin secretion while insulin-glargine directly increases

  ›
• G

  glipizide and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Glipizide and Prednisone: moderate severity. Prednisone activates glucocorticoid receptors, increasing hepatic gluconeogenesi

  ›
• G

  glyburide and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Glyburide and Sulfamethoxazole Trimethoprim: moderate severity. Sulfamethoxazole displaces glyburide from plasma protein binding and inhi

  ›
• G

  glycerol-trinitrate and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Glycerol Trinitrate and Sildenafil: major severity. Glycerol trinitrate increases nitric-oxide-mediated cyclic GMP production, while

  ›
• G

  glyceryl-trinitrate and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Glyceryl Trinitrate and Sildenafil: major severity. Sildenafil potentiates the vasodilatory effect of nitric oxide donors via cGMP a

  ›
• G

  glyceryl-trinitrate and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Glyceryl Trinitrate and Tadalafil: major severity. Glyceryl trinitrate increases nitric-oxide-mediated cyclic GMP production, while

  ›
• G

  grapefruit-juice and nifedipine: Interaction, Risks, and Safer Alternatives

  Interaction between Grapefruit Juice and Nifedipine: moderate severity. Grapefruit juice inhibits intestinal CYP3A4, increasing nifedipine bioavailabili

  ›
• G

  grapefruit-juice and nitrendipine: Interaction, Risks, and Safer Alternatives

  Interaction between Grapefruit Juice and Nitrendipine: minor severity. Grapefruit juice inhibits intestinal CYP3A4, increasing exposure to some dihydro

  ›
• G

  grapefruit-juice and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Grapefruit Juice and Simvastatin: moderate severity. Grapefruit juice inhibits intestinal CYP3A4, increasing simvastatin bioavailabil

  ›
• G

  grapefruit-juice and statins: Interaction, Risks, and Safer Alternatives

  Interaction between Grapefruit Juice and Statins: moderate severity. Grapefruit furanocoumarins irreversibly inhibit intestinal CYP3A4, increasing sy

  ›
• G

  grapefruit-juice and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Grapefruit Juice and Tacrolimus: major severity. Grapefruit juice inhibits intestinal CYP3A4, increasing tacrolimus bioavailabili

  ›
• H

  haloperidol and levodopa: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Levodopa: major severity. Haloperidol blocks central dopamine D2 receptors, directly antagonising the ther

  ›
• H

  haloperidol and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Levofloxacin: major severity. Both haloperidol and levofloxacin can prolong ventricular repolarization through

  ›
• H

  haloperidol and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Lithium: moderate severity. Combination may cause neurotoxicity through unclear mechanism, potentially invol

  ›
• H

  haloperidol and methadone: Interaction, Risks, and Safer

  Interaction between Haloperidol and Methadone: major severity. Both drugs prolong the QT interval through blockade of cardiac potassium channel

  ›
• H

  haloperidol and moxifloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Moxifloxacin: major severity. Both haloperidol and moxifloxacin can prolong ventricular repolarization through

  ›
• H

  haloperidol and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Ondansetron: major severity. Both drugs prolong the QT interval through hERG potassium channel blockade, addi

  ›
• H

  haloperidol and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Sotalol: major severity. Both sotalol and haloperidol can prolong ventricular repolarization through effe

  ›
• H

  haloperidol and ziprasidone: Interaction, Risks, and Safer Alternatives

  Interaction between Haloperidol and Ziprasidone: major severity. Both agents prolong the QT interval via hERG potassium channel blockade; additiv

  ›
• H

  heparin and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Heparin and Ibuprofen: moderate severity. Ibuprofen inhibits platelet cyclooxygenase and can damage gastrointestinal mucos

  ›
• H

  heparin and ketorolac: Interaction, Risks, and Safer Alternatives

  Interaction between Heparin and Ketorolac: major severity. Combination of anticoagulant and NSAID effects on platelet aggregation and gastr

  ›
• H

  heparin and nitroglycerin: Interaction, Risks, and Safer Alternatives

  Interaction between Heparin and Nitroglycerin: moderate severity. Intravenous nitroglycerin may reduce the anticoagulant response to heparin, poss

  ›
• H

  heparin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Heparin and Warfarin: moderate severity. Heparin potentiates antithrombin-mediated inhibition of clotting factors, while

  ›
• H

  human-insulin and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Human Insulin and Metoprolol: moderate severity. Beta-1 blockade can mask adrenergic warning signs of hypoglycaemia, particularly

  ›
• H

  human-insulin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Human Insulin and Prednisolone: moderate severity. Prednisolone promotes hepatic gluconeogenesis and peripheral insulin resistance,

  ›
• H

  human-insulin and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Human Insulin and Prednisone: moderate severity. Prednisone activates glucocorticoid receptors, increasing hepatic gluconeogenesi

  ›
• H

  human-insulin and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Human Insulin and Propranolol: moderate severity. Non-selective beta-adrenoceptor blockade can inhibit glycogenolysis and gluconeo

  ›
• H

  hydrochlorothiazide and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Lisinopril: minor severity. Hydrochlorothiazide reduces plasma volume and activates the renin-angiotensin sy

  ›
• H

  hydrochlorothiazide and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Lithium: major severity. Thiazide diuretics increase proximal tubular sodium and lithium reabsorption, re

  ›
• H

  hydrochlorothiazide and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Losartan: minor severity. Hydrochlorothiazide promotes sodium loss while losartan blocks angiotensin II AT

  ›
• H

  hydrochlorothiazide and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Metformin: minor severity. Thiazide diuretics can mildly impair glucose tolerance through reduced insulin s

  ›
• H

  hydrochlorothiazide and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Prednisolone: moderate severity. Both drugs promote renal potassium loss, with additive hypokalaemia that can pre

  ›
• H

  hydrochlorothiazide and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Prednisone: moderate severity. Thiazide-mediated renal potassium loss can be amplified by the mineralocorticoid

  ›
• H

  hydrochlorothiazide and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Sotalol: moderate severity. Thiazide-induced hypokalemia and hypomagnesemia potentiate sotalol-induced QT pr

  ›
• H

  hydrochlorothiazide and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrochlorothiazide and Topiramate: moderate severity. Hydrochlorothiazide can increase topiramate exposure and both drugs can lower se

  ›
• H

  hydrocortisone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Hydrocortisone and Rifampicin: moderate severity. Rifampicin induces CYP3A4 and accelerates hydrocortisone metabolism, reducing gl

  ›
• H

  hydroxychloroquine and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Hydroxychloroquine and Metformin: minor severity. Hydroxychloroquine can improve insulin sensitivity and reduce glucose concentrat

  ›
• H

  hydroxyzine and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Hydroxyzine and Sotalol: major severity. Both drugs can prolong cardiac repolarization through effects on potassium curre

  ›
• I

  ibrutinib and itraconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ibrutinib and Itraconazole: major severity. Itraconazole strongly inhibits CYP3A4, markedly increasing ibrutinib exposure an

  ›
• I

  ibrutinib and posaconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ibrutinib and Posaconazole: major severity. Posaconazole strongly inhibits CYP3A4, substantially increasing ibrutinib exposu

  ›
• I

  ibrutinib and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ibrutinib and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, markedly accelerating ibrutinib metabolism a

  ›
• I

  ibrutinib and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ibrutinib and Voriconazole: major severity. Voriconazole is a strong CYP3A4 inhibitor and can markedly increase ibrutinib ex

  ›
• I

  ibrutinib and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ibrutinib and Warfarin: major severity. Ibrutinib impairs platelet signalling through BTK-related pathways, producing a

  ›
• I

  ibuprofen and aspirin: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Aspirin: moderate severity. Both NSAIDs increase bleeding risk and reduce aspirin's cardioprotective effect.

  ›
• I

  ibuprofen and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Lisinopril: moderate severity. NSAIDs reduce ACE inhibitor effectiveness and worsen renal function.

  ›
• I

  ibuprofen and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Losartan: moderate severity. NSAID-mediated inhibition of renal prostaglandins can reduce the antihypertensiv

  ›
• I

  ibuprofen and low-dose-aspirin: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Low Dose Aspirin: moderate severity. Ibuprofen competitively occupies the COX-1 acetylation site on platelets, blocki

  ›
• I

  ibuprofen and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Methotrexate: major severity. NSAIDs reduce renal clearance of methotrexate by inhibiting prostaglandin-mediat

  ›
• I

  ibuprofen and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Metoprolol: minor severity. Inhibition of renal prostaglandin synthesis by ibuprofen may promote sodium rete

  ›
• I

  ibuprofen and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Prednisolone: moderate severity. Prednisolone and ibuprofen both increase gastrointestinal mucosal injury risk th

  ›
• I

  ibuprofen and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Prednisone: moderate severity. Glucocorticoids and NSAIDs independently impair gastrointestinal mucosal protect

  ›
• I

  ibuprofen and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Propranolol: minor severity. Ibuprofen inhibits renal prostaglandin synthesis, which may cause sodium retenti

  ›
• I

  ibuprofen and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, blunting the antihypertensive effe

  ›
• I

  ibuprofen and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Rivaroxaban: moderate severity. Ibuprofen inhibits platelet function and can injure gastrointestinal mucosa, whi

  ›
• I

  ibuprofen and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Ibuprofen and Sertraline: moderate severity. SSRIs impair platelet serotonin uptake and platelet aggregation, while NSAIDs in

  ›
• I

  imatinib and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Imatinib and Paracetamol: moderate severity. Imatinib inhibits paracetamol glucuronidation and CYP2E1 metabolism, potentially

  ›
• I

  imatinib and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Imatinib and Rifampicin: major severity. Rifampicin is a potent inducer of CYP3A4, reducing imatinib AUC by approximately

  ›
• I

  imatinib and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Imatinib and Simvastatin: moderate severity. Imatinib inhibits CYP3A4, increasing exposure to simvastatin, a CYP3A4 substrate

  ›
• I

  imatinib and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Imatinib and Warfarin: moderate severity. Imatinib inhibits CYP2C9 and CYP3A4 metabolism of warfarin, potentiating its ant

  ›
• I

  indinavir and rifabutin: Interaction, Risks, and Safer Alternatives

  Interaction between Indinavir and Rifabutin: moderate severity. Indinavir strongly inhibits CYP3A4-mediated rifabutin metabolism, raising rifabu

  ›
• I

  indinavir and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Indinavir and Rifampicin: major severity. Rifampicin is a potent inducer of CYP3A4, reducing indinavir plasma concentratio

  ›
• I

  indinavir and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Indinavir and St Johns Wort: major severity. St John's wort is a potent inducer of CYP3A4 and P-glycoprotein, reducing indina

  ›
• I

  indomethacin and lisinopril: Interaction, Risks, and Safer Alternatives

  Interaction between Indomethacin and Lisinopril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, reducing afferent arteriolar vasod

  ›
• I

  indomethacin and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Indomethacin and Lithium: major severity. NSAIDs inhibit renal prostaglandin synthesis, reducing afferent arteriolar dilat

  ›
• I

  indomethacin and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Indomethacin and Methotrexate: major severity. NSAIDs reduce renal clearance of methotrexate and displace it from plasma protei

  ›
• I

  indomethacin and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Indomethacin and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, attenuating ACE inhibitor-induced

  ›
• I

  indomethacin and triamterene: Interaction, Risks, and Safer

  Interaction between Indomethacin and Triamterene: major severity. NSAIDs reduce renal prostaglandin-dependent perfusion while triamterene blocks d

  ›
• I

  insulin and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Levofloxacin: moderate severity. Levofloxacin can disrupt pancreatic beta-cell potassium-channel function and cau

  ›
• I

  insulin and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Metoprolol: moderate severity. Non-selective and high-dose cardioselective beta-blockers mask adrenergic warnin

  ›
• I

  insulin and pioglitazone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Pioglitazone: moderate severity. Both agents lower glucose, and pioglitazone promotes fluid retention through PPA

  ›
• I

  insulin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Prednisolone: moderate severity. Prednisolone increases hepatic glucose production and causes peripheral insulin

  ›
• I

  insulin and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Prednisone: moderate severity. Prednisone increases hepatic glucose production and induces peripheral insulin r

  ›
• I

  insulin and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Propranolol: moderate severity. Non-selective beta-blockers mask adrenergic warning signs of hypoglycemia (tremo

  ›
• I

  insulin and semaglutide: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin and Semaglutide: moderate severity. Semaglutide enhances glucose-dependent insulin secretion and reduces food intake

  ›
• I

  insulin-aspart and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Aspart and Propranolol: moderate severity. Nonselective beta-adrenoceptor blockade can mask adrenergic warning symptoms of

  ›
• I

  insulin-glargine and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Glargine and Metoprolol: moderate severity. Beta-1 blockade may mask adrenergic warning symptoms of insulin-induced hypoglyc

  ›
• I

  insulin-glargine and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Glargine and Prednisolone: moderate severity. Prednisolone increases hepatic glucose production and peripheral insulin resista

  ›
• I

  insulin-glargine and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Glargine and Prednisone: moderate severity. Prednisone activates glucocorticoid receptors, increasing hepatic gluconeogenesi

  ›
• I

  insulin-glargine and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Glargine and Propranolol: moderate severity. Nonselective beta-adrenoceptor blockade can mask adrenergic warning symptoms of

  ›
• I

  insulin-glargine and semaglutide: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Glargine and Semaglutide: moderate severity. Semaglutide enhances glucose-dependent insulin secretion and lowers glucose inta

  ›
• I

  insulin-human and metoprolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Human and Metoprolol: moderate severity. Beta-adrenoceptor blockade can mask adrenergic warning symptoms of hypoglycaemia

  ›
• I

  insulin-human and pioglitazone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Human and Pioglitazone: moderate severity. Pioglitazone activates PPAR-gamma and promotes sodium and fluid retention, while

  ›
• I

  insulin-human and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Human and Prednisolone: moderate severity. Prednisolone increases hepatic glucose production and peripheral insulin resista

  ›
• I

  insulin-human and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Human and Propranolol: moderate severity. Nonselective beta-adrenoceptor blockade can mask adrenergic warning signs of hyp

  ›
• I

  insulin-lispro and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Insulin Lispro and Propranolol: moderate severity. Non-selective beta-adrenoceptor blockade can mask adrenergic warning symptoms of

  ›
• I

  iodinated-contrast and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iodinated Contrast and Metformin: moderate severity. Iodinated contrast can cause acute kidney injury, which reduces metformin cleara

  ›
• I

  iodinated-contrast-media and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iodinated Contrast Media and Metformin: moderate severity. Iodinated contrast can precipitate acute kidney injury; reduced renal clearanc

  ›
• I

  iodixanol and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iodixanol and Metformin: moderate severity. Iodixanol can precipitate acute kidney injury, which may reduce renal metformin

  ›
• I

  iohexol and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iohexol and Metformin: moderate severity. Iodinated contrast can precipitate acute kidney injury, reducing metformin clear

  ›
• I

  iopamidol and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iopamidol and Metformin: moderate severity. Iopamidol-associated acute kidney injury can reduce metformin elimination, allow

  ›
• I

  iopromide and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Iopromide and Metformin: moderate severity. Iodinated contrast can precipitate acute kidney injury, reducing metformin clear

  ›
• I

  ipratropium and tiotropium: Interaction, Risks, and Safer Alternatives

  Interaction between Ipratropium and Tiotropium: moderate severity. Both are inhaled antimuscarinic bronchodilators acting on muscarinic receptors;

  ›
• I

  irbesartan and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Irbesartan and Lithium: moderate severity. Angiotensin receptor blockers reduce renal lithium clearance via decreased glome

  ›
• I

  irbesartan and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Irbesartan and Potassium Chloride: moderate severity. Angiotensin II receptor blockers reduce aldosterone secretion and decrease renal

  ›
• I

  irbesartan and spironolactone: Interaction, Risks, and Safer

  Interaction between Irbesartan and Spironolactone: moderate severity. Both agents reduce aldosterone-mediated potassium excretion, leading to additive

  ›
• I

  irbesartan and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Irbesartan and Trimethoprim Sulfamethoxazole: moderate severity. Trimethoprim acts as a potassium-sparing agent by blocking distal tubule

  ›
• I

  irbesartan and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Irbesartan and Trimethoprim: moderate severity. Trimethoprim blocks epithelial sodium channels in the distal nephron (amiloride-

  ›
• I

  irinotecan and ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Irinotecan and Ketoconazole: major severity. Ketoconazole inhibits CYP3A4 and UGT1A1, increasing exposure to irinotecan's act

  ›
• I

  irinotecan and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Irinotecan and Rifampicin: major severity. Rifampicin induces CYP3A4 and UGT1A1, reducing exposure to irinotecan and its ac

  ›
• I

  irinotecan and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Irinotecan and St Johns Wort: major severity. St John's wort induces CYP3A4 and UGT1A1, increasing metabolism of the active SN

  ›
• I

  iron and levofloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Iron and Levofloxacin: moderate severity. Iron salts chelate fluoroquinolones in the gastrointestinal tract, forming insol

  ›
• I

  iron and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Iron and Tetracycline: moderate severity. Iron chelates tetracycline in the gastrointestinal tract, forming poorly absorbe

  ›
• I

  iron-salts and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Iron Salts and Levothyroxine: moderate severity. Iron salts chelate levothyroxine in the gut, reducing oral absorption. This may

  ›
• I

  iron-sulfate and levothyroxine: Interaction, Risks, and Safer Alternatives

  Interaction between Iron Sulfate and Levothyroxine: moderate severity. Iron forms insoluble chelates with levothyroxine in the gastrointestinal tract,

  ›
• I

  isavuconazole and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Isavuconazole and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, substantially reducing isavuconazole exposur

  ›
• I

  isoniazid and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Isoniazid and Paracetamol: moderate severity. Isoniazid induces CYP2E1, increasing formation of the hepatotoxic paracetamol me

  ›
• I

  isoniazid and phenytoin: Interaction, Risks, and Safer

  Interaction between Isoniazid and Phenytoin: moderate severity. Isoniazid inhibits CYP2C19 and CYP2C9, slowing phenytoin metabolism, with the ef

  ›
• I

  isoniazid and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Isoniazid and Rifampicin: moderate severity. Rifampicin induces hepatic CYP enzymes that increase production of hepatotoxic i

  ›
• I

  isosorbide-dinitrate and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Isosorbide Dinitrate and Sildenafil: major severity. Nitrate-mediated nitric oxide production and phosphodiesterase-5 inhibition syne

  ›
• I

  isosorbide-dinitrate and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Isosorbide Dinitrate and Tadalafil: major severity. Organic nitrate-derived nitric oxide increases cyclic GMP, while tadalafil inhib

  ›
• I

  isosorbide-mononitrate and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Isosorbide Mononitrate and Sildenafil: major severity. PDE-5 inhibition by sildenafil potentiates nitric oxide-mediated cGMP accumulati

  ›
• I

  isosorbide-mononitrate and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Isosorbide Mononitrate and Tadalafil: major severity. Nitrate-derived nitric oxide increases cyclic GMP production, while tadalafil in

  ›
• I

  isotretinoin and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Isotretinoin and Tetracycline: major severity. Both agents independently raise intracranial pressure; concomitant use markedly

  ›
• I

  itraconazole and ivabradine: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Ivabradine: major severity. Itraconazole is a strong CYP3A4 inhibitor and ivabradine is primarily metabolize

  ›
• I

  itraconazole and methadone: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Methadone: major severity. Itraconazole inhibits CYP3A4 metabolism of methadone and both drugs prolong the

  ›
• I

  itraconazole and midazolam: Interaction, Risks, and Safer

  Interaction between Itraconazole and Midazolam: major severity. Itraconazole strongly inhibits CYP3A4, increasing oral midazolam exposure 6-10 f

  ›
• I

  itraconazole and palbociclib: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Palbociclib: major severity. Itraconazole strongly inhibits CYP3A4, the principal metabolic pathway for palbo

  ›
• I

  itraconazole and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Quetiapine: major severity. Itraconazole is a strong CYP3A4 inhibitor that markedly reduces quetiapine clear

  ›
• I

  itraconazole and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Rivaroxaban: major severity. Itraconazole inhibits CYP3A4 and P-glycoprotein, significantly increasing rivaro

  ›
• I

  itraconazole and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Simvastatin: major severity. Itraconazole is a strong CYP3A4 inhibitor and greatly increases simvastatin expo

  ›
• I

  itraconazole and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Tacrolimus: major severity. Itraconazole strongly inhibits CYP3A4 and P-glycoprotein, dramatically reducing

  ›
• I

  itraconazole and venetoclax: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Venetoclax: major severity. Itraconazole strongly inhibits CYP3A4 and P-glycoprotein, increasing venetoclax

  ›
• I

  itraconazole and vincristine: Interaction, Risks, and Safer Alternatives

  Interaction between Itraconazole and Vincristine: major severity. Itraconazole strongly inhibits CYP3A4 and P-glycoprotein, reducing vincristine c

  ›
• I

  ivabradine and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Ivabradine and Verapamil: major severity. Verapamil inhibits CYP3A4 (increasing ivabradine exposure) and independently slo

  ›
• K

  ketoconazole and lurasidone: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Lurasidone: major severity. Ketoconazole is a strong CYP3A4 inhibitor and lurasidone is primarily metabolize

  ›
• K

  ketoconazole and midazolam: Interaction, Risks, and Safer

  Interaction between Ketoconazole and Midazolam: major severity. Ketoconazole is a potent CYP3A4 inhibitor that increases oral midazolam AUC up t

  ›
• K

  ketoconazole and palbociclib: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Palbociclib: major severity. Ketoconazole strongly inhibits CYP3A4, substantially increasing palbociclib expo

  ›
• K

  ketoconazole and pimozide: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Pimozide: major severity. Ketoconazole strongly inhibits CYP3A4 metabolism of pimozide, increasing plasma

  ›
• K

  ketoconazole and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Prednisolone: moderate severity. Ketoconazole inhibits CYP3A4 metabolism of prednisolone and other corticosteroid

  ›
• K

  ketoconazole and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Quetiapine: major severity. Ketoconazole strongly inhibits CYP3A4, the primary pathway for quetiapine metabo

  ›
• K

  ketoconazole and quinidine: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Quinidine: major severity. Ketoconazole inhibits CYP3A4 and P-glycoprotein, both involved in quinidine meta

  ›
• K

  ketoconazole and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Rivaroxaban: major severity. Ketoconazole is a strong dual inhibitor of CYP3A4 and P-glycoprotein, more than

  ›
• K

  ketoconazole and salmeterol: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Salmeterol: major severity. Ketoconazole strongly inhibits CYP3A4, increasing systemic exposure to salmetero

  ›
• K

  ketoconazole and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Simvastatin: major severity. Ketoconazole strongly inhibits CYP3A4, increasing simvastatin exposure more than

  ›
• K

  ketoconazole and tacrolimus: Interaction, Risks, and Safer

  Interaction between Ketoconazole and Tacrolimus: major severity. Ketoconazole strongly inhibits CYP3A4 and P-glycoprotein, causing major increase

  ›
• K

  ketoconazole and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Tamsulosin: moderate severity. Ketoconazole strongly inhibits CYP3A4 and CYP2D6, the enzymes that metabolise ta

  ›
• K

  ketoconazole and tofacitinib: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Tofacitinib: moderate severity. Ketoconazole strongly inhibits CYP3A4, increasing tofacitinib exposure and risk

  ›
• K

  ketoconazole and tolvaptan: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Tolvaptan: major severity. Ketoconazole strongly inhibits CYP3A4 metabolism of tolvaptan, increasing tolvap

  ›
• K

  ketoconazole and venetoclax: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Venetoclax: major severity. Ketoconazole strongly inhibits CYP3A4 and P-glycoprotein, markedly increasing ve

  ›
• K

  ketoconazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Warfarin: major severity. Ketoconazole strongly inhibits CYP2C9 and CYP3A4, reducing metabolism of both wa

  ›
• K

  ketoconazole and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Ketoconazole and Zolpidem: moderate severity. Ketoconazole inhibits CYP3A4, increasing zolpidem exposure and sedative effects.

  ›
• K

  ketorolac and lithium: Interaction, Risks, and Safer Alternatives

  Interaction between Ketorolac and Lithium: major severity. NSAIDs inhibit renal prostaglandin synthesis, reducing renal blood flow and lith

  ›
• K

  ketorolac and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ketorolac and Warfarin: major severity. Ketorolac inhibits platelet function and damages gastrointestinal mucosa, while

  ›
• L

  lamotrigine and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Lamotrigine and Paracetamol: minor severity. Regular paracetamol administration may enhance glucuronidation of lamotrigine, m

  ›
• L

  lamotrigine and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Lamotrigine and Sertraline: minor severity. Sertraline may modestly inhibit lamotrigine glucuronidation in some patients, in

  ›
• L

  lamotrigine and sodium-valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Lamotrigine and Sodium Valproate: major severity. Valproate inhibits UGT1A4-mediated glucuronidation of lamotrigine, doubling lamo

  ›
• L

  lamotrigine and valproate: Interaction, Risks, and Safer

  Interaction between Lamotrigine and Valproate: major severity. Valproate inhibits UGT1A4-mediated glucuronidation of lamotrigine, more than dou

  ›
• L

  lamotrigine and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Lamotrigine and Valproic Acid: major severity. Valproate inhibits UGT1A4-mediated glucuronidation of lamotrigine, doubling its

  ›
• L

  lansoprazole and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Lansoprazole and Methotrexate: moderate severity. Proton pump inhibitors reduce renal tubular secretion of methotrexate and its me

  ›
• L

  lansoprazole and rilpivirine: Interaction, Risks, and Safer Alternatives

  Interaction between Lansoprazole and Rilpivirine: major severity. Proton pump inhibitors raise gastric pH, markedly reducing the dissolution and a

  ›
• L

  ledipasvir and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ledipasvir and Rosuvastatin: major severity. Ledipasvir inhibits OATP1B1 and BCRP transporters that mediate rosuvastatin hepa

  ›
• L

  leflunomide and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Leflunomide and Methotrexate: major severity. Both drugs are immunosuppressive disease-modifying antirheumatic agents with ove

  ›
• L

  levetiracetam and methotrexate: Interaction, Risks, and Safer Alternatives

  Interaction between Levetiracetam and Methotrexate: moderate severity. Levetiracetam may reduce renal clearance of high-dose methotrexate via competiti

  ›
• L

  levodopa and metoclopramide: Interaction, Risks, and Safer

  Interaction between Levodopa and Metoclopramide: major severity. Metoclopramide is a central dopamine D2 receptor antagonist that opposes the the

  ›
• L

  levodopa and oral-iron: Interaction, Risks, and Safer Alternatives

  Interaction between Levodopa and Oral Iron: minor severity. Iron can chelate levodopa in the gastrointestinal tract and reduce its absorptio

  ›
• L

  levodopa and pyridoxine: Interaction, Risks, and Safer Alternatives

  Interaction between Levodopa and Pyridoxine: moderate severity. Pyridoxine is a cofactor for aromatic L-amino acid decarboxylase, accelerating p

  ›
• L

  levodopa and risperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Levodopa and Risperidone: moderate severity. Risperidone antagonizes dopamine D2 receptors, opposing the pharmacodynamic effe

  ›
• L

  levodopa-carbidopa and metoclopramide: Interaction, Risks, and Safer Alternatives

  Interaction between Levodopa Carbidopa and Metoclopramide: major severity. Metoclopramide blocks central dopamine D2 receptors and can antagonize the thera

  ›
• L

  levofloxacin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Levofloxacin and Prednisolone: moderate severity. Fluoroquinolones and systemic corticosteroids both increase risk of tendinopathy

  ›
• L

  levofloxacin and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Levofloxacin and Prednisone: moderate severity. Fluoroquinolones and systemic corticosteroids have additive toxicity on tendon c

  ›
• L

  levofloxacin and theophylline: Interaction, Risks, and Safer Alternatives

  Interaction between Levofloxacin and Theophylline: moderate severity. Fluoroquinolones may reduce theophylline clearance through CYP1A2-related effect

  ›
• L

  levofloxacin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Levofloxacin and Warfarin: moderate severity. Levofloxacin alters gut flora producing vitamin K and may displace warfarin from

  ›
• L

  levonorgestrel and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Levonorgestrel and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and glucuronidation pathways, accelerating le

  ›
• L

  levothyroxine and calcium: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Calcium: moderate severity. Calcium binds levothyroxine in gut, reducing absorption by up to 30%.

  ›
• L

  levothyroxine and iron: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Iron: moderate severity. Iron binds levothyroxine in gut, reducing absorption.

  ›
• L

  levothyroxine and macrogol: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Macrogol: minor severity. Bulk laxatives and osmotic agents may modestly reduce levothyroxine absorption w

  ›
• L

  levothyroxine and magnesium-oxide: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Magnesium Oxide: moderate severity. Magnesium can adsorb or complex with levothyroxine in the gastrointestinal tract

  ›
• L

  levothyroxine and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Metformin: minor severity. Metformin can lower serum TSH through a central or pituitary effect without cons

  ›
• L

  levothyroxine and omeprazole: Interaction, Risks, and Safer

  Interaction between Levothyroxine and Omeprazole: moderate severity. Reduced gastric acidity from proton pump inhibition impairs dissolution and abso

  ›
• L

  levothyroxine and oral-calcium: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Oral Calcium: moderate severity. Calcium salts chelate or adsorb levothyroxine in the gut, reducing levothyroxine

  ›
• L

  levothyroxine and oral-iron: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Oral Iron: minor severity. Iron salts chelate levothyroxine in the gastrointestinal tract, reducing absorpt

  ›
• L

  levothyroxine and orlistat: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Orlistat: moderate severity. Orlistat may reduce gastrointestinal absorption of levothyroxine, likely through

  ›
• L

  levothyroxine and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Pantoprazole: minor severity. Pantoprazole increases gastric pH, which can reduce dissolution and absorption o

  ›
• L

  levothyroxine and proton-pump-inhibitor: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Proton Pump Inhibitor: moderate severity. PPIs reduce gastric acid secretion, impairing dissolution and absorption of l

  ›
• L

  levothyroxine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Rifampicin: moderate severity. Rifampicin induces hepatic drug-metabolizing enzymes, increasing thyroid hormone

  ›
• L

  levothyroxine and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Sertraline: minor severity. Sertraline has been reported to increase levothyroxine requirements, possibly th

  ›
• L

  levothyroxine and sevelamer: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Sevelamer: moderate severity. Sevelamer binds levothyroxine in the gastrointestinal tract, reducing its absorp

  ›
• L

  levothyroxine and simethicone: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Simethicone: minor severity. Simethicone may adsorb or alter gastrointestinal availability of levothyroxine i

  ›
• L

  levothyroxine and sucralfate: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Sucralfate: moderate severity. Sucralfate binds levothyroxine in the gastrointestinal tract via aluminium chela

  ›
• L

  levothyroxine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Levothyroxine and Warfarin: moderate severity. Levothyroxine can increase catabolism of vitamin K-dependent clotting factors as

  ›
• L

  linagliptin and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Linagliptin and Rifampicin: moderate severity. Rifampicin induces CYP3A4 and P-glycoprotein, reducing linagliptin AUC by approx

  ›
• L

  linezolid and mirtazapine: Interaction, Risks, and Safer

  Interaction between Linezolid and Mirtazapine: major severity. Linezolid's MAO-A inhibition combined with mirtazapine's serotonergic activity c

  ›
• L

  linezolid and phenelzine: Interaction, Risks, and Safer Alternatives

  Interaction between Linezolid and Phenelzine: major severity. Linezolid is a weak reversible MAO inhibitor; combined with another MAOI, it cau

  ›
• L

  linezolid and pseudoephedrine: Interaction, Risks, and Safer

  Interaction between Linezolid and Pseudoephedrine: major severity. Linezolid is a reversible MAO inhibitor; co-administration with sympathomimetic

  ›
• L

  linezolid and serotonergic-agent: Interaction, Risks, and Safer

  Interaction between Linezolid and Serotonergic Agent: major severity. Linezolid is a reversible non-selective MAO inhibitor; combination with SSRIs, S

  ›
• L

  linezolid and sertraline: Interaction, Risks, and Safer

  Interaction between Linezolid and Sertraline: major severity. Linezolid is a reversible non-selective MAO inhibitor; combination with serotone

  ›
• L

  linezolid and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Linezolid and Tramadol: major severity. Linezolid is a reversible non-selective MAO inhibitor; combined with the seroton

  ›
• L

  linezolid and trazodone: Interaction, Risks, and Safer Alternatives

  Interaction between Linezolid and Trazodone: major severity. Linezolid is a reversible monoamine oxidase inhibitor, and trazodone increases s

  ›
• L

  linezolid and tyramine-rich-foods: Interaction, Risks, and Safer Alternatives

  Interaction between Linezolid and Tyramine Rich Foods: major severity. Linezolid is a reversible non-selective monoamine oxidase inhibitor; concurrent

  ›
• L

  linezolid and tyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Linezolid and Tyramine: major severity. Linezolid is a reversible non-selective MAO inhibitor; ingestion of tyramine-ric

  ›
• L

  linezolid and venlafaxine: Interaction, Risks, and Safer

  Interaction between Linezolid and Venlafaxine: major severity. Linezolid is a reversible MAO inhibitor; combined with serotonergic SNRIs it can

  ›
• L

  lisinopril and lithium: Interaction, Risks, and Safer

  Interaction between Lisinopril and Lithium: major severity. ACE inhibitors reduce renal lithium excretion by decreasing glomerular filtratio

  ›
• L

  lisinopril and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Losartan: major severity. Both drugs block the renin-angiotensin system, increasing risk of hyperkalemia,

  ›
• L

  lisinopril and metformin: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Metformin: minor severity. ACE inhibitors may improve insulin sensitivity and glucose uptake, which can sli

  ›
• L

  lisinopril and naproxen: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Naproxen: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, reducing afferent arteriolar dilat

  ›
• L

  lisinopril and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Potassium Chloride: moderate severity. ACE inhibitors reduce aldosterone production, lowering renal potassium excretion

  ›
• L

  lisinopril and sacubitril-valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Sacubitril Valsartan: major severity. Concurrent ACE inhibition and neprilysin inhibition raise bradykinin levels, dra

  ›
• L

  lisinopril and sacubitril: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Sacubitril: major severity. ACE inhibition from lisinopril and neprilysin inhibition from sacubitril both in

  ›
• L

  lisinopril and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Spironolactone: moderate severity. Both drugs reduce renal potassium excretion (ACE inhibition reduces aldosterone;

  ›
• L

  lisinopril and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Sulfamethoxazole Trimethoprim: moderate severity. Trimethoprim acts like a potassium-sparing diuretic by blocking epitheli

  ›
• L

  lisinopril and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Lisinopril and Trimethoprim: moderate severity. Trimethoprim reduces renal potassium excretion through an amiloride-like effect,

  ›
• L

  lithium and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Ibuprofen: major severity. NSAIDs reduce renal lithium clearance, raising lithium levels into toxic range.

  ›
• L

  lithium and losartan: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Losartan: moderate severity. Angiotensin II receptor blockers reduce renal perfusion and aldosterone-mediated

  ›
• L

  lithium and macrogol: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Macrogol: minor severity. Significant diarrhea from osmotic laxatives can cause volume depletion and sodiu

  ›
• L

  lithium and meloxicam: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Meloxicam: moderate severity. NSAIDs reduce renal prostaglandin synthesis, lowering renal blood flow and lithi

  ›
• L

  lithium and metronidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Metronidazole: moderate severity. Metronidazole has been associated with reduced renal lithium clearance, increasi

  ›
• L

  lithium and naproxen: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Naproxen: moderate severity. NSAIDs reduce renal prostaglandin synthesis, decreasing renal blood flow and lit

  ›
• L

  lithium and nsaid: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Nsaid: major severity. NSAIDs reduce renal prostaglandin synthesis, decreasing lithium clearance and ra

  ›
• L

  lithium and nsaids: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Nsaids: major severity. NSAIDs reduce renal prostaglandin synthesis, decreasing renal blood flow and lit

  ›
• L

  lithium and perindopril: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Perindopril: moderate severity. ACE inhibitors can reduce renal lithium clearance through effects on glomerular

  ›
• L

  lithium and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Ramipril: moderate severity. ACE inhibitors reduce renal blood flow and lithium clearance via decreased glome

  ›
• L

  lithium and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Sertraline: moderate severity. Lithium and sertraline have additive serotonergic and central nervous system eff

  ›
• L

  lithium and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Spironolactone: moderate severity. Spironolactone can alter renal sodium and water handling, reducing lithium clear

  ›
• L

  lithium and thiazide-diuretic: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Thiazide Diuretic: major severity. Diuretics reduce lithium clearance, raising levels.

  ›
• L

  lithium and thiazide-diuretics: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Thiazide Diuretics: major severity. Thiazide diuretics reduce renal lithium clearance through enhanced proximal tubu

  ›
• L

  lithium and thiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Thiazide: major severity. Thiazide diuretics reduce sodium reabsorption in distal tubule, triggering compe

  ›
• L

  lithium and thiazides: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Thiazides: major severity. Thiazide diuretics reduce renal sodium reabsorption, leading to compensatory inc

  ›
• L

  lithium and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Lithium and Valsartan: major severity. Angiotensin II receptor blockers reduce renal sodium and lithium excretion throu

  ›
• L

  loperamide and quinidine: Interaction, Risks, and Safer Alternatives

  Interaction between Loperamide and Quinidine: major severity. Quinidine inhibits P-glycoprotein at the blood-brain barrier, allowing loperamid

  ›
• L

  lopinavir and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Lopinavir and Rosuvastatin: moderate severity. Lopinavir/ritonavir inhibits OATP1B1 transporters that mediate hepatic uptake of

  ›
• L

  lopinavir and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Lopinavir and Simvastatin: major severity. Lopinavir boosted with ritonavir strongly inhibits CYP3A4, causing large increas

  ›
• L

  lopinavir-ritonavir and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Lopinavir Ritonavir and Rifampicin: major severity. Rifampicin is a potent CYP3A4 and P-glycoprotein inducer, dramatically reducing

  ›
• L

  lopinavir-ritonavir and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Lopinavir Ritonavir and Rivaroxaban: major severity. Ritonavir potently inhibits both CYP3A4 and P-glycoprotein, more than doubling r

  ›
• L

  lorazepam and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Lorazepam and Morphine: major severity. Both drugs depress central nervous system activity through opioid receptor activ

  ›
• L

  lorazepam and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Lorazepam and Oxycodone: major severity. Lorazepam enhances GABA-A receptor-mediated inhibition while oxycodone activates

  ›
• L

  lorazepam and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Lorazepam and Zolpidem: minor severity. Zolpidem and lorazepam both enhance GABA-A receptor-mediated CNS inhibition. Add

  ›
• L

  losartan and naproxen: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Naproxen: moderate severity. Naproxen inhibits renal prostaglandin synthesis and may reduce renal perfusion,

  ›
• L

  losartan and nsaids: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Nsaids: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, reducing afferent arteriolar vasod

  ›
• L

  losartan and potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Potassium Chloride: moderate severity. Angiotensin II receptor blockade reduces aldosterone-driven renal potassium excr

  ›
• L

  losartan and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Ramipril: major severity. Combined angiotensin-receptor blockade and angiotensin-converting-enzyme inhibit

  ›
• L

  losartan and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Rifampicin: moderate severity. Rifampicin induces CYP2C9 and CYP3A4, increasing metabolism of losartan and its

  ›
• L

  losartan and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Spironolactone: moderate severity. Combined RAAS blockade and potassium-sparing diuretic effect reduce renal potass

  ›
• L

  losartan and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Sulfamethoxazole Trimethoprim: moderate severity. Trimethoprim acts like a potassium-sparing diuretic by blocking epithelial

  ›
• L

  losartan and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Losartan and Trimethoprim: moderate severity. Trimethoprim blocks the renal epithelial sodium channel and inhibits potassium e

  ›
• M

  macitentan and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Macitentan and Rifampicin: moderate severity. Rifampicin induces CYP3A4 and other drug-metabolizing pathways, reducing maciten

  ›
• M

  macrogol and mycophenolate: Interaction, Risks, and Safer Alternatives

  Interaction between Macrogol and Mycophenolate: minor severity. Osmotic laxatives may accelerate gastrointestinal transit and reduce absorption

  ›
• M

  macrogol and oral-potassium-chloride: Interaction, Risks, and Safer Alternatives

  Interaction between Macrogol and Oral Potassium Chloride: minor severity. Osmotic laxatives can accelerate gastrointestinal transit and may reduce absorpt

  ›
• M

  macrogol and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Macrogol and Phenytoin: moderate severity. Enteral nutrition and bulk laxatives bind phenytoin in the gut, reducing oral bi

  ›
• M

  macrogol and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Macrogol and Tacrolimus: minor severity. Macrogol-induced diarrhea or accelerated gastrointestinal transit may reduce tac

  ›
• M

  macrolide and statin: Interaction, Risks, and Safer Alternatives

  Interaction between Macrolide and Statin: major severity. Macrolides (especially clarithromycin and erythromycin) inhibit CYP3A4 metabolis

  ›
• M

  macrolide and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Macrolide and Tacrolimus: major severity. Macrolides (erythromycin, clarithromycin) inhibit CYP3A4 and P-glycoprotein, the

  ›
• M

  magnesium-hydroxide and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Magnesium Hydroxide and Tetracycline: moderate severity. Magnesium chelates tetracycline in the gastrointestinal tract, forming non-absor

  ›
• M

  magnesium-trisilicate and nitrofurantoin: Interaction, Risks, and Safer Alternatives

  Interaction between Magnesium Trisilicate and Nitrofurantoin: moderate severity. Magnesium trisilicate adsorbs nitrofurantoin in the gastrointestinal tract,

  ›
• M

  mao-inhibitor and tyramine-rich-foods: Interaction, Risks, and Safer Alternatives

  Interaction between Mao Inhibitor and Tyramine Rich Foods: major severity. Non-selective MAO inhibitors prevent breakdown of dietary tyramine, causing mass

  ›
• M

  maois and pethidine: Interaction, Risks, and Safer Alternatives

  Interaction between Maois and Pethidine: major severity. Pethidine inhibits serotonin reuptake; combined with MAOIs the resulting excess

  ›
• M

  meperidine and phenelzine: Interaction, Risks, and Safer Alternatives

  Interaction between Meperidine and Phenelzine: major severity. Meperidine (pethidine) inhibits neuronal serotonin reuptake, and combined with a

  ›
• M

  mercaptopurine and mesalazine: Interaction, Risks, and Safer Alternatives

  Interaction between Mercaptopurine and Mesalazine: moderate severity. Mesalazine inhibits thiopurine S-methyltransferase (TPMT), reducing 6-mercaptopu

  ›
• M

  mercaptopurine and olsalazine: Interaction, Risks, and Safer Alternatives

  Interaction between Mercaptopurine and Olsalazine: major severity. 5-Aminosalicylates inhibit thiopurine S-methyltransferase (TPMT), reducing methy

  ›
• M

  mercaptopurine and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Mercaptopurine and Trimethoprim: moderate severity. Trimethoprim-sulfamethoxazole and 6-mercaptopurine both suppress bone marrow; co

  ›
• M

  mercaptopurine and xanthine-oxidase-inhibitors: Interaction, Risks, and Safer Alternatives

  Interaction between Mercaptopurine and Xanthine Oxidase Inhibitors: major severity. Xanthine oxidase inhibitors such as allopurinol or febuxostat inhibit a m

  ›
• M

  meropenem and sodium-valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Meropenem and Sodium Valproate: major severity. Carbapenems reduce valproate plasma levels by 60-90% through inhibition of intes

  ›
• M

  meropenem and valproate: Interaction, Risks, and Safer

  Interaction between Meropenem and Valproate: major severity. Carbapenems lower valproate plasma concentrations by 60–90% within 24–48 hours,

  ›
• M

  meropenem and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Meropenem and Valproic Acid: major severity. Carbapenems inhibit hydrolysis of the valproate glucuronide back to active valpr

  ›
• M

  metformin and alcohol: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Alcohol: moderate severity. Alcohol increases lactic acidosis risk in metformin users, especially with binge

  ›
• M

  metformin and contrast-dye: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Contrast Dye: major severity. Risk of contrast-induced nephropathy and lactic acidosis in metformin users.

  ›
• M

  metformin and iv-contrast: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Iv Contrast: major severity. Risk of lactic acidosis with renal impairment from contrast.

  ›
• M

  metformin and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Prednisolone: moderate severity. Prednisolone increases hepatic gluconeogenesis and induces insulin resistance, o

  ›
• M

  metformin and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Prednisone: moderate severity. Systemic corticosteroids increase hepatic glucose production and induce insulin

  ›
• M

  metformin and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Propranolol: minor severity. Beta-blockers can mask adrenergic warning symptoms of hypoglycaemia such as trem

  ›
• M

  metformin and ranitidine: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Ranitidine: moderate severity. Ranitidine competes for renal tubular secretion via OCT2 transporters, reducing

  ›
• M

  metformin and ranolazine: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Ranolazine: moderate severity. Ranolazine inhibits OCT2-mediated renal tubular secretion of metformin and incre

  ›
• M

  metformin and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Rifampicin: minor severity. Rifampicin can increase metformin intestinal absorption and hepatic uptake throu

  ›
• M

  metformin and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Ritonavir: moderate severity. Ritonavir-containing regimens may affect renal transporters involved in metformi

  ›
• M

  metformin and sitagliptin: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Sitagliptin: minor severity. No significant pharmacokinetic interaction, but additive glucose-lowering effect

  ›
• M

  metformin and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Spironolactone: minor severity. Spironolactone may modestly alter glycemic control through effects on aldosteron

  ›
• M

  metformin and ssr-iodinated-contrast: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Ssr Iodinated Contrast: moderate severity. Although metformin itself does not cause contrast-induced nephropathy, transient

  ›
• M

  metformin and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Sulfamethoxazole Trimethoprim: moderate severity. Trimethoprim inhibits renal organic cation transporters involved in metfo

  ›
• M

  metformin and sulfonylureas: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Sulfonylureas: moderate severity. Metformin improves insulin sensitivity and reduces hepatic glucose production, w

  ›
• M

  metformin and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Topiramate: moderate severity. Topiramate is a carbonic anhydrase inhibitor causing metabolic acidosis, which c

  ›
• M

  metformin and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Trimethoprim Sulfamethoxazole: moderate severity. Trimethoprim inhibits OCT2 and MATE renal transporters that excrete metfo

  ›
• M

  metformin and trimethoprim: Interaction, Risks, and Safer

  Interaction between Metformin and Trimethoprim: moderate severity. Trimethoprim inhibits the renal organic cation transporter OCT2 and MATE1, reduc

  ›
• M

  metformin and vancomycin: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Vancomycin: moderate severity. Vancomycin-associated acute kidney injury can reduce renal clearance of metformi

  ›
• M

  metformin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Metformin and Verapamil: minor severity. Verapamil can inhibit organic cation transporter pathways involved in metformin

  ›
• M

  methadone and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Methadone and Ondansetron: moderate severity. Both drugs can prolong cardiac repolarization through effects on cardiac potassi

  ›
• M

  methadone and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Methadone and Quetiapine: moderate severity. Both drugs can prolong cardiac repolarization through effects on cardiac potassi

  ›
• M

  methadone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Methadone and Rifampicin: major severity. Rifampicin is a potent inducer of CYP3A4 and CYP2B6, accelerating methadone meta

  ›
• M

  methadone and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Methadone and Sertraline: moderate severity. Sertraline can inhibit methadone metabolism and both drugs may contribute to QT

  ›
• M

  methadone and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Methadone and Voriconazole: moderate severity. Voriconazole inhibits CYP3A4 and CYP2B6 pathways involved in methadone metabolis

  ›
• M

  methotrexate and naproxen: Interaction, Risks, and Safer

  Interaction between Methotrexate and Naproxen: major severity. NSAIDs inhibit renal prostaglandin synthesis and compete for tubular secretion,

  ›
• M

  methotrexate and omeprazole: Interaction, Risks, and Safer

  Interaction between Methotrexate and Omeprazole: moderate severity. Proton pump inhibitors reduce renal clearance of methotrexate via inhibition of

  ›
• M

  methotrexate and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Pantoprazole: moderate severity. Proton pump inhibitors may reduce renal tubular transport and clearance of metho

  ›
• M

  methotrexate and penicillin-v: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Penicillin V: moderate severity. Penicillins can reduce renal tubular secretion of methotrexate, increasing metho

  ›
• M

  methotrexate and penicillin: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Penicillin: major severity. Penicillins compete with methotrexate for renal tubular secretion via organic an

  ›
• M

  methotrexate and penicillins: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Penicillins: moderate severity. Penicillins may reduce renal tubular secretion of methotrexate through competiti

  ›
• M

  methotrexate and phenoxymethylpenicillin: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Phenoxymethylpenicillin: moderate severity. Penicillins may reduce renal tubular secretion of methotrexate, increasing m

  ›
• M

  methotrexate and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Probenecid: major severity. Probenecid inhibits renal tubular organic anion transporters (OAT1/OAT3) that se

  ›
• M

  methotrexate and proton-pump-inhibitor: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Proton Pump Inhibitor: moderate severity. PPIs inhibit renal tubular secretion of methotrexate via BCRP and MRP transpor

  ›
• M

  methotrexate and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Sulfamethoxazole Trimethoprim: major severity. Trimethoprim and methotrexate both inhibit folate pathways, and sulfameth

  ›
• M

  methotrexate and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Trimethoprim Sulfamethoxazole: major severity. Both drugs inhibit dihydrofolate reductase and trimethoprim-sulfamethoxaz

  ›
• M

  methotrexate and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Trimethoprim: major severity. Both inhibit folate metabolism — risk of severe pancytopenia.

  ›
• M

  methotrexate and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Methotrexate and Valproic Acid: moderate severity. Methotrexate may displace valproate from protein binding and can alter valproate

  ›
• M

  methylene-blue and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Methylene Blue and Sertraline: major severity. Methylene blue inhibits monoamine oxidase A, while sertraline increases synaptic

  ›
• M

  methylphenidate and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Methylphenidate and Warfarin: moderate severity. Methylphenidate inhibits hepatic metabolism of S-warfarin (via CYP2C9), potentia

  ›
• M

  metoclopramide and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Morphine: minor severity. Metoclopramide increases gastrointestinal motility, whereas morphine slows gastr

  ›
• M

  metoclopramide and olanzapine: Interaction, Risks, and Safer

  Interaction between Metoclopramide and Olanzapine: moderate severity. Both drugs are dopamine D2 antagonists; combined use increases the risk of extra

  ›
• M

  metoclopramide and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Ondansetron: moderate severity. Both agents prolong the QT interval; metoclopramide also has dopamine antagonist

  ›
• M

  metoclopramide and paracetamol: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Paracetamol: minor severity. Metoclopramide increases gastric emptying, which can accelerate paracetamol abso

  ›
• M

  metoclopramide and paroxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Paroxetine: moderate severity. Paroxetine inhibits CYP2D6, which contributes to metoclopramide clearance, and b

  ›
• M

  metoclopramide and prochlorperazine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Prochlorperazine: moderate severity. Both drugs antagonise central D2 dopamine receptors, producing additive risk of

  ›
• M

  metoclopramide and promethazine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Promethazine: moderate severity. Both drugs block central dopamine pathways and can produce additive extrapyramid

  ›
• M

  metoclopramide and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Quetiapine: moderate severity. Both drugs antagonize dopamine D2 receptors, increasing the risk of extrapyramid

  ›
• M

  metoclopramide and risperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Risperidone: moderate severity. Both drugs antagonise central dopamine D2 receptors, producing additive risk of

  ›
• M

  metoclopramide and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Sertraline: moderate severity. Metoclopramide has dopamine antagonist and serotonergic activity, while sertrali

  ›
• M

  metoclopramide and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Tacrolimus: moderate severity. Metoclopramide increases gastric emptying and may enhance tacrolimus absorption,

  ›
• M

  metoclopramide and tetrabenazine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoclopramide and Tetrabenazine: major severity. Both drugs antagonise central dopamine D2 receptors, additively increasing risk

  ›
• M

  metoprolol and mirabegron: Interaction, Risks, and Safer Alternatives

  Interaction between Metoprolol and Mirabegron: moderate severity. Mirabegron is a moderate CYP2D6 inhibitor, increasing exposure to CYP2D6 substra

  ›
• M

  metoprolol and paroxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Metoprolol and Paroxetine: moderate severity. Paroxetine is a potent CYP2D6 inhibitor and metoprolol is a CYP2D6 substrate; co

  ›
• M

  metoprolol and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Metoprolol and Sertraline: minor severity. Sertraline weakly inhibits CYP2D6 and may modestly reduce metoprolol metabolism,

  ›
• M

  metoprolol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Metoprolol and Verapamil: major severity. Both reduce heart rate and AV conduction — risk of bradycardia, heart block.

  ›
• M

  metronidazole and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Metronidazole and Phenytoin: moderate severity. Metronidazole inhibits CYP2C9, reducing phenytoin metabolism and producing supra

  ›
• M

  metronidazole and tinidazole: Interaction, Risks, and Safer Alternatives

  Interaction between Metronidazole and Tinidazole: moderate severity. Both drugs inhibit aldehyde dehydrogenase; concurrent alcohol exposure causes ac

  ›
• M

  metronidazole and warfarin: Interaction, Risks, and Safer

  Interaction between Metronidazole and Warfarin: major severity. Metronidazole inhibits CYP2C9-mediated metabolism of the more potent S-enantiome

  ›
• M

  miconazole and warfarin: Interaction, Risks, and Safer

  Interaction between Miconazole and Warfarin: major severity. Even topical/oral-gel miconazole inhibits CYP2C9 and CYP3A4, markedly potentiati

  ›
• M

  miconazole-oral-gel and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Miconazole Oral Gel and Warfarin: major severity. Even topically applied oral miconazole gel undergoes sufficient systemic absorpt

  ›
• M

  midazolam and morphine: Interaction, Risks, and Safer Alternatives

  Interaction between Midazolam and Morphine: major severity. Morphine activates opioid receptors and midazolam enhances GABA-A signaling, pro

  ›
• M

  midazolam and oral-ketoconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Midazolam and Oral Ketoconazole: major severity. Oral ketoconazole strongly inhibits intestinal and hepatic CYP3A4, markedly incr

  ›
• M

  midazolam and posaconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Midazolam and Posaconazole: major severity. Posaconazole strongly inhibits CYP3A4, markedly increasing midazolam exposure an

  ›
• M

  midazolam and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Midazolam and Ritonavir: major severity. Ritonavir is a potent CYP3A4 inhibitor that increases oral midazolam exposure 20

  ›
• M

  midazolam and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Midazolam and Voriconazole: major severity. Voriconazole strongly inhibits CYP3A4 metabolism of midazolam, increasing benzod

  ›
• M

  mifepristone and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Mifepristone and Simvastatin: major severity. Mifepristone inhibits CYP3A4 and can increase exposure to simvastatin, a CYP3A4

  ›
• M

  mineral-oil and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Mineral Oil and Warfarin: minor severity. Mineral oil may reduce absorption of fat-soluble vitamin K with prolonged use, p

  ›
• M

  minocycline and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Minocycline and Warfarin: moderate severity. Tetracyclines may enhance anticoagulation by altering gut vitamin K production a

  ›
• M

  mirtazapine and phenelzine: Interaction, Risks, and Safer Alternatives

  Interaction between Mirtazapine and Phenelzine: major severity. Phenelzine irreversibly inhibits monoamine oxidase, while mirtazapine enhances n

  ›
• M

  mirtazapine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Mirtazapine and Tramadol: moderate severity. Both drugs increase central serotonergic activity (mirtazapine via 5-HT2/3 antag

  ›
• M

  moclobemide and pethidine: Interaction, Risks, and Safer

  Interaction between Moclobemide and Pethidine: major severity. Pethidine has serotonergic activity and combined with the MAO-A inhibitor moclob

  ›
• M

  moclobemide and pseudoephedrine: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Pseudoephedrine: major severity. MAO-A inhibition by moclobemide prevents breakdown of noradrenaline released by

  ›
• M

  moclobemide and selegiline: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Selegiline: major severity. Combined inhibition of MAO-A (moclobemide) and MAO-B (selegiline at higher doses

  ›
• M

  moclobemide and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Sertraline: major severity. Combined MAO-A inhibition (moclobemide) and serotonin reuptake inhibition (sertr

  ›
• M

  moclobemide and sumatriptan: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Sumatriptan: major severity. Moclobemide inhibits MAO-A, the enzyme that metabolizes sumatriptan, doubling tr

  ›
• M

  moclobemide and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Tramadol: major severity. Tramadol is a serotonin and noradrenaline reuptake inhibitor; combined with the

  ›
• M

  moclobemide and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Moclobemide and Venlafaxine: major severity. Combining the MAO-A inhibitor moclobemide with the serotonin-noradrenaline reupt

  ›
• M

  monoamine-oxidase-inhibitors and pseudoephedrine: Interaction, Risks, and Safer Alternatives

  Interaction between Monoamine Oxidase Inhibitors and Pseudoephedrine: major severity. Monoamine oxidase inhibitors reduce catecholamine breakdown, while pseu

  ›
• M

  morphine and nalbuphine: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Nalbuphine: moderate severity. Nalbuphine is a mixed opioid agonist-antagonist with mu-opioid receptor antagoni

  ›
• M

  morphine and naloxegol: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Naloxegol: minor severity. Naloxegol is a peripherally acting mu-opioid receptor antagonist that can oppose

  ›
• M

  morphine and naloxone: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Naloxone: minor severity. Naloxone competitively antagonizes opioid receptors and can reverse morphine eff

  ›
• M

  morphine and naltrexone: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Naltrexone: major severity. Naltrexone is a competitive opioid receptor antagonist that blocks the analgesic

  ›
• M

  morphine and oxazepam: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Oxazepam: major severity. Additive CNS depression and respiratory depression through synergistic effects o

  ›
• M

  morphine and pregabalin: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Pregabalin: moderate severity. Morphine activates opioid receptors and pregabalin reduces excitatory neurotrans

  ›
• M

  morphine and promethazine: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Promethazine: moderate severity. Both agents depress central nervous system activity through opioid receptor agon

  ›
• M

  morphine and propranolol: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Propranolol: minor severity. Both drugs can lower blood pressure through pharmacodynamic effects, including v

  ›
• M

  morphine and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Quetiapine: moderate severity. Both drugs depress the central nervous system through opioid receptor activity a

  ›
• M

  morphine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Rifampicin: moderate severity. Rifampicin induces UGT2B7 and CYP3A4, accelerating morphine glucuronidation and

  ›
• M

  morphine and temazepam: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Temazepam: major severity. Both drugs depress central nervous system activity through opioid receptor and G

  ›
• M

  morphine and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Zolpidem: major severity. Both drugs depress central nervous system activity through opioid and GABAergic

  ›
• M

  morphine and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Morphine and Zopiclone: moderate severity. Morphine and zopiclone produce additive central nervous system depression throug

  ›
• M

  moxifloxacin and ondansetron: Interaction, Risks, and Safer Alternatives

  Interaction between Moxifloxacin and Ondansetron: moderate severity. Both agents block the hERG potassium channel and prolong the QT interval, with a

  ›
• M

  mycophenolate and oral-contraceptives: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate and Oral Contraceptives: moderate severity. Mycophenolate may reduce ethinylestradiol exposure through enterohepatic disrup

  ›
• M

  mycophenolate and proton-pump-inhibitor: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate and Proton Pump Inhibitor: moderate severity. PPI-induced gastric pH elevation reduces dissolution and absorption of mycoph

  ›
• M

  mycophenolate and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate and Rifampicin: major severity. Rifampicin induces UGT enzymes and disrupts enterohepatic recirculation of mycop

  ›
• M

  mycophenolate and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate and Tacrolimus: minor severity. Tacrolimus reduces enterohepatic recycling of mycophenolic acid through inhibiti

  ›
• M

  mycophenolate-mofetil and omeprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate Mofetil and Omeprazole: minor severity. Proton pump inhibitors can increase gastric pH and reduce dissolution or absorpt

  ›
• M

  mycophenolate-mofetil and oral-magnesium: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate Mofetil and Oral Magnesium: minor severity. Magnesium-containing antacids can bind mycophenolic acid products in the gut an

  ›
• M

  mycophenolate-mofetil and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate Mofetil and Pantoprazole: minor severity. Pantoprazole raises gastric pH and can reduce dissolution and absorption of myco

  ›
• M

  mycophenolate-mofetil and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate Mofetil and Rifampicin: major severity. Rifampicin induces UGT enzymes responsible for mycophenolic acid glucuronidation

  ›
• M

  mycophenolate-mofetil and sevelamer: Interaction, Risks, and Safer Alternatives

  Interaction between Mycophenolate Mofetil and Sevelamer: moderate severity. Sevelamer binds mycophenolic acid in the gut, reducing AUC by approximately 25-3

  ›
• N

  naltrexone and oxycodone: Interaction, Risks, and Safer Alternatives

  Interaction between Naltrexone and Oxycodone: major severity. Naltrexone competitively antagonizes opioid receptors, blocking oxycodone analge

  ›
• N

  naproxen and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Prednisolone: moderate severity. Naproxen can injure gastric mucosa through COX inhibition, and prednisolone inde

  ›
• N

  naproxen and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Prednisone: moderate severity. Naproxen inhibits cyclooxygenase-dependent gastroprotective prostaglandins, whil

  ›
• N

  naproxen and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, attenuating ACE inhibitor antihype

  ›
• N

  naproxen and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Rivaroxaban: moderate severity. Naproxen inhibits platelet function and can injure gastrointestinal mucosa, whil

  ›
• N

  naproxen and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Sertraline: moderate severity. SSRIs deplete platelet serotonin and impair platelet aggregation; combined with

  ›
• N

  naproxen and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Naproxen and Warfarin: major severity. NSAIDs inhibit platelet aggregation, damage gastric mucosa, and displace warfari

  ›
• N

  natalizumab and ocrelizumab: Interaction, Risks, and Safer Alternatives

  Interaction between Natalizumab and Ocrelizumab: major severity. Both agents suppress immune function through different pathways, increasing risk

  ›
• N

  nelfinavir and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Nelfinavir and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and drug transporters, markedly reducing nelf

  ›
• N

  neostigmine and succinylcholine: Interaction, Risks, and Safer Alternatives

  Interaction between Neostigmine and Succinylcholine: major severity. Neostigmine inhibits plasma cholinesterase, the enzyme that hydrolyses succinylc

  ›
• N

  nifedipine and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Nifedipine and Phenytoin: moderate severity. Phenytoin induces CYP3A4, increasing nifedipine metabolism and reducing calcium-

  ›
• N

  nifedipine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Nifedipine and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, reducing nifedipine AUC by up to 90% and abo

  ›
• N

  nifedipine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Nifedipine and Simvastatin: minor severity. Nifedipine and simvastatin are both CYP3A4 substrates, and nifedipine may slight

  ›
• N

  nifedipine and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Nifedipine and Tacrolimus: moderate severity. Nifedipine and tacrolimus both undergo CYP3A4 metabolism; nifedipine increases t

  ›
• N

  nilotinib and pantoprazole: Interaction, Risks, and Safer Alternatives

  Interaction between Nilotinib and Pantoprazole: moderate severity. Nilotinib has pH-dependent solubility; proton pump inhibitors raise gastric pH a

  ›
• N

  nirmatrelvir-ritonavir and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Nirmatrelvir Ritonavir and Rivaroxaban: major severity. Ritonavir strongly inhibits CYP3A4 and P-glycoprotein, increasing rivaroxaban ex

  ›
• N

  nirmatrelvir-ritonavir and rosuvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Nirmatrelvir Ritonavir and Rosuvastatin: moderate severity. Ritonavir inhibits drug transporters including BCRP and OATP1B1, which can in

  ›
• N

  nirmatrelvir-ritonavir and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Nirmatrelvir Ritonavir and Simvastatin: major severity. Ritonavir is a strong CYP3A4 inhibitor and markedly reduces simvastatin metaboli

  ›
• N

  nirmatrelvir-ritonavir and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Nirmatrelvir Ritonavir and Tacrolimus: major severity. Ritonavir is a potent CYP3A4 and P-glycoprotein inhibitor, and tacrolimus is hig

  ›
• N

  nitrate and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrate and Sildenafil: major severity. Both drugs increase cGMP (sildenafil via PDE5 inhibition, nitrates via NO donati

  ›
• N

  nitrate and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrate and Tadalafil: major severity. PDE5 inhibitors potentiate nitrate-induced increases in cyclic GMP, producing pr

  ›
• N

  nitrates and riociguat: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrates and Riociguat: major severity. Both drugs increase nitric oxide-cGMP signaling and produce additive vasodilatio

  ›
• N

  nitrates and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrates and Sildenafil: major severity. Severe hypotension risk — both lower blood pressure dramatically.

  ›
• N

  nitrates and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrates and Tadalafil: major severity. Tadalafil inhibits phosphodiesterase type 5, increasing cyclic GMP, while nitrat

  ›
• N

  nitrendipine and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrendipine and Phenytoin: moderate severity. Phenytoin induces CYP3A4, which metabolizes many dihydropyridine calcium-channel

  ›
• N

  nitrendipine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrendipine and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, accelerating metabolism of dihydropyridine c

  ›
• N

  nitrofurantoin and norfloxacin: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrofurantoin and Norfloxacin: moderate severity. Quinolones antagonise the bactericidal action of nitrofurantoin in vitro and may

  ›
• N

  nitrofurantoin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrofurantoin and Probenecid: moderate severity. Probenecid blocks renal tubular secretion of nitrofurantoin, reducing urinary co

  ›
• N

  nitrofurantoin and sodium-bicarbonate: Interaction, Risks, and Safer Alternatives

  Interaction between Nitrofurantoin and Sodium Bicarbonate: moderate severity. Alkalinization of urine reduces tubular reabsorption of nitrofurantoin, lowerin

  ›
• N

  nitroglycerin and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitroglycerin and Sildenafil: major severity. Sildenafil potentiates nitric oxide-mediated cGMP accumulation, and concomitant

  ›
• N

  nitroglycerin and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Nitroglycerin and Tadalafil: major severity. PDE5 inhibitors potentiate the vasodilatory effects of nitric oxide donors by ac

  ›
• N

  nivolumab and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Nivolumab and Tacrolimus: major severity. Nivolumab blocks PD-1 signaling and enhances T-cell immune activity, while tacro

  ›
• N

  norethisterone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Norethisterone and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and other metabolic pathways, substantially l

  ›
• N

  nortriptyline and terbinafine: Interaction, Risks, and Safer Alternatives

  Interaction between Nortriptyline and Terbinafine: moderate severity. Terbinafine is a strong CYP2D6 inhibitor with a long elimination half-life. Co-a

  ›
• N

  nsaid and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaid and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis reducing afferent arteriolar vasodi

  ›
• N

  nsaid and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaid and Tacrolimus: major severity. NSAIDs reduce renal prostaglandin synthesis and afferent arteriolar vasodilation

  ›
• N

  nsaid and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaid and Warfarin: major severity. NSAIDs impair platelet function, damage gastric mucosa and (for some agents) dis

  ›
• N

  nsaids and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaids and Ramipril: moderate severity. NSAIDs inhibit renal prostaglandin synthesis, opposing the afferent arteriolar v

  ›
• N

  nsaids and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaids and Sertraline: moderate severity. Sertraline impairs platelet serotonin uptake and platelet aggregation, while NSA

  ›
• N

  nsaids and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaids and Spironolactone: moderate severity. NSAIDs reduce renal prostaglandin synthesis, which can impair renal perfusion an

  ›
• N

  nsaids and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Nsaids and Warfarin: major severity. NSAIDs displace warfarin from plasma proteins, inhibit platelet aggregation, and

  ›
• O

  olanzapine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Rifampicin: moderate severity. Rifampicin induces CYP1A2 and glucuronidation pathways involved in olanzapine me

  ›
• O

  olanzapine and smoking-cessation: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Smoking Cessation: moderate severity. Tobacco smoke induces CYP1A2, which increases olanzapine clearance; stopping smo

  ›
• O

  olanzapine and smoking-tobacco: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Smoking Tobacco: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing olan

  ›
• O

  olanzapine and smoking: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Smoking: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing olan

  ›
• O

  olanzapine and tobacco-smoking: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Tobacco Smoking: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing olan

  ›
• O

  olanzapine and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Olanzapine and Valproate: minor severity. Valproate may modestly alter olanzapine glucuronidation and systemic exposure, w

  ›
• O

  olaparib and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Olaparib and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, markedly reducing olaparib exposure and pote

  ›
• O

  omeprazole and phenytoin: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Phenytoin: moderate severity. Omeprazole can inhibit CYP2C19, reducing phenytoin metabolism in some patients.

  ›
• O

  omeprazole and posaconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Posaconazole: moderate severity. Omeprazole increases gastric pH, which can reduce absorption of some posaconazol

  ›
• O

  omeprazole and rilpivirine: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Rilpivirine: major severity. Omeprazole increases gastric pH, reducing absorption of rilpivirine, which requi

  ›
• O

  omeprazole and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Tacrolimus: moderate severity. Omeprazole inhibits CYP3A4 and CYP2C19, particularly in CYP2C19 poor metabolizer

  ›
• O

  omeprazole and vitamin-b12: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Vitamin B12: minor severity. Long-term gastric acid suppression can reduce the release of protein-bound vitam

  ›
• O

  omeprazole and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Voriconazole: moderate severity. Voriconazole inhibits CYP2C19 and CYP3A4 metabolism of omeprazole, doubling omep

  ›
• O

  omeprazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Omeprazole and Warfarin: minor severity. Omeprazole can inhibit CYP2C19 and may modestly affect metabolism of some warfar

  ›
• O

  ondansetron and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Quetiapine: moderate severity. Both ondansetron and quetiapine can prolong cardiac repolarization through effec

  ›
• O

  ondansetron and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Rifampicin: moderate severity. Rifampicin induces CYP3A4-mediated metabolism of ondansetron, reducing its plasm

  ›
• O

  ondansetron and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Sertraline: moderate severity. Both drugs prolong the QT interval and increase serotonergic tone, raising the r

  ›
• O

  ondansetron and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Sotalol: major severity. Both drugs prolong the QT interval (ondansetron via hERG potassium channel block

  ›
• O

  ondansetron and tramadol: Interaction, Risks, and Safer

  Interaction between Ondansetron and Tramadol: moderate severity. Ondansetron blocks 5-HT3 receptors central to tramadol's analgesic action and ma

  ›
• O

  ondansetron and trazodone: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Trazodone: moderate severity. Both ondansetron and trazodone can prolong ventricular repolarization through ef

  ›
• O

  ondansetron and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Ondansetron and Venlafaxine: moderate severity. Both agents can prolong cardiac repolarization through effects on cardiac ion ch

  ›
• O

  oral-calcium and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Oral Calcium and Tetracycline: moderate severity. Calcium chelates tetracycline in the gastrointestinal tract, forming poorly abso

  ›
• O

  oral-contraceptive and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Oral Contraceptive and Rifampicin: major severity. Rifampicin induces hepatic enzymes, dramatically reducing contraceptive effectiv

  ›
• O

  oral-contraceptives and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Oral Contraceptives and Rifampicin: major severity. Rifampicin induces CYP3A4 metabolism of estrogens and progestogens, reducing con

  ›
• O

  oral-potassium-chloride and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Oral Potassium Chloride and Spironolactone: major severity. Spironolactone blocks aldosterone receptors and reduces renal potassium excre

  ›
• O

  orlistat and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Orlistat and Warfarin: moderate severity. Orlistat can reduce absorption of fat-soluble vitamin K. Reduced vitamin K avail

  ›
• O

  oxycodone and paroxetine: Interaction, Risks, and Safer Alternatives

  Interaction between Oxycodone and Paroxetine: moderate severity. Paroxetine strongly inhibits CYP2D6, reducing formation of oxymorphone from oxyc

  ›
• O

  oxycodone and pregabalin: Interaction, Risks, and Safer Alternatives

  Interaction between Oxycodone and Pregabalin: major severity. Additive CNS and respiratory depression through gabapentinoid α2δ binding and µ-

  ›
• O

  oxycodone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Oxycodone and Rifampicin: moderate severity. Rifampicin strongly induces CYP3A4, increasing oxycodone metabolism and reducing

  ›
• O

  oxycodone and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Oxycodone and Zopiclone: major severity. Both drugs depress central nervous system activity through GABAergic and opioid

  ›
• P

  paclitaxel and trastuzumab: Interaction, Risks, and Safer Alternatives

  Interaction between Paclitaxel and Trastuzumab: moderate severity. Paclitaxel and trastuzumab can both contribute to cardiac dysfunction through ph

  ›
• P

  palbociclib and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Palbociclib and Rifampicin: major severity. Rifampicin strongly induces CYP3A4, markedly reducing palbociclib exposure and p

  ›
• P

  pantoprazole and rilpivirine: Interaction, Risks, and Safer Alternatives

  Interaction between Pantoprazole and Rilpivirine: major severity. Proton pump inhibitors markedly increase gastric pH, reducing rilpivirine solubi

  ›
• P

  paracetamol and alcohol: Interaction, Risks, and Safer Alternatives

  Interaction between Paracetamol and Alcohol: moderate severity. Chronic heavy alcohol use induces CYP2E1, increasing paracetamol's hepatotoxic m

  ›
• P

  paracetamol and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Paracetamol and Warfarin: minor severity. Repeated high-dose paracetamol may enhance warfarin anticoagulation, possibly th

  ›
• P

  paroxetine and risperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Paroxetine and Risperidone: moderate severity. Paroxetine inhibits CYP2D6, blocking risperidone conversion and clearance, raisi

  ›
• P

  paroxetine and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Paroxetine and Tamoxifen: major severity. Paroxetine is a potent CYP2D6 inhibitor and blocks the conversion of tamoxifen t

  ›
• P

  paroxetine and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Paroxetine and Tamsulosin: moderate severity. Paroxetine potently inhibits CYP2D6 metabolism of tamsulosin, doubling its expos

  ›
• P

  paroxetine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Paroxetine and Tramadol: major severity. Paroxetine inhibits CYP2D6, the enzyme that converts tramadol to its active opio

  ›
• P

  paroxetine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Paroxetine and Warfarin: moderate severity. Paroxetine impairs platelet serotonin-mediated aggregation and may modestly inhi

  ›
• P

  paxlovid and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Paxlovid and Simvastatin: major severity. Ritonavir in Paxlovid is a strong CYP3A4 inhibitor, and simvastatin depends heav

  ›
• P

  pembrolizumab and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Pembrolizumab and Prednisolone: moderate severity. Systemic corticosteroids suppress T-cell activation and cytokine signaling, whic

  ›
• P

  pembrolizumab and prednisone: Interaction, Risks, and Safer Alternatives

  Interaction between Pembrolizumab and Prednisone: moderate severity. Prednisone produces glucocorticoid receptor-mediated immunosuppression, which ca

  ›
• P

  penicillamine and zinc: Interaction, Risks, and Safer Alternatives

  Interaction between Penicillamine and Zinc: moderate severity. Zinc and penicillamine form a chelate complex in the gut, reducing absorption of

  ›
• P

  penicillin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Penicillin and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters, reducing tubular secretion

  ›
• P

  penicillin-v and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Penicillin V and Probenecid: minor severity. Probenecid inhibits renal organic anion transporters responsible for tubular sec

  ›
• P

  phenelzine and pseudoephedrine: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Pseudoephedrine: major severity. Pseudoephedrine releases stored noradrenaline from sympathetic nerve terminals;

  ›
• P

  phenelzine and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Sertraline: major severity. MAO inhibition combined with SSRI-mediated serotonin reuptake blockade causes ex

  ›
• P

  phenelzine and sumatriptan: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Sumatriptan: major severity. Monoamine oxidase inhibition reduces sumatriptan metabolism and, together with s

  ›
• P

  phenelzine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Tramadol: major severity. Phenelzine inhibits monoamine oxidase, while tramadol inhibits serotonin and nor

  ›
• P

  phenelzine and tyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Tyramine: major severity. Phenelzine irreversibly inhibits MAO-A in the gut and liver, preventing the brea

  ›
• P

  phenelzine and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Phenelzine and Venlafaxine: major severity. Irreversible monoamine oxidase inhibition combined with serotonin and noradrenal

  ›
• P

  phenobarbital and prednisolone: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Prednisolone: moderate severity. Phenobarbital induces CYP3A4, accelerating prednisolone metabolism and reducing

  ›
• P

  phenobarbital and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Quetiapine: major severity. Phenobarbital strongly induces CYP3A4, dramatically reducing quetiapine plasma c

  ›
• P

  phenobarbital and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Rivaroxaban: major severity. Phenobarbital induces CYP3A4 and P-glycoprotein, both involved in rivaroxaban di

  ›
• P

  phenobarbital and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Valproate: moderate severity. Sodium valproate inhibits hepatic microsomal enzymes that metabolize phenobarbit

  ›
• P

  phenobarbital and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Valproic Acid: moderate severity. Valproate inhibits the hepatic metabolism of phenobarbital, raising phenobarbita

  ›
• P

  phenobarbital and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Voriconazole: major severity. Phenobarbital strongly induces CYP enzymes including CYP2C19, CYP2C9, and CYP3A4

  ›
• P

  phenobarbital and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Phenobarbital and Warfarin: moderate severity. Phenobarbital induces CYP2C9 and CYP3A4, increasing warfarin clearance and reduc

  ›
• P

  phenoxymethylpenicillin and probenecid: Interaction, Risks, and Safer Alternatives

  Interaction between Phenoxymethylpenicillin and Probenecid: minor severity. Probenecid inhibits organic anion transporters responsible for renal tubular sec

  ›
• P

  phenytoin and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Quetiapine: moderate severity. Phenytoin strongly induces CYP3A4, increasing quetiapine metabolism and lowering

  ›
• P

  phenytoin and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Rifampicin: major severity. Rifampicin is a potent inducer of CYP2C9, CYP2C19 and CYP3A4, accelerating pheny

  ›
• P

  phenytoin and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Rivaroxaban: major severity. Phenytoin is a strong inducer of CYP3A4 and P-glycoprotein, lowering rivaroxaban

  ›
• P

  phenytoin and sodium-valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Sodium Valproate: moderate severity. Valproate displaces phenytoin from plasma protein binding and can inhibit phenyt

  ›
• P

  phenytoin and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Sulfamethoxazole Trimethoprim: moderate severity. Sulfamethoxazole inhibits CYP2C9 and displaces phenytoin from plasma prot

  ›
• P

  phenytoin and sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Sulfamethoxazole: moderate severity. Sulfamethoxazole inhibits CYP2C9 metabolism of phenytoin and displaces it from p

  ›
• P

  phenytoin and theophylline: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Theophylline: moderate severity. Phenytoin induces hepatic CYP enzymes, increasing theophylline clearance. Theoph

  ›
• P

  phenytoin and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Trimethoprim Sulfamethoxazole: moderate severity. Sulfamethoxazole inhibits CYP2C9-mediated metabolism of phenytoin and may

  ›
• P

  phenytoin and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Trimethoprim: moderate severity. Trimethoprim inhibits CYP2C9-mediated phenytoin metabolism and adds antifolate e

  ›
• P

  phenytoin and tube-feeding: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Tube Feeding: moderate severity. Enteral nutrition formulas reduce phenytoin absorption by 60-75%, likely through

  ›
• P

  phenytoin and ulipristal: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Ulipristal: major severity. Phenytoin is a potent CYP3A4 inducer that accelerates metabolism of ulipristal a

  ›
• P

  phenytoin and valproate: Interaction, Risks, and Safer

  Interaction between Phenytoin and Valproate: moderate severity. Valproate displaces phenytoin from albumin and inhibits its metabolism, raising

  ›
• P

  phenytoin and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Phenytoin and Valproic Acid: moderate severity. Valproate displaces phenytoin from albumin binding sites and inhibits its metabo

  ›
• P

  phenytoin and voriconazole: Interaction, Risks, and Safer

  Interaction between Phenytoin and Voriconazole: major severity. Phenytoin induces CYP2C19 and CYP3A4 metabolism of voriconazole (reducing antifu

  ›
• P

  phenytoin and warfarin: Interaction, Risks, and Safer

  Interaction between Phenytoin and Warfarin: major severity. Phenytoin causes biphasic effects: initial inhibition of CYP2C9 raises INR, foll

  ›
• P

  pimozide and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Pimozide and Ritonavir: major severity. Ritonavir is a potent CYP3A4 inhibitor that markedly increases pimozide plasma c

  ›
• P

  pimozide and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Pimozide and Sertraline: major severity. Sertraline can increase pimozide exposure and both drugs may prolong the QT inte

  ›
• P

  pimozide and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Pimozide and Voriconazole: major severity. Voriconazole inhibits CYP3A4, reducing pimozide metabolism. Increased pimozide e

  ›
• P

  pioglitazone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Pioglitazone and Rifampicin: moderate severity. Rifampicin strongly induces CYP2C8, reducing pioglitazone AUC by approximately 5

  ›
• P

  piperacillin-tazobactam and vancomycin: Interaction, Risks, and Safer Alternatives

  Interaction between Piperacillin Tazobactam and Vancomycin: moderate severity. Co-administration is associated with increased incidence of acute kidney injur

  ›
• P

  posaconazole and sirolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Posaconazole and Sirolimus: major severity. Posaconazole strongly inhibits CYP3A4 and P-glycoprotein, which are key pathways

  ›
• P

  posaconazole and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Posaconazole and Tacrolimus: major severity. Posaconazole strongly inhibits CYP3A4, the main metabolic pathway for tacrolimus

  ›
• P

  posaconazole and venetoclax: Interaction, Risks, and Safer Alternatives

  Interaction between Posaconazole and Venetoclax: major severity. Posaconazole strongly inhibits CYP3A4, the main metabolic pathway for venetoclax

  ›
• P

  posaconazole and vincristine: Interaction, Risks, and Safer Alternatives

  Interaction between Posaconazole and Vincristine: major severity. Posaconazole inhibits CYP3A4-mediated vincristine metabolism, increasing exposur

  ›
• P

  potassium and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium and Spironolactone: major severity. Spironolactone reduces renal potassium excretion through mineralocorticoid recep

  ›
• P

  potassium-chloride and ramipril: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium Chloride and Ramipril: moderate severity. ACE inhibitors reduce aldosterone secretion, decreasing renal potassium excretio

  ›
• P

  potassium-chloride and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium Chloride and Spironolactone: major severity. Spironolactone blocks aldosterone-mediated potassium excretion in the collecting

  ›
• P

  potassium-chloride and triamterene: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium Chloride and Triamterene: moderate severity. Triamterene reduces distal renal potassium secretion, while potassium chloride d

  ›
• P

  potassium-chloride and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium Chloride and Trimethoprim: moderate severity. Trimethoprim blocks epithelial sodium channels in the distal nephron in an amilo

  ›
• P

  potassium-sparing-diuretics and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Potassium Sparing Diuretics and Trimethoprim: major severity. Trimethoprim has amiloride-like epithelial sodium channel blocking activity

  ›
• P

  prednisolone and quinolones: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisolone and Quinolones: moderate severity. Systemic corticosteroids and fluoroquinolones both increase risk of tendon injur

  ›
• P

  prednisolone and rifampicin: Interaction, Risks, and Safer

  Interaction between Prednisolone and Rifampicin: moderate severity. Rifampicin is a potent CYP3A4 inducer, accelerating corticosteroid metabolism an

  ›
• P

  prednisolone and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisolone and Ritonavir: moderate severity. Ritonavir strongly inhibits CYP3A4, reducing metabolism of systemic and some loc

  ›
• P

  prednisolone and salbutamol: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisolone and Salbutamol: minor severity. Systemic corticosteroids and beta2 agonists can both lower serum potassium throu

  ›
• P

  prednisolone and varicella-vaccine: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisolone and Varicella Vaccine: major severity. Immunosuppressive doses of systemic prednisolone impair cell-mediated immunity a

  ›
• P

  prednisolone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisolone and Warfarin: moderate severity. Corticosteroids potentiate warfarin's anticoagulant effect through unclear mecha

  ›
• P

  prednisone and quetiapine: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisone and Quetiapine: minor severity. Prednisone and quetiapine can both worsen glucose regulation through glucocortic

  ›
• P

  prednisone and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisone and Rifampicin: moderate severity. Rifampicin strongly induces CYP3A4, accelerating prednisone metabolism and reduc

  ›
• P

  prednisone and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisone and Ritonavir: moderate severity. Ritonavir strongly inhibits CYP3A4, reducing metabolism of systemic corticostero

  ›
• P

  prednisone and salbutamol: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisone and Salbutamol: moderate severity. Systemic corticosteroids and beta-2 agonists can each shift or promote loss of p

  ›
• P

  prednisone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Prednisone and Warfarin: moderate severity. Systemic corticosteroids may alter warfarin response through effects on hepatic

  ›
• P

  pregabalin and tapentadol: Interaction, Risks, and Safer Alternatives

  Interaction between Pregabalin and Tapentadol: moderate severity. Additive CNS depression through GABAergic (pregabalin) and opioid/noradrenergic

  ›
• P

  pregabalin and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Pregabalin and Tramadol: moderate severity. Both drugs cause additive CNS depression and lower the seizure threshold; tramad

  ›
• P

  primidone and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Primidone and Valproate: moderate severity. Valproate inhibits the metabolism of primidone's active metabolite phenobarbital

  ›
• P

  primidone and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Primidone and Valproic Acid: moderate severity. Valproate inhibits the metabolism of phenobarbital (an active metabolite of prim

  ›
• P

  probenecid and tenofovir-disoproxil: Interaction, Risks, and Safer Alternatives

  Interaction between Probenecid and Tenofovir Disoproxil: moderate severity. Probenecid inhibits renal organic anion transporters involved in tubular secreti

  ›
• P

  probenecid and valaciclovir: Interaction, Risks, and Safer Alternatives

  Interaction between Probenecid and Valaciclovir: minor severity. Probenecid inhibits renal tubular organic anion transport, reducing renal cleara

  ›
• P

  probenecid and zidovudine: Interaction, Risks, and Safer Alternatives

  Interaction between Probenecid and Zidovudine: moderate severity. Probenecid inhibits renal tubular secretion and glucuronidation pathways involve

  ›
• P

  propafenone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Propafenone and Warfarin: moderate severity. Propafenone inhibits CYP1A2, CYP2C9, and CYP3A4, reducing warfarin clearance and

  ›
• P

  propofol and remifentanil: Interaction, Risks, and Safer Alternatives

  Interaction between Propofol and Remifentanil: moderate severity. Pharmacodynamic synergy at GABA-A receptors (propofol) and mu-opioid receptors (

  ›
• P

  propranolol and rizatriptan: Interaction, Risks, and Safer Alternatives

  Interaction between Propranolol and Rizatriptan: moderate severity. Propranolol inhibits monoamine oxidase A and sulphotransferase metabolism of riz

  ›
• P

  propranolol and salbutamol: Interaction, Risks, and Safer Alternatives

  Interaction between Propranolol and Salbutamol: major severity. Propranolol non-selectively blocks β2-adrenergic receptors in bronchial smooth m

  ›
• P

  propranolol and sumatriptan: Interaction, Risks, and Safer Alternatives

  Interaction between Propranolol and Sumatriptan: minor severity. Propranolol has minimal clinically relevant effect on sumatriptan exposure compa

  ›
• P

  propranolol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Propranolol and Verapamil: major severity. Beta-blockade combined with non-dihydropyridine calcium channel blockade produce

  ›
• P

  pseudoephedrine and tranylcypromine: Interaction, Risks, and Safer Alternatives

  Interaction between Pseudoephedrine and Tranylcypromine: major severity. Monoamine oxidase inhibition prevents breakdown of noradrenaline released by ind

  ›
• Q

  quetiapine and rifampicin: Interaction, Risks, and Safer

  Interaction between Quetiapine and Rifampicin: major severity. Rifampicin is a potent CYP3A4 inducer that reduces quetiapine plasma concentrati

  ›
• Q

  quetiapine and ritonavir: Interaction, Risks, and Safer Alternatives

  Interaction between Quetiapine and Ritonavir: major severity. Ritonavir strongly inhibits CYP3A4, dramatically increasing quetiapine exposure

  ›
• Q

  quinapril and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Quinapril and Spironolactone: moderate severity. ACE inhibition reduces aldosterone-mediated potassium excretion, and spironolact

  ›
• Q

  quinapril and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Quinapril and Tetracycline: minor severity. Some quinapril formulations contain magnesium, which can chelate tetracycline in

  ›
• Q

  quinidine and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Rifampicin: major severity. Rifampicin strongly induces CYP3A4 and P-glycoprotein, increasing quinidine clea

  ›
• Q

  quinidine and risperidone: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Risperidone: moderate severity. Quinidine strongly inhibits CYP2D6, reducing risperidone metabolism to 9-hydroxy

  ›
• Q

  quinidine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Simvastatin: moderate severity. Quinidine inhibits CYP3A4 and P-glycoprotein to a clinically variable degree, wh

  ›
• Q

  quinidine and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Sotalol: major severity. Both are class III antiarrhythmics (quinidine also class Ia) that prolong the QT

  ›
• Q

  quinidine and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Tamsulosin: moderate severity. Quinidine inhibits CYP2D6, one of the metabolic pathways for tamsulosin. Increas

  ›
• Q

  quinidine and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Tramadol: moderate severity. Quinidine inhibits CYP2D6, blocking conversion of tramadol to its active O-desme

  ›
• Q

  quinidine and venetoclax: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Venetoclax: major severity. Quinidine inhibits P-glycoprotein and can inhibit CYP3A pathways relevant to ven

  ›
• Q

  quinidine and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Quinidine and Verapamil: major severity. Both drugs depress cardiac conduction, and verapamil can inhibit P-glycoprotein

  ›
• Q

  quinine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Quinine and Warfarin: moderate severity. Quinine can potentiate anticoagulation through hepatic metabolic effects and may

  ›
• Q

  quinolone and sucralfate: Interaction, Risks, and Safer

  Interaction between Quinolone and Sucralfate: moderate severity. Sucralfate contains aluminum that chelates fluoroquinolones in the GI tract, red

  ›
• Q

  quinolone and sulfonylurea: Interaction, Risks, and Safer Alternatives

  Interaction between Quinolone and Sulfonylurea: moderate severity. Fluoroquinolones may displace sulfonylureas from binding sites and influence pan

  ›
• Q

  quinolone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Quinolone and Warfarin: moderate severity. Ciprofloxacin and other fluoroquinolones inhibit CYP1A2 and CYP3A4, and may alte

  ›
• Q

  quinolones and sucralfate: Interaction, Risks, and Safer Alternatives

  Interaction between Quinolones and Sucralfate: moderate severity. Sucralfate's aluminium content chelates fluoroquinolones in the gut, reducing or

  ›
• Q

  quinolones and tizanidine: Interaction, Risks, and Safer Alternatives

  Interaction between Quinolones and Tizanidine: major severity. Ciprofloxacin and other fluoroquinolones are potent CYP1A2 inhibitors, dramatica

  ›
• R

  raltegravir and rifampicin: Interaction, Risks, and Safer Alternatives

  Interaction between Raltegravir and Rifampicin: moderate severity. Rifampicin induces UGT1A1, the enzyme responsible for raltegravir glucuronidatio

  ›
• R

  ramipril and sacubitril-valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Ramipril and Sacubitril Valsartan: major severity. Concurrent ACE inhibition and neprilysin inhibition raise bradykinin levels mark

  ›
• R

  ramipril and sacubitril: Interaction, Risks, and Safer Alternatives

  Interaction between Ramipril and Sacubitril: major severity. ACE inhibitors increase bradykinin, and sacubitril inhibits neprilysin-mediated

  ›
• R

  ramipril and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Ramipril and Spironolactone: moderate severity. ACE inhibitors reduce aldosterone-mediated potassium excretion; combined with po

  ›
• R

  ramipril and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ramipril and Trimethoprim Sulfamethoxazole: major severity. Trimethoprim blocks renal epithelial sodium channels (amiloride-like effect)

  ›
• R

  ramipril and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Ramipril and Trimethoprim: moderate severity. Trimethoprim blocks the epithelial sodium channel in the distal nephron (amilori

  ›
• R

  ranolazine and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ranolazine and Simvastatin: moderate severity. Ranolazine inhibits CYP3A4 and P-glycoprotein, increasing simvastatin exposure a

  ›
• R

  ranolazine and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Ranolazine and Verapamil: major severity. Verapamil inhibits CYP3A4 and P-glycoprotein, increasing ranolazine concentratio

  ›
• R

  rasagiline and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Rasagiline and Sertraline: moderate severity. Rasagiline inhibits monoamine oxidase B and sertraline increases serotonergic ne

  ›
• R

  rasagiline and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Rasagiline and Tramadol: major severity. Rasagiline (selective MAO-B inhibitor) loses selectivity at higher doses; tramad

  ›
• R

  rasagiline and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Rasagiline and Venlafaxine: major severity. Rasagiline selectively inhibits MAO-B but loses selectivity at higher doses; com

  ›
• R

  repaglinide and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Repaglinide and Trimethoprim: moderate severity. Trimethoprim can inhibit CYP2C8, which contributes to repaglinide metabolism. In

  ›
• R

  ribavirin and zidovudine: Interaction, Risks, and Safer Alternatives

  Interaction between Ribavirin and Zidovudine: major severity. Ribavirin inhibits phosphorylation of zidovudine to its active form, reducing an

  ›
• R

  ribociclib and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ribociclib and Simvastatin: major severity. Ribociclib inhibits CYP3A4, substantially increasing simvastatin exposure and th

  ›
• R

  ribociclib and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Ribociclib and Tamoxifen: major severity. Both drugs prolong the QT interval through different mechanisms, additively incr

  ›
• R

  rifabutin and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Rifabutin and Voriconazole: major severity. Rifabutin induces CYP enzymes and lowers voriconazole exposure, while voriconazo

  ›
• R

  rifampicin and rivaroxaban: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Rivaroxaban: major severity. Rifampicin is a strong inducer of CYP3A4 and P-glycoprotein, markedly reducing r

  ›
• R

  rifampicin and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Sertraline: moderate severity. Rifampicin induces CYP3A4 and CYP2C19, accelerating sertraline metabolism and lo

  ›
• R

  rifampicin and tacrolimus: Interaction, Risks, and Safer

  Interaction between Rifampicin and Tacrolimus: major severity. Rifampicin is a potent inducer of CYP3A4 and P-glycoprotein, dramatically reduci

  ›
• R

  rifampicin and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Tamoxifen: major severity. Rifampicin strongly induces CYP3A4 and CYP2C9, reducing tamoxifen plasma exposur

  ›
• R

  rifampicin and ticagrelor: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Ticagrelor: major severity. Rifampicin strongly induces CYP3A4 and reduces ticagrelor exposure, resulting in

  ›
• R

  rifampicin and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Voriconazole: major severity. Rifampicin induces CYP2C19 and CYP3A4, reducing voriconazole exposure by more th

  ›
• R

  rifampicin and warfarin: Interaction, Risks, and Safer

  Interaction between Rifampicin and Warfarin: major severity. Rifampicin induces CYP2C9, CYP3A4, and CYP1A2, accelerating metabolism of both w

  ›
• R

  rifampicin and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Rifampicin and Zolpidem: moderate severity. Rifampicin induces CYP3A4, accelerating zolpidem metabolism and reducing plasma

  ›
• R

  riociguat and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Riociguat and Sildenafil: major severity. Riociguat stimulates soluble guanylate cyclase and sildenafil inhibits phosphodi

  ›
• R

  risperidone and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Risperidone and Valproic Acid: minor severity. Co-administration has been associated with increased risk of generalized edema a

  ›
• R

  ritonavir and rivaroxaban: Interaction, Risks, and Safer

  Interaction between Ritonavir and Rivaroxaban: major severity. Ritonavir is a strong inhibitor of both CYP3A4 and P-glycoprotein, the dual elim

  ›
• R

  ritonavir and salmeterol: Interaction, Risks, and Safer

  Interaction between Ritonavir and Salmeterol: major severity. Ritonavir potently inhibits CYP3A4 metabolism of salmeterol, producing markedly

  ›
• R

  ritonavir and sildenafil: Interaction, Risks, and Safer

  Interaction between Ritonavir and Sildenafil: major severity. Ritonavir is a potent CYP3A4 inhibitor that increases sildenafil exposure up to

  ›
• R

  ritonavir and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Ritonavir and Simvastatin: major severity. Ritonavir is a potent CYP3A4 inhibitor that raises simvastatin exposure dramatic

  ›
• R

  ritonavir and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Ritonavir and Tacrolimus: major severity. Ritonavir is a potent CYP3A4 and P-glycoprotein inhibitor, causing large increas

  ›
• R

  ritonavir and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Ritonavir and Tadalafil: major severity. Ritonavir potently inhibits CYP3A4, dramatically increasing tadalafil exposure w

  ›
• R

  ritonavir and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Ritonavir and Tamsulosin: major severity. Ritonavir potently inhibits CYP3A4 and CYP2D6, dual pathways for tamsulosin meta

  ›
• R

  ritonavir and triazolam: Interaction, Risks, and Safer Alternatives

  Interaction between Ritonavir and Triazolam: major severity. Ritonavir strongly inhibits CYP3A4, the primary clearance pathway for triazolam.

  ›
• R

  rivaroxaban and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Rivaroxaban and St Johns Wort: major severity. St John's wort induces CYP3A4 and P-glycoprotein, increasing rivaroxaban metabol

  ›
• R

  rivaroxaban and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Rivaroxaban and Verapamil: moderate severity. Verapamil is a moderate inhibitor of both CYP3A4 and P-glycoprotein, increasing

  ›
• R

  rosuvastatin and ticagrelor: Interaction, Risks, and Safer Alternatives

  Interaction between Rosuvastatin and Ticagrelor: minor severity. Ticagrelor may inhibit breast cancer resistance protein and other transport path

  ›
• R

  rosuvastatin and transplant-cyclosporine: Interaction, Risks, and Safer Alternatives

  Interaction between Rosuvastatin and Transplant Cyclosporine: major severity. Cyclosporine inhibits OATP1B1, OATP1B3, BCRP, and other transport pathways, sub

  ›
• R

  rosuvastatin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Rosuvastatin and Warfarin: moderate severity. Rosuvastatin may potentiate warfarin's effect through displacement from plasma p

  ›
• S

  sacubitril and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril and Valsartan: minor severity. Although marketed as a fixed combination, when prescribed alongside additional v

  ›
• S

  sacubitril-valsartan and sildenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril Valsartan and Sildenafil: moderate severity. Both drugs lower systemic vascular resistance — sacubitril/valsartan via natriur

  ›
• S

  sacubitril-valsartan and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril Valsartan and Simvastatin: minor severity. Sacubitril-valsartan may inhibit hepatic uptake transporters such as OATP1B1 and

  ›
• S

  sacubitril-valsartan and sodium-aurothiomalate: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril Valsartan and Sodium Aurothiomalate: minor severity. Gold compounds may cause nitritoid reactions, and renin-angiotensin syste

  ›
• S

  sacubitril-valsartan and spironolactone: Interaction, Risks, and

  Interaction between Sacubitril Valsartan and Spironolactone: moderate severity. Both drugs raise serum potassium — sacubitril/valsartan via angiotensin recep

  ›
• S

  sacubitril-valsartan and trandolapril: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril Valsartan and Trandolapril: major severity. Combining neprilysin inhibition with ACE inhibition increases bradykinin accumul

  ›
• S

  sacubitril-valsartan and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Sacubitril Valsartan and Valsartan: major severity. Sacubitril-valsartan already contains valsartan, so additional valsartan duplica

  ›
• S

  salbutamol and sotalol: Interaction, Risks, and Safer Alternatives

  Interaction between Salbutamol and Sotalol: moderate severity. Sotalol blocks beta receptors and may antagonise salbutamol bronchodilation; it

  ›
• S

  salbutamol and spironolactone: Interaction, Risks, and Safer Alternatives

  Interaction between Salbutamol and Spironolactone: minor severity. Beta-2 agonists drive potassium intracellularly while spironolactone retains pot

  ›
• S

  salbutamol and theophylline: Interaction, Risks, and Safer Alternatives

  Interaction between Salbutamol and Theophylline: moderate severity. Both drugs increase intracellular cAMP and produce additive sympathomimetic and

  ›
• S

  salbutamol and timolol: Interaction, Risks, and Safer Alternatives

  Interaction between Salbutamol and Timolol: major severity. Ophthalmic timolol systemically blocks beta-2 receptors on bronchial smooth musc

  ›
• S

  salmeterol and timolol: Interaction, Risks, and Safer Alternatives

  Interaction between Salmeterol and Timolol: moderate severity. Timolol, including ophthalmic formulations, can block beta-2 receptors and antag

  ›
• S

  salmeterol and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Salmeterol and Voriconazole: major severity. Voriconazole inhibits CYP3A4, increasing systemic salmeterol exposure and risk o

  ›
• S

  selegiline and sertraline: Interaction, Risks, and Safer Alternatives

  Interaction between Selegiline and Sertraline: major severity. Combined MAO-B inhibition (selegiline) and serotonin reuptake inhibition (sertra

  ›
• S

  selegiline and sumatriptan: Interaction, Risks, and Safer Alternatives

  Interaction between Selegiline and Sumatriptan: major severity. Selegiline (MAO-B inhibitor; loses selectivity at higher doses) combined with th

  ›
• S

  selegiline and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Selegiline and Tramadol: major severity. Tramadol inhibits serotonin and noradrenaline reuptake; combined with selegiline

  ›
• S

  selegiline and tyramine-containing-foods: Interaction, Risks, and Safer Alternatives

  Interaction between Selegiline and Tyramine Containing Foods: major severity. At higher doses, selegiline loses MAO-B selectivity and inhibits MAO-A, prevent

  ›
• S

  selegiline and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Selegiline and Venlafaxine: major severity. Selegiline irreversibly inhibits MAO-B (and MAO-A at higher doses); combined wit

  ›
• S

  sertraline and st-johns-wort: Interaction, Risks, and Safer Alternatives

  Interaction between Sertraline and St Johns Wort: major severity. St John's wort has serotonergic activity and induces CYP enzymes and P-glycoprot

  ›
• S

  sertraline and sumatriptan: Interaction, Risks, and Safer

  Interaction between Sertraline and Sumatriptan: moderate severity. Both increase serotonergic activity — sertraline by blocking 5-HT reuptake, suma

  ›
• S

  sertraline and tramadol: Interaction, Risks, and Safer

  Interaction between Sertraline and Tramadol: major severity. Sertraline inhibits CYP2D6 (reducing analgesic activation of tramadol) while com

  ›
• S

  sertraline and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sertraline and Warfarin: moderate severity. Sertraline modestly inhibits CYP2C9 and impairs platelet aggregation via seroton

  ›
• S

  sevelamer and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Sevelamer and Tacrolimus: moderate severity. Sevelamer binds tacrolimus in the gastrointestinal tract, reducing absorption an

  ›
• S

  sevoflurane and succinylcholine: Interaction, Risks, and Safer Alternatives

  Interaction between Sevoflurane and Succinylcholine: major severity. Volatile anaesthetics together with depolarising neuromuscular blockers can trig

  ›
• S

  sevoflurane and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Sevoflurane and Verapamil: moderate severity. Both agents depress cardiac conduction and contractility; combined use can produ

  ›
• S

  sildenafil and simvastatin: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Simvastatin: minor severity. Sildenafil is a weak CYP3A4 substrate and minor inhibitor; co-administration wit

  ›
• S

  sildenafil and sodium-nitrite: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Sodium Nitrite: major severity. Both agents increase nitric oxide-cyclic guanosine monophosphate-mediated vasodi

  ›
• S

  sildenafil and sodium-nitroprusside: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Sodium Nitroprusside: major severity. Sildenafil inhibits phosphodiesterase type 5, increasing cGMP signalling, while

  ›
• S

  sildenafil and tadalafil: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Tadalafil: major severity. Both are PDE5 inhibitors; concurrent use produces additive systemic vasodilation

  ›
• S

  sildenafil and tamsulosin: Interaction, Risks, and Safer

  Interaction between Sildenafil and Tamsulosin: moderate severity. Both drugs cause vasodilation; PDE-5 inhibition combined with alpha-1 blockade c

  ›
• S

  sildenafil and terazosin: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Terazosin: moderate severity. Sildenafil increases cyclic GMP-mediated vasodilation, while terazosin blocks al

  ›
• S

  sildenafil and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Sildenafil and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and can increase sildenafil exposure. Both drugs have

  ›
• S

  simvastatin and ticagrelor: Interaction, Risks, and Safer Alternatives

  Interaction between Simvastatin and Ticagrelor: moderate severity. Ticagrelor inhibits CYP3A4, increasing simvastatin exposure and risk of myopathy

  ›
• S

  simvastatin and verapamil: Interaction, Risks, and Safer

  Interaction between Simvastatin and Verapamil: major severity. Verapamil inhibits CYP3A4 metabolism of simvastatin, raising plasma levels and t

  ›
• S

  simvastatin and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Simvastatin and Warfarin: moderate severity. Simvastatin may modestly increase warfarin anticoagulant effect, possibly throug

  ›
• S

  sirolimus and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Sirolimus and Voriconazole: major severity. Voriconazole is a potent CYP3A4 inhibitor that increases sirolimus exposure up t

  ›
• S

  sodium-bicarbonate and tetracycline: Interaction, Risks, and Safer Alternatives

  Interaction between Sodium Bicarbonate and Tetracycline: moderate severity. Sodium bicarbonate raises gastric pH which reduces dissolution of tetracycline,

  ›
• S

  sodium-polystyrene-sulfonate and sorbitol: Interaction, Risks, and Safer Alternatives

  Interaction between Sodium Polystyrene Sulfonate and Sorbitol: major severity. Concomitant sorbitol increases colonic exposure to sodium polystyrene sulfonat

  ›
• S

  sodium-valproate and topiramate: Interaction, Risks, and Safer Alternatives

  Interaction between Sodium Valproate and Topiramate: moderate severity. Combination increases risk of hyperammonaemic encephalopathy through synergistic

  ›
• S

  sodium-valproate and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sodium Valproate and Warfarin: moderate severity. Valproate displaces warfarin from albumin binding and may inhibit its metabolism

  ›
• S

  sotalol and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Tacrolimus: moderate severity. Sotalol prolongs cardiac repolarisation through potassium channel blockade. Tacr

  ›
• S

  sotalol and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Tamsulosin: minor severity. Sotalol can lower heart rate and blood pressure, while tamsulosin causes alpha-1

  ›
• S

  sotalol and terbutaline: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Terbutaline: moderate severity. Sotalol blocks beta receptors and may antagonize beta-2 agonist bronchodilation,

  ›
• S

  sotalol and terfenadine: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Terfenadine: major severity. Both drugs can prolong cardiac repolarization and the QT interval. Additive elec

  ›
• S

  sotalol and thiazide-diuretic: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Thiazide Diuretic: moderate severity. Thiazide-induced hypokalemia and hypomagnesemia increase the proarrhythmic risk

  ›
• S

  sotalol and thiazide-diuretics: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Thiazide Diuretics: moderate severity. Sotalol prolongs cardiac repolarization, and thiazide-induced hypokalaemia or hy

  ›
• S

  sotalol and thiazide: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Thiazide: moderate severity. Thiazide diuretics can cause hypokalemia and hypomagnesemia, which increase susc

  ›
• S

  sotalol and thioridazine: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Thioridazine: major severity. Both drugs prolong the QT interval through blockade of the IKr potassium channel

  ›
• S

  sotalol and tizanidine: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Tizanidine: moderate severity. Both drugs can lower heart rate and blood pressure through pharmacodynamic effec

  ›
• S

  sotalol and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Tramadol: minor severity. Sotalol prolongs cardiac repolarization through potassium channel blockade, and

  ›
• S

  sotalol and trazodone: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Trazodone: major severity. Sotalol prolongs cardiac repolarization through potassium channel blockade, and

  ›
• S

  sotalol and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Trimethoprim Sulfamethoxazole: major severity. Sotalol prolongs cardiac repolarization by potassium channel blockade, and tri

  ›
• S

  sotalol and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Trimethoprim: moderate severity. Trimethoprim can reduce renal tubular secretion of cationic drugs and may increa

  ›
• S

  sotalol and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Venlafaxine: moderate severity. Sotalol prolongs cardiac repolarization by potassium channel blockade, and venla

  ›
• S

  sotalol and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Verapamil: major severity. Sotalol has beta-blocking and QT-prolonging effects, while verapamil slows AV no

  ›
• S

  sotalol and ziprasidone: Interaction, Risks, and Safer Alternatives

  Interaction between Sotalol and Ziprasidone: major severity. Both drugs prolong the QT interval through delayed cardiac repolarisation (sotal

  ›
• S

  spironolactone and sulfamethoxazole-trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Spironolactone and Sulfamethoxazole Trimethoprim: major severity. Trimethoprim blocks epithelial sodium channels in the distal nephron in

  ›
• S

  spironolactone and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between Spironolactone and Tacrolimus: moderate severity. Both drugs raise serum potassium — spironolactone by aldosterone receptor antago

  ›
• S

  spironolactone and tolvaptan: Interaction, Risks, and Safer Alternatives

  Interaction between Spironolactone and Tolvaptan: moderate severity. Tolvaptan promotes free water excretion and can elevate serum sodium and potassi

  ›
• S

  spironolactone and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Spironolactone and Trimethoprim Sulfamethoxazole: major severity. Trimethoprim blocks distal tubular potassium secretion (acting like ami

  ›
• S

  spironolactone and trimethoprim: Interaction, Risks, and Safer

  Interaction between Spironolactone and Trimethoprim: moderate severity. Trimethoprim blocks distal tubular sodium channels in a manner similar to amilor

  ›
• S

  spironolactone and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Spironolactone and Valsartan: moderate severity. Both drugs reduce renal potassium excretion — spironolactone via aldosterone ant

  ›
• S

  ssri and maoi: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Maoi: major severity. Risk of fatal serotonin syndrome.

  ›
• S

  ssri and nsaid: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Nsaid: moderate severity. Combined increases gastrointestinal bleeding risk by 4-5x.

  ›
• S

  ssri and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Tamoxifen: major severity. Strong CYP2D6 inhibitors among the SSRIs (paroxetine, fluoxetine) reduce convers

  ›
• S

  ssri and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Tamsulosin: minor severity. SSRIs may mildly potentiate alpha-1 adrenergic blockade by tamsulosin via centra

  ›
• S

  ssri and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Tramadol: major severity. Both increase serotonin — risk of serotonin syndrome (agitation, hyperthermia, r

  ›
• S

  ssri and triptan: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Triptan: moderate severity. Both classes increase serotonergic activity; combined use can theoretically prec

  ›
• S

  ssri and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Ssri and Warfarin: moderate severity. Increased bleeding risk via platelet effects.

  ›
• S

  ssris and tamoxifen: Interaction, Risks, and Safer Alternatives

  Interaction between Ssris and Tamoxifen: major severity. Strong CYP2D6 inhibitors such as paroxetine and fluoxetine reduce tamoxifen conv

  ›
• S

  ssris and tramadol: Interaction, Risks, and Safer Alternatives

  Interaction between Ssris and Tramadol: major severity. Tramadol inhibits serotonin reuptake and lowers seizure threshold; combination w

  ›
• S

  st-john's-wort and tacrolimus: Interaction, Risks, and Safer Alternatives

  Interaction between St John'S Wort and Tacrolimus: major severity. St John's wort is a potent CYP3A4 and P-glycoprotein inducer that markedly reduc

  ›
• S

  st-john-s-wort and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between St John S Wort and Warfarin: moderate severity. St John's wort induces CYP3A4, CYP2C9, and P-glycoprotein through pregnane X rec

  ›
• S

  st-johns-wort and tacrolimus: Interaction, Risks, and Safer

  Interaction between St Johns Wort and Tacrolimus: major severity. St John's wort induces CYP3A4 and P-glycoprotein, substantially lowering tacroli

  ›
• S

  statin and fibrate: Interaction, Risks, and Safer Alternatives

  Interaction between Statin and Fibrate: major severity. Combined increases myopathy/rhabdomyolysis risk substantially, especially with g

  ›
• S

  statin and grapefruit-juice: Interaction, Risks, and Safer Alternatives

  Interaction between Statin and Grapefruit Juice: moderate severity. Grapefruit inhibits CYP3A4 — increases atorvastatin/simvastatin levels and myopa

  ›
• S

  statin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Statin and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, increasing exposure of simvastatin

  ›
• S

  statins and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Statins and Verapamil: moderate severity. Verapamil inhibits CYP3A4 metabolism of simvastatin, lovastatin and atorvastatin

  ›
• S

  sucralfate and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sucralfate and Warfarin: minor severity. Sucralfate may bind warfarin in the gastrointestinal tract, reducing absorption

  ›
• S

  sulfamethoxazole and sulfonylurea: Interaction, Risks, and Safer

  Interaction between Sulfamethoxazole and Sulfonylurea: moderate severity. Sulfamethoxazole inhibits CYP2C9, reducing sulfonylurea metabolism (especially g

  ›
• S

  sulfamethoxazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sulfamethoxazole and Warfarin: major severity. Sulfamethoxazole inhibits CYP2C9 metabolism of S-warfarin and displaces it from

  ›
• S

  sulfamethoxazole-trimethoprim and warfarin: Interaction, Risks

  Interaction between Sulfamethoxazole Trimethoprim and Warfarin: major severity. Sulfamethoxazole inhibits CYP2C9-mediated metabolism of S-warfarin and displa

  ›
• S

  sulfasalazine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sulfasalazine and Warfarin: moderate severity. Sulfasalazine displaces warfarin from plasma proteins and may inhibit CYP2C9 met

  ›
• S

  sulfonylurea and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Sulfonylurea and Warfarin: moderate severity. Warfarin displaces sulfonylureas from protein binding and inhibits their CYP2C9

  ›
• S

  sulfonylureas and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Sulfonylureas and Trimethoprim Sulfamethoxazole: moderate severity. Sulfamethoxazole inhibits CYP2C9 metabolism of sulfonylureas (especia

  ›
• S

  sumatriptan and venlafaxine: Interaction, Risks, and Safer

  Interaction between Sumatriptan and Venlafaxine: moderate severity. Both drugs increase serotonergic activity (triptan via 5-HT1B/1D agonism, venlaf

  ›
• T

  tacrolimus and trimethoprim-sulfamethoxazole: Interaction, Risks, and Safer Alternatives

  Interaction between Tacrolimus and Trimethoprim Sulfamethoxazole: moderate severity. Trimethoprim inhibits tubular secretion of creatinine and potassium and

  ›
• T

  tacrolimus and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Tacrolimus and Trimethoprim: moderate severity. Both drugs can impair renal function and increase serum potassium, with trimetho

  ›
• T

  tacrolimus and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Tacrolimus and Verapamil: major severity. Verapamil inhibits CYP3A4 and P-glycoprotein, raising tacrolimus trough levels a

  ›
• T

  tacrolimus and voriconazole: Interaction, Risks, and Safer

  Interaction between Tacrolimus and Voriconazole: major severity. Voriconazole strongly inhibits CYP3A4-mediated tacrolimus metabolism, increasing

  ›
• T

  tadalafil and tamsulosin: Interaction, Risks, and Safer Alternatives

  Interaction between Tadalafil and Tamsulosin: moderate severity. Both drugs cause vascular smooth-muscle relaxation via alpha-1 blockade and PDE5

  ›
• T

  tadalafil and terazosin: Interaction, Risks, and Safer Alternatives

  Interaction between Tadalafil and Terazosin: moderate severity. Tadalafil enhances nitric oxide-cGMP vasodilation, while terazosin causes alpha-

  ›
• T

  tamoxifen and terbinafine: Interaction, Risks, and Safer Alternatives

  Interaction between Tamoxifen and Terbinafine: moderate severity. Terbinafine inhibits CYP2D6, which contributes to conversion of tamoxifen to the

  ›
• T

  tamoxifen and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Tamoxifen and Venlafaxine: minor severity. Tamoxifen requires CYP2D6-mediated bioactivation to endoxifen, while venlafaxine

  ›
• T

  tamoxifen and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Tamoxifen and Warfarin: major severity. Tamoxifen inhibits CYP2C9-mediated metabolism of S-warfarin, potentiating its an

  ›
• T

  tamsulosin and vardenafil: Interaction, Risks, and Safer Alternatives

  Interaction between Tamsulosin and Vardenafil: moderate severity. Both agents cause vasodilation via different mechanisms (alpha-1 blockade and PD

  ›
• T

  tamsulosin and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Tamsulosin and Verapamil: moderate severity. Verapamil inhibits CYP3A4, increasing tamsulosin exposure, and both drugs have a

  ›
• T

  telmisartan and trimethoprim: Interaction, Risks, and Safer Alternatives

  Interaction between Telmisartan and Trimethoprim: moderate severity. Trimethoprim blocks epithelial sodium channels in the distal nephron, behaving a

  ›
• T

  tetracycline and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Tetracycline and Warfarin: moderate severity. Tetracycline antibiotics may enhance warfarin's effect by reducing intestinal vi

  ›
• T

  theophylline and thiabendazole: Interaction, Risks, and Safer Alternatives

  Interaction between Theophylline and Thiabendazole: minor severity. Thiabendazole can inhibit hepatic metabolism of theophylline, likely involving C

  ›
• T

  theophylline and ticlopidine: Interaction, Risks, and Safer Alternatives

  Interaction between Theophylline and Ticlopidine: moderate severity. Ticlopidine inhibits CYP1A2, reducing theophylline clearance by approximately 40

  ›
• T

  theophylline and tobacco-smoking: Interaction, Risks, and Safer Alternatives

  Interaction between Theophylline and Tobacco Smoking: moderate severity. Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, increasing theo

  ›
• T

  theophylline and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Theophylline and Verapamil: moderate severity. Verapamil inhibits CYP1A2 and CYP3A4-mediated metabolism of theophylline, raisin

  ›
• T

  theophylline and zileuton: Interaction, Risks, and Safer Alternatives

  Interaction between Theophylline and Zileuton: moderate severity. Zileuton inhibits CYP1A2-mediated theophylline metabolism, increasing theophylli

  ›
• T

  thiazide and tolterodine: Interaction, Risks, and Safer Alternatives

  Interaction between Thiazide and Tolterodine: minor severity. Both agents can prolong the QT interval and thiazide-induced hypokalemia further

  ›
• T

  thiazide-diuretic and tolvaptan: Interaction, Risks, and Safer Alternatives

  Interaction between Thiazide Diuretic and Tolvaptan: moderate severity. Tolvaptan is a vasopressin V2 receptor antagonist promoting free water excretion

  ›
• T

  thiopurine and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Thiopurine and Warfarin: moderate severity. Azathioprine and mercaptopurine reduce the anticoagulant effect of warfarin thro

  ›
• T

  thyroid-hormone and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Thyroid Hormone and Warfarin: moderate severity. Thyroid hormones increase catabolism of vitamin K-dependent clotting factors and

  ›
• T

  ticagrelor and verapamil: Interaction, Risks, and Safer Alternatives

  Interaction between Ticagrelor and Verapamil: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, increasing ticagrelor exposure and

  ›
• T

  ticagrelor and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Ticagrelor and Voriconazole: major severity. Voriconazole strongly inhibits CYP3A4, which metabolizes ticagrelor. Increased t

  ›
• T

  topiramate and valproate: Interaction, Risks, and Safer Alternatives

  Interaction between Topiramate and Valproate: moderate severity. Combination increases ammonia production and inhibits its metabolism, causing hy

  ›
• T

  topiramate and valproic-acid: Interaction, Risks, and Safer Alternatives

  Interaction between Topiramate and Valproic Acid: moderate severity. The combination can impair ammonia metabolism through effects on mitochondrial a

  ›
• T

  tramadol and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Tramadol and Venlafaxine: major severity. Both drugs are serotonin-norepinephrine reuptake inhibitors, and tramadol additi

  ›
• T

  tramadol and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Tramadol and Warfarin: moderate severity. Tramadol is reported to potentiate warfarin effect through unclear mechanisms po

  ›
• T

  tranylcypromine and tyramine: Interaction, Risks, and Safer Alternatives

  Interaction between Tranylcypromine and Tyramine: major severity. Tranylcypromine irreversibly inhibits monoamine oxidase A in the gut and liver,

  ›
• T

  tranylcypromine and venlafaxine: Interaction, Risks, and Safer Alternatives

  Interaction between Tranylcypromine and Venlafaxine: major severity. Combination of a non-selective MAO inhibitor with a serotonin-noradrenaline reup

  ›
• T

  trimethoprim and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Trimethoprim and Valsartan: moderate severity. Trimethoprim blocks epithelial sodium channels in the distal nephron (amiloride-

  ›
• T

  trimethoprim and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Trimethoprim and Warfarin: major severity. Trimethoprim-sulfamethoxazole inhibits CYP2C9 and can reduce vitamin K-producing

  ›
• T

  trimethoprim-sulfamethoxazole and valsartan: Interaction, Risks, and Safer Alternatives

  Interaction between Trimethoprim Sulfamethoxazole and Valsartan: moderate severity. Trimethoprim reduces distal tubular potassium excretion, while valsartan

  ›
• T

  trimethoprim-sulfamethoxazole and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Trimethoprim Sulfamethoxazole and Warfarin: major severity. Sulfamethoxazole inhibits CYP2C9 metabolism of (S)-warfarin and displaces it

  ›
• V

  valproate and warfarin: Interaction, Risks, and Safer

  Interaction between Valproate and Warfarin: moderate severity. Valproate displaces warfarin from albumin binding sites and may inhibit CYP2C9 m

  ›
• V

  valproate and zidovudine: Interaction, Risks, and Safer Alternatives

  Interaction between Valproate and Zidovudine: moderate severity. Valproate can inhibit glucuronidation of zidovudine, increasing zidovudine expos

  ›
• V

  valproate and zonisamide: Interaction, Risks, and Safer Alternatives

  Interaction between Valproate and Zonisamide: minor severity. Both valproate and zonisamide can impair thermoregulation and have been associat

  ›
• V

  valproic-acid and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Valproic Acid and Warfarin: moderate severity. Valproate displaces warfarin from plasma albumin and inhibits CYP2C9 metabolism,

  ›
• V

  valproic-acid and zidovudine: Interaction, Risks, and Safer Alternatives

  Interaction between Valproic Acid and Zidovudine: moderate severity. Valproic acid can inhibit glucuronidation of zidovudine, reducing zidovudine cle

  ›
• V

  vancomycin and vecuronium: Interaction, Risks, and Safer Alternatives

  Interaction between Vancomycin and Vecuronium: moderate severity. Vancomycin potentiates non-depolarising neuromuscular blockers, possibly through

  ›
• V

  venetoclax and voriconazole: Interaction, Risks, and Safer Alternatives

  Interaction between Venetoclax and Voriconazole: major severity. Voriconazole strongly inhibits CYP3A4, substantially increasing venetoclax expos

  ›
• V

  venlafaxine and warfarin: Interaction, Risks, and Safer

  Interaction between Venlafaxine and Warfarin: moderate severity. Venlafaxine inhibits platelet serotonin reuptake reducing platelet aggregation,

  ›
• V

  venlafaxine and zolpidem: Interaction, Risks, and Safer Alternatives

  Interaction between Venlafaxine and Zolpidem: minor severity. Venlafaxine and zolpidem can both cause central nervous system adverse effects,

  ›
• V

  verapamil and warfarin: Interaction, Risks, and Safer Alternatives

  Interaction between Verapamil and Warfarin: moderate severity. Verapamil inhibits CYP3A4 and P-glycoprotein, modestly increasing warfarin expos

  ›
• V

  vincristine and voriconazole: Interaction, Risks, and Safer

  Interaction between Vincristine and Voriconazole: major severity. Voriconazole inhibits CYP3A4, increasing vincristine exposure and dramatically w

  ›
• V

  voriconazole and warfarin: Interaction, Risks, and Safer

  Interaction between Voriconazole and Warfarin: major severity. Voriconazole strongly inhibits CYP2C9 and CYP3A4, raising S-warfarin levels and

  ›
• W

  warfarin and antibiotic: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Antibiotic: major severity. Many antibiotics potentiate warfarin via gut flora disruption or CYP inhibition.

  ›
• W

  warfarin and aspirin: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Aspirin: major severity. Both anticoagulants — significantly increased bleeding risk, especially gastroin

  ›
• W

  warfarin and ibuprofen: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Ibuprofen: major severity. Ibuprofen increases bleeding risk in patients on warfarin via platelet inhibitio

  ›
• W

  warfarin and zafirlukast: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Zafirlukast: moderate severity. Zafirlukast can inhibit CYP2C9-mediated warfarin metabolism. This may increase w

  ›
• W

  warfarin and zeranol: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Zeranol: minor severity. Zeranol is not used as a therapeutic medicine in standard prescribing, and no cl

  ›
• W

  warfarin and zileuton: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Zileuton: moderate severity. Zileuton can increase warfarin exposure, likely through inhibition of hepatic me

  ›
• W

  warfarin and ziprasidone: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Ziprasidone: minor severity. Ziprasidone may modestly increase warfarin's anticoagulant effect via minor CYP3

  ›
• W

  warfarin and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Warfarin and Zopiclone: minor severity. Zopiclone does not meaningfully alter warfarin pharmacokinetics, but sedation ma

  ›
• Z

  zolpidem and zopiclone: Interaction, Risks, and Safer Alternatives

  Interaction between Zolpidem and Zopiclone: minor severity. Both drugs are hypnotics that enhance GABA-A receptor-mediated central nervous s

  ›